{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:13:56Z","timestamp":1793402036237,"version":"4.5.0"},"reference-count":884,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following\nexposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this\ndisorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and\npharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs)). However, a significant\nproportion of patients receiving standard-of-care therapies for PTSD remain symptomatic, and\nnew approaches for this and other trauma-related mental health conditions are greatly needed. Psychedelic\ncompounds that alter cognition, perception, and mood are currently being examined for their efficacy\nin treating PTSD despite their current status as Drug Enforcement Administration (DEA)-\nscheduled substances. Initial clinical trials have demonstrated the potential value of psychedelicassisted\ntherapy to treat PTSD and other psychiatric disorders. In this comprehensive review, we\nsummarize the state of the science of PTSD clinical care, including current treatments and their shortcomings.\nWe review clinical studies of psychedelic interventions to treat PTSD, trauma-related disorders,\nand common comorbidities. The classic psychedelics psilocybin, lysergic acid diethylamide\n(LSD), and N,N-dimethyltryptamine (DMT) and DMT-containing ayahuasca, as well as the entactogen\n3,4-methylenedioxymethamphetamine (MDMA) and the dissociative anesthetic ketamine, are\nreviewed. For each drug, we present the history of use, psychological and somatic effects, pharmacology,\nand safety profile. The rationale and proposed mechanisms for use in treating PTSD and traumarelated\ndisorders are discussed. This review concludes with an in-depth consideration of future directions\nfor the psychiatric applications of psychedelics to maximize therapeutic benefit and minimize\nrisk in individuals and communities impacted by trauma-related conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570159x22666231027111147","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T05:14:58Z","timestamp":1704431698000},"page":"636-735","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["The Psychedelic Future of Post-Traumatic Stress Disorder Treatment"],"prefix":"10.2174","volume":"22","author":[{"given":"Tamar Glatman","family":"Zaretsky","sequence":"first","affiliation":[{"name":"James J. Peters Veterans Affairs Medical Center, New York, NY, USA"},{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Jagodnik","sequence":"additional","affiliation":[{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Barsic","sequence":"additional","affiliation":[{"name":"James J. Peters Veterans Affairs Medical Center, New York, NY, USA"},{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josimar Hernandez","family":"Antonio","sequence":"additional","affiliation":[{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"},{"name":"Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Bonanno","sequence":"additional","affiliation":[{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"MacLeod","sequence":"additional","affiliation":[{"name":"James J. Peters Veterans Affairs Medical Center, New York, NY, USA"},{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pierce","sequence":"additional","affiliation":[{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"},{"name":"Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Carney","sequence":"additional","affiliation":[{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan T.","family":"Morrison","sequence":"additional","affiliation":[{"name":"James J. Peters Veterans Affairs Medical Center, New York, NY, USA"},{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Saylor","sequence":"additional","affiliation":[{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"},{"name":"Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Danias","sequence":"additional","affiliation":[{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"},{"name":"Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Lepow","sequence":"additional","affiliation":[{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"},{"name":"Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Yehuda","sequence":"additional","affiliation":[{"name":"James J. Peters Veterans Affairs Medical Center, New York, NY, USA"},{"name":"The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA"},{"name":"Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/jts.21848","volume":"26","author":"Kilpatrick D.G.","year":"2013","unstructured":"Kilpatrick D.G.; Resnick H.S.; Milanak M.E.; Miller M.W.; Keyes K.M.; Friedman M.J.; National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 Criteria. J Trauma Stress  2013,26(5),537-547","journal-title":"J Trauma Stress"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1056\/NEJMra012941","volume":"346","author":"Yehuda R.","year":"2002","unstructured":"Yehuda R.; Post-traumatic stress disorder. N Engl J Med  2002,346(2),108-114","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/archpsyc.1995.03950240066012","volume":"52","author":"Kessler R.C.","year":"1995","unstructured":"Kessler R.C.; Sonnega A.; Bromet E.; Hughes M.; Nelson C.B.; Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry  1995,52(12),1048-1060","journal-title":"Arch Gen Psychiatry"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/da.22469","volume":"33","author":"De Jongh A.","year":"2016","unstructured":"De Jongh A.; Resick P.A.; Zoellner L.A.; van Minnen A.; Lee C.W.; Monson C.M.; Foa E.B.; Wheeler K.; Broeke E.; Feeny N.; Rauch S.A.M.; Chard K.M.; Mueser K.T.; Sloan D.M.; van der Gaag M.; Rothbaum B.O.; Neuner F.; de Roos C.; Hehenkamp L.M.J.; Rosner R.; Bicanic I.A.E.; Critical analysis of the current treatment guidelines for complex PTSD in adults. Depress Anxiety  2016,33(5),359-369","journal-title":"Depress Anxiety"},{"key":"ref=5","year":"2017","unstructured":"VA\/DOD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. Affairs DoV Available at:  https:\/\/www.healthquality.va.gov\/guidelines\/MH\/ptsd\/VADoDPTSDCPGFinal012418.pdf\/2017"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e2136921","DOI":"10.1001\/jamanetworkopen.2021.36921","volume":"5","author":"Schnurr P.P.","year":"2022","unstructured":"Schnurr P.P.; Chard K.M.; Ruzek J.I.; Chow B.K.; Resick P.A.; Foa E.B.; Marx B.P.; Friedman M.J.; Bovin M.J.; Caudle K.L.; Castillo D.; Curry K.T.; Hollifield M.; Huang G.D.; Chee C.L.; Astin M.C.; Dickstein B.; Renner K.; Clancy C.P.; Collie C.; Maieritsch K.; Bailey S.; Thompson K.; Messina M.; Franklin L.; Lindley S.; Kattar K.; Luedtke B.; Romesser J.; McQuaid J.; Sylvers P.; Varkovitzky R.; Davis L.; MacVicar D.; Shih M-C.; Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among us veterans. JAMA Netw Open  2022,5(1),e2136921","journal-title":"JAMA Netw Open"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1709709","DOI":"10.1080\/20008198.2019.1709709","volume":"11","author":"Lewis C.","year":"2020","unstructured":"Lewis C.; Roberts N.P.; Gibson S.; Bisson J.I.; Dropout from psychological therapies for posttraumatic stress disorder (PTSD) in adults: Systematic review and metaanalysis. Eur J Psychotraumatol  2020,11(1),1709709","journal-title":"Eur J Psychotraumatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1521\/psyc.2008.71.2.134","volume":"71","author":"Schottenbauer M.A.","year":"2008","unstructured":"Schottenbauer M.A.; Glass C.R.; Arnkoff D.B.; Tendick V.; Gray S.H.; Nonresponse and dropout rates in outcome studies on PTSD: Review and methodological considerations. Psychiatry  2008,71(2),134-168","journal-title":"Psychiatry"},{"key":"ref=9","author":"Ogden P.","year":"2006","unstructured":"Ogden P.; Minton K.; Pain C.;  Trauma and the body: A sensorimotor approach to psychotherapy (norton series on interpersonal neurobiology)  2006","journal-title":"Trauma and the body: A sensorimotor approach to psychotherapy (norton series on interpersonal neurobiology)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1176\/appi.ajp.162.2.214","volume":"162","author":"Bradley R.","year":"2005","unstructured":"Bradley R.; Greene J.; Russ E.; Dutra L.; Westen D.; A multidimensional metaanalysis of psychotherapy for PTSD. Am J Psychiatry  2005,162(2),214-227","journal-title":"Am J Psychiatry"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1017\/S0033291718001800","volume":"49","author":"Bell V.","year":"2019","unstructured":"Bell V.; Robinson B.; Katona C.; Fett A.K.; Shergill S.; When trust is lost: The impact of interpersonal trauma on social interactions. Psychol Med  2019,49(6),1041-1046","journal-title":"Psychol Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.4236\/psych.2017.813132","volume":"8","author":"Zepinic V.","year":"2017","unstructured":"Zepinic V.; Trauma focused dynamic therapy model in treating complex psychological trauma. Psychology  2017,8(13),2059-2101","journal-title":"Psychology"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.janxdis.2013.12.008","volume":"28","author":"Armour C.","year":"2014","unstructured":"Armour C.; Elklit A.; Lauterbach D.; Elhai J.D.; The DSM-5 dissociative-PTSD subtype: Can levels of depression, anxiety, hostility, and sleeping difficulties differentiate between dissociative-PTSD and PTSD in rape and sexual assault victims? J Anxiety Disord  2014,28(4),418-426","journal-title":"J Anxiety Disord"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1521\/bumc.2014.78.4.335","volume":"78","author":"Williams W.","year":"2014","unstructured":"Williams W.; Graham D.P.; McCurry K.; Sanders A.; Eiseman J.; Chiu P.H.; King-Casas B.; Group psychotherapy\u2019s impact on trust in veterans with PTSD: A pilot study. Bull Menninger Clin  2014,78(4),335-348","journal-title":"Bull Menninger Clin"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev.psych.121208.131631","volume":"63","author":"Milad M.R.","year":"2012","unstructured":"Milad M.R.; Quirk G.J.; Fear extinction as a model for translational neuroscience: Ten years of progress. Annu Rev Psychol  2012,63(1),129-151","journal-title":"Annu Rev Psychol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1001\/archpsyc.62.3.273","volume":"62","author":"Shin L.M.","year":"2005","unstructured":"Shin L.M.; Wright C.I.; Cannistraro P.A.; Wedig M.M.; McMullin K.; Martis B.; Macklin M.L.; Lasko N.B.; Cavanagh S.R.; Krangel T.S.; Orr S.P.; Pitman R.K.; Whalen P.J.; Rauch S.L.; A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. Arch Gen Psychiatry  2005,62(3),273-281","journal-title":"Arch Gen Psychiatry"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2013.04.032","volume":"547","author":"Yan X.","year":"2013","unstructured":"Yan X.; Brown A.D.; Lazar M.; Cressman V.L.; Henn-Haase C.; Neylan T.C.; Shalev A.; Wolkowitz O.M.; Hamilton S.P.; Yehuda R.; Sodickson D.K.; Weiner M.W.; Marmar C.R.; Spontaneous brain activity in combat related PTSD. Neurosci Lett  2013,547,1-5","journal-title":"Neurosci Lett"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0006-3223(93)90001-T","volume":"33","author":"Yehuda R.","year":"1993","unstructured":"Yehuda R.; Antelman S.M.; Criteria for rationally evaluating animal models of postraumatic stress disorder. Biol Psychiatry  1993,33(7),479-486","journal-title":"Biol Psychiatry"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/inm.12792","volume":"29","author":"Jamieson N.","year":"2020","unstructured":"Jamieson N.; Maple M.; Ratnarajah D.; Usher K.; Military moral injury: A concept analysis. Int J Ment Health Nurs  2020,29(6),1049-1066","journal-title":"Int J Ment Health Nurs"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1177\/1524838020979667","volume":"23","author":"Salter M.","year":"2022","unstructured":"Salter M.; Hall H.; Reducing shame, promoting dignity: A model for the primary prevention of complex post-traumatic stress disorder. Trauma Violence Abuse  2022,23(3),906-919","journal-title":"Trauma Violence Abuse"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2202060","DOI":"10.1080\/20008066.2023.2202060","volume":"14","author":"Fine N.B.","year":"2023","unstructured":"Fine N.B.; Ben-Zion Z.; Biran I.; Hendler T.; Neuroscientific account of guilt and shame driven PTSD phenotypes. Eur J Psychotraumatol  2023,14(2),2202060","journal-title":"Eur J Psychotraumatol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41583-018-0039-7","volume":"19","author":"Fenster R.J.","year":"2018","unstructured":"Fenster R.J.; Lebois L.A.M.; Ressler K.J.; Suh J.; Brain circuit dysfunction in posttraumatic stress disorder: From mouse to man. Nat Rev Neurosci  2018,19(9),535-551","journal-title":"Nat Rev Neurosci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.biopsych.2019.07.009","volume":"86","author":"DePierro J.","year":"2019","unstructured":"DePierro J.; Lepow L.; Feder A.; Yehuda R.; Translating molecular and neuroendocrine findings in posttraumatic stress disorder and resilience to novel therapies. Biol Psychiatry  2019,86(6),454-463","journal-title":"Biol Psychiatry"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0006-3223(95)00451-3","volume":"40","author":"Yehuda R.","year":"1996","unstructured":"Yehuda R.; Teicher M.H.; Trestman R.L.; Levengood R.A.; Siever L.J.; Cortisol regulation in posttraumatic stress disorder and major depression: A chronobiological analysis. Biol Psychiatry  1996,40(2),79-88","journal-title":"Biol Psychiatry"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1017\/S003329171700349X","volume":"48","author":"Cipriani A.","year":"2018","unstructured":"Cipriani A.; Williams T.; Nikolakopoulou A.; Salanti G.; Chaimani A.; Ipser J.; Cowen P.J.; Geddes J.R.; Stein D.J.; Comparative efficacy and acceptability of pharmacological treatments for posttraumatic stress disorder in adults: A network meta-analysis. Psychol Med  2018,48(12),1975-1984","journal-title":"Psychol Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1192\/bjp.bp.114.148551","volume":"206","author":"Hoskins M.","year":"2015","unstructured":"Hoskins M.; Pearce J.; Bethell A.; Dankova L.; Barbui C.; Tol W.A.; van Ommeren M.; de Jong J.; Seedat S.; Chen H.; Bisson J.I.; Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. Br J Psychiatry  2015,206(2),93-100","journal-title":"Br J Psychiatry"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cct.2019.04.009","volume":"81","author":"Abdallah C.G.","year":"2019","unstructured":"Abdallah C.G.; Roache J.D.; Averill L.A.; Young-McCaughan S.; Martini B.; Gueorguieva R.; Amoroso T.; Southwick S.M.; Guthmiller K.; L\u00f3pez-Roca A.L.; Lautenschlager K.; Mintz J.; Litz B.T.; Williamson D.E.; Keane T.M.; Peterson A.L.; Krystal J.H.; Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemp Clin Trials  2019,81,11-18","journal-title":"Contemp Clin Trials"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","volume":"41","author":"De Gregorio D.","year":"2021","unstructured":"De Gregorio D.; Aguilar-Valles A.; Preller K.H.; Heifets B.D.; Hibicke M.; Mitchell J.; Gobbi G.; Hallucinogens in mental health: Pre-clinical and clinical studies on LSD, Psilocybin, MDMA, and Ketamine. J Neurosci  2021,41(5),891-900","journal-title":"J Neurosci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"Nichols D.E.","year":"2016","unstructured":"Nichols D.E.; Psychedelics. Pharmacol Rev  2016,68(2),264-355","journal-title":"Pharmacol Rev"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1073\/pnas.1524187113","volume":"113","author":"Preller K.H.","year":"2016","unstructured":"Preller K.H.; Pokorny T.; Hock A.; Effects of serotonin 2A\/1A receptor stimulation on social exclusion processing. Proc Nat Acad Sci: PNAS  2016,113(18),5119-5124","journal-title":"Proc Nat Acad Sci: PNAS"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.euroneuro.2016.01.005","volume":"26","author":"Pokorny T.","year":"2016","unstructured":"Pokorny T.; Preller K.H.; Kraehenmann R.; Vollenweider F.X.; Modulatory effect of the 5-HT agonist buspirone and the mixed non-hallucinogenic 5-HT\/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol  2016,26(4),756-766","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s00213-021-05978-6","volume":"239","author":"Holze F.","year":"2022","unstructured":"Holze F.; Caluori T.V.; Vizeli P.; Liechti M.E.; Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology  2022,239(6),1893-1905","journal-title":"Psychopharmacology"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"Holze F.","year":"2021","unstructured":"Holze F.; Vizeli P.; Ley L.; M\u00fcller F.; Dolder P.; Stocker M.; Duthaler U.; Varghese N.; Eckert A.; Borgwardt S.; Liechti M.E.; Acute dose-dependent effects of lysergic acid diethylamide in a doubleblind placebo-controlled study in healthy subjects. Neuropsychopharmacology  2021,46(3),537-544","journal-title":"Neuropsychopharmacology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0269881114568040","volume":"29","author":"Maji\u0107 T.","year":"2015","unstructured":"Maji\u0107 T.; Schmidt T.T.; Gallinat J.; Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol  2015,29(3),241-253","journal-title":"J Psychopharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","volume":"78","author":"Schmid Y.","year":"2015","unstructured":"Schmid Y.; Enzler F.; Gasser P.; Grouzmann E.; Preller K.H.; Vollenweider F.X.; Brenneisen R.; M\u00fcller F.; Borgwardt S.; Liechti M.E.; Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry  2015,78(8),544-553","journal-title":"Biol Psychiatry"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"Griffiths R.R.","year":"2011","unstructured":"Griffiths R.R.; Johnson M.W.; Richards W.A.; Richards B.D.; McCann U.; Jesse R.; Psilocybin occasioned mystical-type experiences: Immediate and persisting doserelated effects. Psychopharmacology  2011,218(4),649-665","journal-title":"Psychopharmacology"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"MacLean K.A.","year":"2011","unstructured":"MacLean K.A.; Johnson M.W.; Griffiths R.R.; Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol  2011,25(11),1453-1461","journal-title":"J Psychopharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/17512433.2020.1772054","volume":"13","author":"Greenway K.T.","year":"2020","unstructured":"Greenway K.T.; Garel N.; Jerome L.; Feduccia A.A.; Integrating psychotherapy and psychopharmacology: Psychedelic-assisted psychotherapy and other combined treatments. Expert Rev Clin Pharmacol  2020,13(6),655-670","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","volume":"237","author":"Jerome L.","year":"2020","unstructured":"Jerome L.; Feduccia A.A.; Wang J.B.; Hamilton S.; Yazar-Klosinski B.; Emerson A.; Mithoefer M.C.; Doblin R.; Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology  2020,237(8),2485-2497","journal-title":"Psychopharmacology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"Mitchell J.M.","year":"2021","unstructured":"Mitchell J.M.; Bogenschutz M.; Lilienstein A.; Harrison C.; Kleiman S.; Parker-Guilbert K.; Ot\u2019alora G, M.; Garas W.; Paleos C.; Gorman I.; Nicholas C.; Mithoefer M.; Carlin S.; Poulter B.; Mithoefer A.; Quevedo S.; Wells G.; Klaire S.S.; van der\nKolk B.; Tzarfaty K.; Amiaz R.; Worthy R.; Shannon S.; Woolley J.D.; Marta C.; Gelfand Y.; Hapke E.; Amar S.; Wallach Y.; Brown R.; Hamilton S.; Wang J.B.; Coker A.; Matthews R.; de\nBoer A.; Yazar-Klosinski B.; Emerson A.; Doblin R.; MDMA-assisted therapy for severe PTSD : A randomized, double-blind, placebo-controlled phase 3 study. Nat Med  2021,27(6),1025-1033","journal-title":"Nat Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/02791072.2019.1580805","volume":"51","author":"Barone W.","year":"2019","unstructured":"Barone W.; Beck J.; Mitsunaga-Whitten M.; Perl P.; Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: Qualitative Follow-Up study of a clinical trial for individuals with treatmentresistant PTSD. J Psychoactive Drugs  2019,51(2),199-208","journal-title":"J Psychoactive Drugs"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jts.22479","volume":"33","author":"Gorman I.","year":"2020","unstructured":"Gorman I.; Belser A.B.; Jerome L.; Hennigan C.; Shechet B.; Hamilton S.; Yazar-Klosinski B.; Emerson A.; Feduccia A.A.; Posttraumatic growth after MDMA-Assisted psychotherapy for posttraumatic stress disorder. J Trauma Stress  2020,33(2),161-170","journal-title":"J Trauma Stress"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"Schlag A.K.","year":"2022","unstructured":"Schlag A.K.; Aday J.; Salam I.; Neill J.C.; Nutt D.J.; Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol  2022,36(3),258-272","journal-title":"J Psychopharmacol"},{"key":"ref=44","author":"Lepow L.","year":"2023","unstructured":"Lepow L.; Jagodnik K.M.; Glatman Zaretsky T.; Hernandez Antonio J.; Bonanno P.A.; Yehuda R.;  Charney and Nestler\u2019s Neurobiology of Mental Illness, 6th  2023","journal-title":"Charney and Nestler\u2019s Neurobiology of Mental Illness, 6th"},{"key":"ref=45","author":"Association A.P.","year":"2013","unstructured":"Association A.P.;  Posttraumatic Stress Disorder  2013","journal-title":"Posttraumatic Stress Disorder"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1176\/ajp.131.9.981","volume":"131","author":"Burgess A.W.","year":"1974","unstructured":"Burgess A.W.; Holmstrom L.L.; Rape trauma syndrome. Am J Psychiatry  1974,131(9),981-986","journal-title":"Am J Psychiatry"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/jcm5110105","volume":"5","author":"Lancaster C.","year":"2016","unstructured":"Lancaster C.; Teeters J.; Gros D.; Back S.; Posttraumatic stress disorder: Overview of evidence-based assessment and treatment. J Clin Med  2016,5(11),105","journal-title":"J Clin Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jts.2490050309","volume":"5","author":"Rothbaum B.O.","year":"1992","unstructured":"Rothbaum B.O.; Foa E.B.; Riggs D.S.; Murdock T.; Walsh W.; A prospective examination of post traumatic stress disorder in rape victims. J Trauma Stress  1992,5(3),455-475","journal-title":"J Trauma Stress"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e59236","DOI":"10.1371\/journal.pone.0059236","volume":"8","author":"Santiago P.N.","year":"2013","unstructured":"Santiago P.N.; Ursano R.J.; Gray C.L.; Pynoos R.S.; Spiegel D.; Lewis-Fernandez R.; Friedman M.J.; Fullerton C.S.; A systematic review of PTSD prevalence and trajectories in DSM-5 defined trauma exposed populations: Intentional and nonintentional traumatic events. PLoS One  2013,8(4),e59236","journal-title":"PLoS One"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/da.20767","volume":"28","author":"Friedman M.J.","year":"2011","unstructured":"Friedman M.J.; Resick P.A.; Bryant R.A.; Brewin C.R.; Considering PTSD for DSM-V. Depression and Anxiety  2011,28(9),750-769","journal-title":"Depression and Anxiety"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.4088\/JCP.08r04484","volume":"70","author":"Smid G.E.","year":"2009","unstructured":"Smid G.E.; Mooren T.T.M.; van der Mast R.C.; Gersons B.P.R.; Kleber R.J.; Delayed posttraumatic stress disorder: Systematic review, meta-analysis, and metaregression analysis of prospective studies. J Clin Psychiatry  2009,70(11),1572-1582","journal-title":"J Clin Psychiatry"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5271\/sjweh.3420","volume":"40","author":"Utzon-Frank N.","year":"2014","unstructured":"Utzon-Frank N.; Breinegaard N.; Bertelsen M.; Borritz M.; Eller N.H.; Nordentoft M.; Olesen K.; Rod N.H.; Rugulies R.; Bonde J.P.; Occurrence of delayed-onset posttraumatic stress disorder: A systematic review and meta-analysis of prospective studies. Scand J Work Environ Health  2014,40(3),215-229","journal-title":"Scand J Work Environ Health"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1176\/appi.ajp.2007.06091491","volume":"164","author":"Andrews B.","year":"2007","unstructured":"Andrews B.; Brewin C.R.; Philpott R.; Stewart L.; Delayed-onset posttraumatic stress disorder: A systematic review of the evidence. Am J Psychiatry  2007,164(9),1319-1326","journal-title":"Am J Psychiatry"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/acps.13372","volume":"145","author":"Bonde J.P.E.","year":"2022","unstructured":"Bonde J.P.E.; Jensen J.H.; Smid G.E.; Flachs E.M.; Elklit A.; Mors O.; Videbech P.; Time course of symptoms in posttraumatic stress disorder with delayed expression: A systematic review. Acta Psychiatr Scand  2022,145(2),116-131","journal-title":"Acta Psychiatr Scand"},{"key":"ref=55","year":"2013","unstructured":"Diagnostic and statistical manual of mental disorders: DSM-5: American Psychiatric Association D. Association AP 2013"},{"key":"ref=56","author":"Organization W.H.","year":"2019","unstructured":"Organization W.H.;  International statistical classification of diseases and related health problems, 11th; who  Available at:  https:\/\/icd.who.int\/ 2019","journal-title":"International statistical classification of diseases and related health problems, 11th; who"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1353383","DOI":"10.1080\/20008198.2017.1353383","author":"Kessler RC","year":"2017","unstructured":"Kessler RC; Aguilar-Gaxiola S; Alonso J; Trauma and PTSD in the WHO world mental health surveys. Eurp J Psychotraumatol  2017(sup5),1353383","journal-title":"Eurp J Psychotraumatol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1017\/S0033291717000708","volume":"47","author":"Koenen K.C.","year":"2017","unstructured":"Koenen K.C.; Ratanatharathorn A.; Ng L.; McLaughlin K.A.; Bromet E.J.; Stein D.J.; Karam E.G.; Meron Ruscio A.; Benjet C.; Scott K.; Atwoli L.; Petukhova M.; Lim C.C.W.; Aguilar-Gaxiola S.; Al-Hamzawi A.; Alonso J.; Bunting B.; Ciutan M.; de Girolamo G.; Degenhardt L.; Gureje O.; Haro J.M.; Huang Y.; Kawakami N.; Lee S.; Navarro-Mateu F.; Pennell B-E.; Piazza M.; Sampson N.; ten Have M.; Torres Y.; Viana M.C.; Williams D.; Xavier M.; Kessler R.C.; Posttraumatic stress disorder in the world mental health surveys. Psychol Med  2017,47(13),2260-2274","journal-title":"Psychol Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"15057","DOI":"10.1038\/nrdp.2015.57","volume":"1","author":"Yehuda R.","year":"2015","unstructured":"Yehuda R.; Hoge C.W.; McFarlane A.C.; Vermetten E.; Lanius R.A.; Nievergelt C.M.; Hobfoll S.E.; Koenen K.C.; Neylan T.C.; Hyman S.E.; Post-traumatic stress disorder. Nat Rev Dis Primers  2015,1(1),15057","journal-title":"Nat Rev Dis Primers"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41582-022-00635-8","volume":"18","author":"Ressler K.J.","year":"2022","unstructured":"Ressler K.J.; Berretta S.; Bolshakov V.Y.; Rosso I.M.; Meloni E.G.; Rauch S.L.; Carlezon W.A.; Posttraumatic stress disorder: Clinical and translational neuroscience from cells to circuits. Nat Rev Neurol  2022,18(5),273-288","journal-title":"Nat Rev Neurol"},{"key":"ref=61","year":"2023","unstructured":"National Center for PTSD PTSD Available at:  https:\/\/www.ptsd.va.gov\/understand\/common\/common_adults.asp2023","journal-title":"National Center for PTSD"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.psychres.2016.01.011","volume":"236","author":"Dekel S.","year":"2016","unstructured":"Dekel S.; Mamon D.; Solomon Z.; Lanman O.; Dishy G.; Can guilt lead to psychological growth following trauma exposure? Psychiatry Res  2016,236,196-198","journal-title":"Psychiatry Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/jts.20341","volume":"21","author":"Terhakopian A.","year":"2008","unstructured":"Terhakopian A.; Sinaii N.; Engel C.C.; Schnurr P.P.; Hoge C.W.; Estimating population prevalence of posttraumatic stress disorder : An example using the PTSD checklist. J Trauma Stress  2008,21(3),290-300","journal-title":"J Trauma Stress"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/da.22169","volume":"31","author":"Karam E.G.","year":"2014","unstructured":"Karam E.G.; Friedman M.J.; Hill E.D.; Kessler R.C.; McLaughlin K.A.; Petukhova M.; Sampson L.; Shahly V.; Angermeyer M.C.; Bromet E.J.; de Girolamo G.; de Graaf R.; Demyttenaere K.; Ferry F.; Florescu S.E.; Haro J.M.; He Y.; Karam A.N.; Kawakami N.; Kovess-Masfety V.; Medina-Mora M.E.; Browne M.A.O.; Posada-Villa J.A.; Shalev A.Y.; Stein D.J.; Viana M.C.; Zarkov Z.; Koenen K.C.; Cumulative traumas and risk thresholds : 12-month PTSD in the world mental health (WMH) surveys. Depress Anxiety  2014,31(2),130-142","journal-title":"Depress Anxiety"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/978-3-030-85372-3_38","author":"DeRight J.","year":"2022","unstructured":"DeRight J.;  Essential Neuropsychology:\nA Concise Handbook for Adult Practitioners  2022,269-277","journal-title":"Essential Neuropsychology:\nA Concise Handbook for Adult Practitioners"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/978-1-4615-4177-6_25","author":"Marshall R.D.","year":"2000","unstructured":"Marshall R.D.; Yehuda R.; Bone S.; Trauma-focused psychodynamic psychotherapy for individuals with posttraumatic stress symptoms. Inter handbook of human response to trauma  2000,347-361","journal-title":"Inter handbook of human response to trauma"},{"key":"ref=67","author":"Friedman M.J.","year":"2021","unstructured":"Friedman M.J.; Schnurr P.P.; Keane T.M.;  Handbook of PTSD :\nScience and practice  2021","journal-title":"Handbook of PTSD :\nScience and practice"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/YCO.0000000000000167","volume":"28","author":"Atwoli L.","year":"2015","unstructured":"Atwoli L.; Stein D.J.; Koenen K.C.; McLaughlin K.A.; Epidemiology of posttraumatic stress disorder. Curr Opin Psychiatry  2015,28(4),307-311","journal-title":"Curr Opin Psychiatry"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/EDE.0b013e31815c1dbf","volume":"19","author":"Galea S.","year":"2008","unstructured":"Galea S.; Ahern J.; Tracy M.; Hubbard A.; Cerda M.; Goldmann E.; Vlahov D.; Longitudinal determinants of posttraumatic stress in a population-based cohort study. Epidemiology  2008,19(1),47-54","journal-title":"Epidemiology"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/wps.20150","volume":"13","author":"Kessler R.C.","year":"2014","unstructured":"Kessler R.C.; Rose S.; Koenen K.C.; Karam E.G.; Stang P.E.; Stein D.J.; Heeringa S.G.; Hill E.D.; Liberzon I.; McLaughlin K.A.; McLean S.A.; Pennell B.E.; Petukhova M.; Rosellini A.J.; Ruscio A.M.; Shahly V.; Shalev A.Y.; Silove D.; Zaslavsky A.M.; Angermeyer M.C.; Bromet E.J.; de Almeida J.M.C.; de Girolamo G.; de Jonge P.; Demyttenaere K.; Florescu S.E.; Gureje O.; Haro J.M.; Hinkov H.; Kawakami N.; Kovess-Masfety V.; Lee S.; Medina-Mora M.E.; Murphy S.D.; Navarro-Mateu F.; Piazza M.; Posada-Villa J.; Scott K.; Torres Y.; Carmen Viana M.; How well can post-traumatic stress disorder be predicted from pre-trauma risk factors? An exploratory study in the WHO World Mental Health Surveys. World Psychiatry  2014,13(3),265-274","journal-title":"World Psychiatry"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00005053-200204000-00001","volume":"190","author":"Koenen K.C.","year":"2002","unstructured":"Koenen K.C.; Harley R.; Lyons M.J.; Wolfe J.; Simpson J.C.; Goldberg J.; Eisen S.A.; Tsuang M.; A twin registry study of familial and individual risk factors for trauma exposure and posttraumatic stress disorder. J Nerv Ment Dis  2002,190(4),209-218","journal-title":"J Nerv Ment Dis"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/archpsyc.1993.01820160019002","volume":"50","author":"True W.R.","year":"1993","unstructured":"True W.R.; Rice J.; Eisen S.A.; A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms. Arch Gen Psychiatry  1993,50(4),257-264","journal-title":"Arch Gen Psychiatry"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4088\/JCP.v62n0109","volume":"62","author":"Yehuda R.","year":"2001","unstructured":"Yehuda R.; Biology of posttraumatic stress disorder. J Clin Psychiatry  2001,62(17),41-46","journal-title":"J Clin Psychiatry"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1097\/00004583-199509000-00013","volume":"34","author":"Sack W.H.","year":"1995","unstructured":"Sack W.H.; Clarke G.N.; Seeley J.; Posttraumatic stress disorder across two generations of cambodian refugees. J Am Acad Child Adolesc Psychiatry  1995,34(9),1160-1166","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1038\/s41467-019-12576-w","volume":"10","author":"Nievergelt C.M.","year":"2019","unstructured":"Nievergelt C.M.; Maihofer A.X.; Klengel T.; Atkinson E.G.; Chen C-Y.; Choi K.W.; Coleman J.R.I.; Dalvie S.; Duncan L.E.; Gelernter J.; Levey D.F.; Logue M.W.; Polimanti R.; Provost A.C.; Ratanatharathorn A.; Stein M.B.; Torres K.; Aiello A.E.; Almli L.M.; Amstadter A.B.; Andersen S.B.; Andreassen O.A.; Arbisi P.A.; Ashley-Koch A.E.; Austin S.B.; Avdibegovic E.; Babi\u0107 D.; B\u00e6kvad-Hansen M.; Baker D.G.; Beckham J.C.; Bierut L.J.; Bisson J.I.; Boks M.P.; Bolger E.A.; B\u00f8rglum A.D.; Bradley B.; Brashear M.; Breen G.; Bryant R.A.; Bustamante A.C.; Bybjerg-Grauholm J.; Calabrese J.R.; Caldas- de- Almeida, J.M.; Dale, A.M.; Daly, M.J.; Daskalakis, N.P.; Deckert, J.; Delahanty, D.L.; Dennis, M.F.; Disner, S.G.; Domschke, K.; Dzubur-Kulenovic, A.; Erbes, C.R.; Evans, A.; Farrer, L.A.; Feeny, N.C.; Flory, J.D.; Forbes, D.; Franz, C.E.; Galea, S.; Garrett, M.E.; Gelaye, B.; Geuze, E.; Gillespie, C.; Uka, A.G.; Gordon, S.D.; Guffanti, G.; Hammamieh, R.; Harnal, S.; Hauser, M.A.; Heath, A.C.; Hemmings, S.M.J.; Hougaard, D.M.; Jakovljevic, M.; Jett, M.; Johnson, E.O.; Jones, I.; Jovanovic, T.; Qin, X-J.; Junglen, A.G.; Karstoft, K-I.; Kaufman, M.L.; Kessler, R.C.; Khan, A.; Kimbrel, N.A.; King, A.P.; Koen, N.; Kranzler, H.R.; Kremen, W.S.; Lawford, B.R.; Lebois, L.A.M.; Lewis, C.E.; Linnstaedt, S.D.; Lori, A.; Lugonja, B.; Luykx, J.J.; Lyons, M.J.; Maples-Keller, J.; Marmar, C.; Martin, A.R.; Martin, N.G.; Maurer, D.; Mavissakalian, M.R.; McFarlane, A.; McGlinchey, R.E.; McLaughlin, K.A.; McLean, S.A.; McLeay, S.; Mehta, D.; Milberg, W.P.; Miller, M.W.; Morey, R.A.; Morris, C.P.; Mors, O.; Mortensen, P.B.; Neale, B.M.; Nelson, E.C.; Nordentoft, M.; Norman, S.B.; O\u2019Donnell, M.; Orcutt, H.K.; Panizzon, M.S.; Peters, E.S.; Peterson, A.L.; Peverill, M.; Pietrzak, R.H.; Polusny, M.A.; Rice, J.P.; Ripke, S.; Risbrough, V.B.; Roberts, A.L.; Rothbaum, A.O.; Rothbaum, B.O.; Roy-Byrne, P.; Ruggiero, K.; Rung, A.; Rutten, B.P.F.; Saccone, N.L.; Sanchez, S.E.; Schijven, D.; Seedat, S.; Seligowski, A.V.; Seng, J.S.; Sheerin, C.M.; Silove, D.; Smith, A.K.; Smoller, J.W.; Sponheim, S.R.; Stein, D.J.; Stevens, J.S.; Sumner, J.A.; Teicher, M.H.; Thompson, W.K.; Trapido, E.; Uddin, M.; Ursano, R.J.; van den Heuvel, L.L.; Van Hooff, M.; Vermetten, E.; Vinkers, C.H.; Voisey, J.; Wang, Y.; Wang, Z.; Werge, T.; Williams, M.A.; Williamson, D.E.; Winternitz, S.; Wolf, C.; Wolf, E.J.; Wolff, J.D.; Yehuda, R.; Young, R.M.D.; Young, K.A.; Zhao, H.; Zoellner, L.A.; Liberzon, I.; Ressler, K.J.; Haas, M.; Koenen, K.C. International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat Commun  2019,10(1),4558","journal-title":"Nat Commun"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1176\/appi.ajp.159.10.1675","volume":"159","author":"Stein M.B.","year":"2002","unstructured":"Stein M.B.; Jang K.L.; Taylor S.; Vernon P.A.; Livesley W.J.; Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms: A twin study. Am J Psychiatry  2002,159(10),1675-1681","journal-title":"Am J Psychiatry"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00213-004-2137-7","volume":"180","author":"Lang U.E.","year":"2005","unstructured":"Lang U.E.; Hellweg R.; Kalus P.; Bajbouj M.; Lenzen K.P.; Sander T.; Kunz D.; Gallinat J.; Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology  2005,180(1),95-99","journal-title":"Psychopharmacology"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1534765608319085","volume":"14","author":"Renaud E.F.","year":"2008","unstructured":"Renaud E.F.; The attachment characteristics of combat veterans with PTSD. Traumatology  2008,14(3),1-12","journal-title":"Traumatology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00406-007-0787-2","volume":"258","author":"Koenen K.C.","year":"2008","unstructured":"Koenen K.C.; Nugent N.R.; Amstadter A.B.; Gene-environment interaction in posttraumatic stress disorder. Eur Arch Psychiatry Clin Neurosci  2008,258(2),82-96","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1080\/15622975.2021.1907721","volume":"22","author":"Asch R.H.","year":"2021","unstructured":"Asch R.H.; Esterlis I.; Wendt F.R.; Kachadourian L.; Southwick S.M.; Gelernter J.; Polimanti R.; Pietrzak R.H.; Polygenic risk for traumatic loss-related PTSD in US military veterans: Protective effect of secure attachment style. World J Biol Psychiatry  2021,22(10),792-799","journal-title":"World J Biol Psychiatry"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/HRP.0000000000000194","volume":"26","author":"Horn S.R.","year":"2018","unstructured":"Horn S.R.; Feder A.; Understanding resilience and preventing and treating PTSD. Harv Rev Psychiatry  2018,26(3),158-174","journal-title":"Harv Rev Psychiatry"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1037\/abn0000571","volume":"129","author":"Lee D.J.","year":"2020","unstructured":"Lee D.J.; Lee L.O.; Bovin M.J.; Moshier S.J.; Dutra S.J.; Kleiman S.E.; Rosen R.C.; Vasterling J.J.; Keane T.M.; Marx B.P.; The 20-year course of posttraumatic stress disorder symptoms among veterans. J Abnorm Psychol  2020,129(6),658-669","journal-title":"J Abnorm Psychol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11920-019-1042-z","volume":"21","author":"Able M.L.","year":"2019","unstructured":"Able M.L.; Benedek D.M.; Severity and symptom trajectory in combat-related PTSD: A review of the literature. Curr Psychiatry Rep  2019,21(7),58","journal-title":"Curr Psychiatry Rep"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/08039488.2015.1005023","volume":"69","author":"Steinert C.","year":"2015","unstructured":"Steinert C.; Hofmann M.; Leichsenring F.; Kruse J.; The course of PTSD in naturalistic long-term studies: High variability of outcomes. A systematic review. Nord J Psychiatry  2015,69(7),483-496","journal-title":"Nord J Psychiatry"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cpr.2014.03.002","volume":"34","author":"Morina N.","year":"2014","unstructured":"Morina N.; Wicherts J.M.; Lobbrecht J.; Priebe S.; Remission from post-traumatic stress disorder in adults: A systematic review and meta-analysis of long term outcome studies. Clin Psychol Rev  2014,34(3),249-255","journal-title":"Clin Psychol Rev"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1017\/S0033291717001817","volume":"48","author":"Rosellini A.J.","year":"2018","unstructured":"Rosellini A.J.; Liu H.; Petukhova M.V.; Sampson N.A.; Aguilar-Gaxiola S.; Alonso J.; Borges G.; Bruffaerts R.; Bromet E.J.; de Girolamo G.; de Jonge P.; Fayyad J.; Florescu S.; Gureje O.; Haro J.M.; Hinkov H.; Karam E.G.; Kawakami N.; Koenen K.C.; Lee S.; L\u00e9pine J.P.; Levinson D.; Navarro-Mateu F.; Oladeji B.D.; O\u2019Neill S.; Pennell B-E.; Piazza M.; Posada-Villa J.; Scott K.M.; Stein D.J.; Torres Y.; Viana M.C.; Zaslavsky A.M.; Kessler R.C.; Recovery from DSM-IV post-traumatic stress disorder in the WHO World Mental Health surveys. Psychol Med  2018,48(3),437-450","journal-title":"Psychol Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"113279","DOI":"10.1016\/j.psychres.2020.113279","volume":"291","author":"Tripp J.C.","year":"2020","unstructured":"Tripp J.C.; Norman S.B.; Kim H.M.; Venners M.R.; Martis B.; Simon N.M.; Stein M.B.; Allard C.B.; Rauch S.A.M.; Residual symptoms of PTSD following Sertraline plus enhanced medication management, Sertraline plus PE, and PE plus placebo. Psychiatry Res  2020,291,113279","journal-title":"Psychiatry Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1037\/tra0000384","volume":"11","author":"Larsen S.E.","year":"2019","unstructured":"Larsen S.E.; Fleming C.J.E.; Resick P.A.; Residual symptoms following empirically supported treatment for PTSD. Psychol Trauma  2019,11(2),207-215","journal-title":"Psychol Trauma"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/da.22871","volume":"36","author":"Schnurr P.P.","year":"2019","unstructured":"Schnurr P.P.; Lunney C.A.; Residual symptoms following prolonged exposure and present-centered therapy for PTSD in female veterans and soldiers. Depress Anxiety  2019,36(2),162-169","journal-title":"Depress Anxiety"},{"key":"ref=90","first-page":"39","volume":"12","author":"Usman M.","year":"2015","unstructured":"Usman M.; Rehman A.; Bakhtawar N.; Bhatti A.; Prognosis of ptsd in treated vs. non-treated groups. J Pak Psychiatr Soc  2015,12(1),39-42","journal-title":"J Pak Psychiatr Soc"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1176\/ps.62.3.pss6203_0272","volume":"62","author":"Doctor J.N.","year":"2011","unstructured":"Doctor J.N.; Zoellner L.A.; Feeny N.C.; Predictors of health-related quality-of-life utilities among persons with posttraumatic stress disorder. Psychiatr Serv  2011,62(3),272-277","journal-title":"Psychiatr Serv"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.comppsych.2015.01.002","volume":"58","author":"Pagotto L.F.","year":"2015","unstructured":"Pagotto L.F.; Mendlowicz M.V.; Coutinho E.S.F.; Figueira I.; Luz M.P.; Araujo A.X.; Berger W.; The impact of posttraumatic symptoms and comorbid mental disorders on the health-related quality of life in treatment-seeking PTSD patients. Compr Psychiatry  2015,58,68-73","journal-title":"Compr Psychiatry"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/MLR.0b013e31815dc5d2","volume":"46","author":"Kartha A.","year":"2008","unstructured":"Kartha A.; Brower V.; Saitz R.; Samet J.H.; Keane T.M.; Liebschutz J.; The impact of trauma exposure and post-traumatic stress disorder on healthcare utilization among primary care patients. Med Care  2008,46(4),388-393","journal-title":"Med Care"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/mp.2010.101","volume":"16","author":"Alonso J.","year":"2011","unstructured":"Alonso J.; Petukhova M.; Vilagut G.; Chatterji S.; Heeringa S.; \u00dcst\u00fcn T.B.; Alhamzawi A.O.; Viana M.C.; Angermeyer M.; Bromet E.; Bruffaerts R.; de Girolamo G.; Florescu S.; Gureje O.; Haro J.M.; Hinkov H.; Hu C.; Karam E.G.; Kovess V.; Levinson D.; Medina-Mora, M.E.; Nakamura, Y.; Ormel, J.; Posada-Villa, J.; Sagar, R.; Scott, K.M.; Tsang, A.; Williams, D.R.; Kessler, R.C. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol Psychiatry  2011,16(12),1234-1246","journal-title":"Mol Psychiatry"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cpr.2018.08.003","volume":"65","author":"Campbell S.B.","year":"2018","unstructured":"Campbell S.B.; Renshaw K.D.; Posttraumatic stress disorder and relationship functioning: A comprehensive review and organizational framework. Clin Psychol Rev  2018,65,152-162","journal-title":"Clin Psychol Rev"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jad.2006.09.018","volume":"101","author":"Bernal M.","year":"2007","unstructured":"Bernal M.; Haro J.M.; Bernert S.; Brugha T.; de Graaf R.; Bruffaerts R.; L\u00e9pine J.P.; de Girolamo G.; Vilagut G.; Gasquet I.; Torres J.V.; Kovess V.; Heider D.; Neeleman J.; Kessler R.; Alonso J.; Risk factors for suicidality in Europe: Results from the ESEMED study. J Affect Disord  2007,101(1-3),27-34","journal-title":"J Affect Disord"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.janxdis.2010.11.010","volume":"25","author":"Pietrzak R.H.","year":"2011","unstructured":"Pietrzak R.H.; Goldstein R.B.; Southwick S.M.; Grant B.F.; Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: Results from wave 2 of the national epidemiologic survey on alcohol and related conditions. J Anxiety Disord  2011,25(3),456-465","journal-title":"J Anxiety Disord"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/archgenpsychiatry.2008.557","volume":"66","author":"Wilcox H.C.","year":"2009","unstructured":"Wilcox H.C.; Storr C.L.; Breslau N.; Posttraumatic stress disorder and suicide attempts in a community sample of urban american young adults. Arch Gen Psychiatry  2009,66(3),305-311","journal-title":"Arch Gen Psychiatry"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/da.22160","volume":"30","author":"Stevens D.","year":"2013","unstructured":"Stevens D.; Wilcox H.C.; MacKinnon DF; Posttraumatic stress disorder increases risk for suicide attempt in adults with recurrent major depression. Depress Anxiety  2013,30(10),940-946","journal-title":"Depress Anxiety"},{"key":"ref=100","first-page":"121","author":"Pausch M.J.","year":"2022","unstructured":"Pausch M.J.; Matten S.J.;  Trauma and Trauma Consequence Disorder:\nIn Media, Management and Public; Springer Nature  2022,121","journal-title":"Trauma and Trauma Consequence Disorder:\nIn Media, Management and Public; Springer Nature"},{"key":"ref=101","first-page":"1","volume":"1","author":"Kraepelin E.","year":"1896","unstructured":"Kraepelin E.; Der psychologische Versuch in der Psychiatrie. Psychologische Arbeiten  1896,1,1-91","journal-title":"Psychologische Arbeiten"},{"key":"ref=102","author":"Freud S.","year":"2004","unstructured":"Freud S.; Breuer J.;  Studies in hysteria  2004","journal-title":"Studies in hysteria"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/0964704X.2019.1711350","volume":"29","author":"Gasquoine P.G.","year":"2020","unstructured":"Gasquoine P.G.; Railway spine: The advent of compensation for concussive symptoms. J Hist Neurosci  2020,29(2),234-245","journal-title":"J Hist Neurosci"},{"key":"ref=104","author":"Dutil A.","year":"1889","unstructured":"Dutil A.;  Hysteria and associated neurasthenia (railway-spine and traumatic neurosis), by A Dutil: O Doin; P  1889","journal-title":"Hysteria and associated neurasthenia (railway-spine and traumatic neurosis), by A Dutil: O Doin; P"},{"key":"ref=105","author":"Erichsen J.E.","year":"1866","unstructured":"Erichsen J.E.;  Clinical Lecture  1866","journal-title":"Clinical Lecture"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1176\/ajp.98.4.624","volume":"98","author":"Steckel H.A.","year":"1942","unstructured":"Steckel H.A.; The traumatic neuroses of war. Am J Psychiatry  1942,98(4),624-625","journal-title":"Am J Psychiatry"},{"key":"ref=107","doi-asserted-by":"publisher","DOI":"10.1037\/10784-000","year":"1945","unstructured":"GrinkerRRSpiegelJPMen under stress. Blakiston  1945","journal-title":"Blakiston"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1037\/10784-004","author":"Grinker R.R.","year":"1945","unstructured":"Grinker R.R.; Spiegel J.P.; Reactions to combat, based on previous emotional disorders. Men under stress  1945,53-81","journal-title":"Men under stress"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.mayocp.2020.06.002","volume":"95","author":"Vance M.C.","year":"2020","unstructured":"Vance M.C.; Howell J.D.; Shell shock and PTSD: A tale of two diagnoses. Mayo Clin Proc  2020,95(9),1827-1830","journal-title":"Mayo Clin Proc"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-09081-8_1","author":"Miller L.","year":"2015","unstructured":"Miller L.;  History of the PTSD Concept and Its Relation to the LawPTSD and Forensic Psychology: Applications to Civil and Criminal Law SpringerBriefs in Psychology  2015,1-7","journal-title":"History of the PTSD Concept and Its Relation to the LawPTSD and Forensic Psychology: Applications to Civil and Criminal Law SpringerBriefs in Psychology"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1098\/rstb.2006.1814","volume":"361","author":"Jones E.","year":"2006","unstructured":"Jones E.; Historical approaches to post-combat disorders. Philos Trans R Soc Lond B Biol Sci  2006,361(1468),533-542","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=112","first-page":"669","volume":"11","author":"Jablonski R.K.","year":"2015","unstructured":"Jablonski R.K.; Leszek J.; Rosi\u0144czuk J.; Uchmanowicz I.; Panaszek B.; Impact of incarceration in Nazi concentration camps on multi-morbidity of former prisoners. Neuropsychiatr Dis Treat  2015,11,669-674","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=113","author":"Trautman E.C.","year":"1967","unstructured":"Trautman E.C.;  Concentration Camp Survivors in Norway and Israel  1967","journal-title":"Concentration Camp Survivors in Norway and Israel"},{"key":"ref=114","year":"1952","unstructured":"Diagnostic and Statistical Manual of Mental Disorders American Psychiatric Association (APA) 1952","journal-title":"Diagnostic and Statistical Manual of Mental Disorders"},{"key":"ref=115","year":"1968","unstructured":"Diagnostic and Statistical Manual of Mental Disorders American Psychiatric Association (APA) 1968","journal-title":"Diagnostic and Statistical Manual of Mental Disorders"},{"key":"ref=116","year":"1980","unstructured":"The Diagnostic and\nStatistical Manual of Mental Disorders, Third Edition (DSM-III) American Psychiatric Association (APA) 1980","journal-title":"The Diagnostic and\nStatistical Manual of Mental Disorders, Third Edition (DSM-III)"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamapsychiatry.2022.4092","volume":"80","author":"Bryant R.A.","year":"2023","unstructured":"Bryant R.A.; Galatzer-Levy I.; Hadzi-Pavlovic D.; The heterogeneity of posttraumatic stress disorder in DSM-5. JAMA Psychiat  2023,80(2),189-191","journal-title":"JAMA Psychiat"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"ecollection\n2014","DOI":"10.3402\/ejpt.v5.23797","volume":"5","author":"Lehrner A.","year":"2014","unstructured":"Lehrner A.; Yehuda R.; Biomarkers of PTSD: Military applications\nand considerations. Eur J Psychotraumatol  2014,5,ecollection\n2014","journal-title":"Eur J Psychotraumatol"},{"key":"ref=119","first-page":"352","volume":"1071","year":"2006","unstructured":"Psychobiology of\nPosttraumatic Stress Disorder: A Decade of Progress  2006,1071,352","journal-title":"Psychobiology of\nPosttraumatic Stress Disorder: A Decade of Progress"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/da.22133","volume":"31","author":"Zoellner L.A.","year":"2014","unstructured":"Zoellner L.A.; Pruitt L.D.; Farach F.J.; Jun J.J.; Understanding heterogeneity in PTSD: Fear, dysphoria, and distress. Depress Anxiety  2014,31(2),97-106","journal-title":"Depress Anxiety"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"141","DOI":"10.31887\/DCNS.2015.17.2\/jflory","volume":"17","author":"Flory J.D.","year":"2015","unstructured":"Flory J.D.; Yehuda R.; Comorbidity between post-traumatic stress disorder and major depressive disorder: Alternative explanations and treatment considerations. Dialogues Clin Neurosci  2015,17(2),141-150","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/070674371405900902","volume":"59","author":"Sareen J.","year":"2014","unstructured":"Sareen J.; Posttraumatic stress disorder in adults: Impact, comorbidity, risk factors, and treatment. Can J Psychiatry  2014,59(9),460-467","journal-title":"Can J Psychiatry"},{"key":"ref=123","author":"Van der Kolk B.A.","year":"2012","unstructured":"Van der Kolk B.A.; McFarlane A.C.; Weisaeth L.;  Traumatic stress: The effects of overwhelming experience on mind, body, and society  2012","journal-title":"Traumatic stress: The effects of overwhelming experience on mind, body, and society"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1037\/a0016401","volume":"40","author":"Bernal G.","year":"2009","unstructured":"Bernal G.; Jim\u00e9nez-Chafey M.I.; Domenech R.M.M.; Cultural adaptation of treatments: A resource for considering culture in evidence-based practice. Prof Psychol Res Pr  2009,40(4),361-368","journal-title":"Prof Psychol Res Pr"},{"key":"ref=125","author":"Yehuda R.","year":"2008","unstructured":"Yehuda R.; Treating trauma survivors with PTSD: American Psychiatric\nPub,  2008"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1037\/pas0000223","volume":"28","author":"Monson E.","year":"2016","unstructured":"Monson E.; Lonergan M.; Caron J.; Brunet A.; Assessing trauma and posttraumatic stress disorder: Single, open-ended question versus list-based inventory. Psychol Assess  2016,28(8),1001-1008","journal-title":"Psychol Assess"},{"key":"ref=127","author":"Livingston N.A.","unstructured":"Livingston N.A.; Brief D.; Miller M.; Keane T.;   Assessment of\nPTSD and its comorbidities in adults; Handbook of PTSD; Science\nand practice, 2021, p. 283."},{"key":"ref=128","author":"Weathers F.W.","year":"2013","unstructured":"Weathers F.W.; Blake D.D.; Schnurr P.P.; Kaloupek D.G.; Marx B.P.; Keane T.M.;  The Clinician-Administered PTSD Scale\nfor DSM-5 (CAPS-5) [Assessment]  Available from  www.ptsd.va.gov2013","journal-title":"The Clinician-Administered PTSD Scale\nfor DSM-5 (CAPS-5) [Assessment]"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/9781118625392.wbecp351","author":"First M.B.","year":"2015","unstructured":"First M.B.;  Structured Clinical Interview for the DSM (SCID) The Encyclopedia of Clinical Psychology  2015,1-6","journal-title":"Structured Clinical Interview for the DSM (SCID) The Encyclopedia of Clinical Psychology"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-1781(96)03001-6","volume":"69","author":"Shalev A.Y.","year":"1997","unstructured":"Shalev A.Y.; Peri T.; Orr S.P.; Bonne O.; Pitman R.K.; Auditory startle responses in help-seeking trauma survivors. Psychiatry Res  1997,69(1),1-7","journal-title":"Psychiatry Res"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1037\/0021-843X.104.1.75","volume":"104","author":"Orr S.P.","year":"1995","unstructured":"Orr S.P.; Lasko N.B.; Shalev A.Y.; Pitman R.K.; Physiologic responses to loud tones in Vietnam veterans with posttraumatic stress disorder. J Abnorm Psychol  1995,104(1),75-82","journal-title":"J Abnorm Psychol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neuron.2007.09.006","volume":"56","author":"Yehuda R.","year":"2007","unstructured":"Yehuda R.; LeDoux J.; Response variation following trauma: A translational neuroscience approach to understanding PTSD. Neuron  2007,56(1),19-32","journal-title":"Neuron"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0006-3223(99)00009-8","volume":"45","author":"Bremner J.D.","year":"1999","unstructured":"Bremner J.D.; Does stress damage the brain? Biol Psychiatry  1999,45(7),797-805","journal-title":"Biol Psychiatry"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0006-3223(96)00162-X","volume":"41","author":"Bremner J.D.","year":"1997","unstructured":"Bremner J.D.; Randall P.; Vermetten E.; Staib L.; Bronen R.A.; Mazure C.; Capelli S.; McCarthy G.; Innis R.B.; Charney D.S.; Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse\u2014a preliminary report. Biol Psychiatry  1997,41(1),23-32","journal-title":"Biol Psychiatry"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0079-6123(07)67026-5","volume":"167","author":"Geuze E.","year":"2007","unstructured":"Geuze E.; Vermetten E.; de Kloet C.S.; Westenberg H.G.M.; Precuneal activity during encoding in veterans with posttraumatic\nstress disorder. Prog Brain Res  2007,167,293-297","journal-title":"Prog Brain Res"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/brain\/awl004","volume":"129","author":"Cavanna A.E.","year":"2006","unstructured":"Cavanna A.E.; Trimble M.R.; The precuneus: A review of its functional anatomy and behavioural correlates. Brain  2006,129(3),564-583","journal-title":"Brain"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/09540261.2021.1919062","volume":"33","author":"Bird C.I.V.","year":"2021","unstructured":"Bird C.I.V.; Modlin N.L.; Rucker J.J.H.; Psilocybin and MDMA for the treatment of trauma-related psychopathology. Int Rev Psychiatry  2021,33(3),229-249","journal-title":"Int Rev Psychiatry"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00406-005-0617-3","volume":"256","author":"Jatzko A.","year":"2006","unstructured":"Jatzko A.; Schmitt A.; Demirakca T.; Weimer E.; Braus D.F.; Disturbance in the neural circuitry underlying positive emotional processing in post-traumatic stress disorder (PTSD). Eur Arch Psychiatry Clin Neurosci  2006,256(2),112-114","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.neuroimage.2005.02.032","volume":"26","author":"Sakamoto H.","year":"2005","unstructured":"Sakamoto H.; Fukuda R.; Okuaki T.; Rogers M.; Kasai K.; Machida T.; Shirouzu I.; Yamasue H.; Akiyama T.; Kato N.; Parahippo-campal activation evoked by masked traumatic images in posttraumatic stress disorder: A functional MRI study. Neuroimage  2005,26(3),813-821","journal-title":"Neuroimage"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jpsychires.2010.10.011","volume":"45","author":"St. Jacques P.L.","year":"2011","unstructured":"St. Jacques P.L.; Botzung A.; Miles A.; Rubin D.C.; Functional neuroimaging of emotionally intense autobiographical memories in post-traumatic stress disorder. J Psychiatr Res  2011,45(5),630-637","journal-title":"J Psychiatr Res"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.biopsych.2010.07.018","volume":"68","author":"Brohawn K.H.","year":"2010","unstructured":"Brohawn K.H.; Offringa R.; Pfaff D.L.; Hughes K.C.; Shin L.M.; The neural correlates of emotional memory in posttraumatic stress disorder. Biol Psychiatry  2010,68(11),1023-1030","journal-title":"Biol Psychiatry"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1503\/jpn.110069","volume":"37","author":"Sripada R.K.","year":"2012","unstructured":"Sripada R.K.; King A.P.; Garfinkel S.N.; Wang X.; Sripada C.S.; Welsh R.C.; Liberzon I.; Altered resting-state amygdala functional connectivity in men with posttraumatic stress disorder. J Psychiatry Neurosci  2012,37(4),241-249","journal-title":"J Psychiatry Neurosci"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/HRP.0000000000000185","volume":"26","author":"Fitzgerald J.M.","year":"2018","unstructured":"Fitzgerald J.M.; DiGangi J.A.; Phan K.L.; Functional neuroanatomy of emotion and its regulation in PTSD. Harv Rev Psychiatry  2018,26(3),116-128","journal-title":"Harv Rev Psychiatry"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"445","DOI":"10.31887\/DCNS.2006.8.4\/jbremner","volume":"8","author":"Bremner J.D.","year":"2006","unstructured":"Bremner J.D.; Traumatic stress: Effects on the brain. Dialogues Clin Neurosci  2006,8(4),445-461","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1196\/annals.1364.007","volume":"1071","author":"Shin L.M.","year":"2006","unstructured":"Shin L.M.; Rauch S.L.; Pitman R.K.; Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann N Y Acad Sci  2006,1071(1),67-79","journal-title":"Ann N Y Acad Sci"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/jmri.26929","volume":"52","author":"Kunimatsu A.","year":"2020","unstructured":"Kunimatsu A.; Yasaka K.; Akai H.; Kunimatsu N.; Abe O.; MRI findings in posttraumatic stress disorder. J Magn Reson Imaging  2020,52(2),380-396","journal-title":"J Magn Reson Imaging"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0006-3223(02)01466-X","volume":"53","author":"Lanius R.A.","year":"2003","unstructured":"Lanius R.A.; Williamson P.C.; Hopper J.; Densmore M.; Boksman K.; Gupta M.A.; Neufeld R.W.J.; Gati J.S.; Menon R.S.; Recall of emotional states in posttraumatic stress disorder: An fMRI investigation. Biol Psychiatry  2003,53(3),204-210","journal-title":"Biol Psychiatry"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/da.21889","volume":"29","author":"Lanius R.A.","year":"2012","unstructured":"Lanius R.A.; Brand B.; Vermetten E.; Frewen P.A.; Spiegel D.; The dissociative subtype of posttraumatic stress disorder: Rationale, clinical and neurobiological evidence, and implications. Depress Anxiety  2012,29(8),701-708","journal-title":"Depress Anxiety"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.pnpbp.2018.10.010","volume":"89","author":"Dunlop B.W.","year":"2019","unstructured":"Dunlop B.W.; Wong A.; The hypothalamicpituitaryadrenal axis in PTSD: Pathophysiology and treatment interventions. Prog Neuropsychopharmacol Biol Psychiatry  2019,89,361-379","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.psyneuen.2011.07.003","volume":"37","author":"Klaassens E.R.","year":"2012","unstructured":"Klaassens E.R.; Giltay E.J.; Cuijpers P.; van Veen T.; Zitman F.G.; Adulthood trauma and HPA-axis functioning in healthy subjects and PTSD patients: A meta-analysis. Psychoneuroendocrinology  2012,37(3),317-331","journal-title":"Psychoneuroendocrinology"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0306-4530(03)00052-0","volume":"29","author":"Yehuda R.","year":"2004","unstructured":"Yehuda R.; Halligan S.L.; Golier J.A.; Grossman R.; Bierer L.M.; Effects of trauma exposure on the cortisol response to dexamethasone administration in PTSD and major depressive disorder. Psychoneuroendocrinology  2004,29(3),389-404","journal-title":"Psychoneuroendocrinology"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.janxdis.2021.102443","volume":"82","author":"Shi C.","year":"2021","unstructured":"Shi C.; Ren Z.; Zhao C.; Zhang T.; Chan S.H.; Shame, guilt, and\nposttraumatic stress symptoms: A three-level meta-analysis. J Anxiety\nDisord  Epub 2021 Jul 22021,82,102443","journal-title":"J Anxiety\nDisord"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.neubiorev.2016.09.019","volume":"71","author":"Bastin C.","year":"2016","unstructured":"Bastin C.; Harrison B.J.; Davey C.G.; Moll J.; Whittle S.; Feelings of shame, embarrassment and guilt and their neural correlates: A systematic review. Neurosci Biobehav Rev  2016,71,455-471","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/da.23128","volume":"38","author":"Lloyd C.S.","year":"2021","unstructured":"Lloyd C.S.; Nicholson A.A.; Densmore M.; Th\u00e9berge J.; Neufeld R.W.J.; Jetly R.; McKinnon M.C.; Lanius R.A.; Shame on the brain: Neural correlates of moral injury event recall in posttraumatic stress disorder. Depress Anxiety  2021,38(6),596-605","journal-title":"Depress Anxiety"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0006-3223(02)01909-1","volume":"53","author":"Cohen H.","year":"2003","unstructured":"Cohen H.; Zohar J.; Matar M.; The relevance of differential response to trauma in an animal model of posttraumatic stress disorder. Biol Psychiatry  2003,53(6),463-473","journal-title":"Biol Psychiatry"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41583-021-00540-x","volume":"23","author":"Sanacora G.","year":"2022","unstructured":"Sanacora G.; Yan Z.; Popoli M.; The stressed synapse 2.0: Pathophysiological mechanisms in stress-related neuropsychiatric disorders. Nat Rev Neurosci  2022,23(2),86-103","journal-title":"Nat Rev Neurosci"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nm.4050","volume":"22","author":"Duman R.S.","year":"2016","unstructured":"Duman R.S.; Aghajanian G.K.; Sanacora G.; Krystal J.H.; Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med  2016,22(3),238-249","journal-title":"Nat Med"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bbi.2012.08.015","volume":"30","author":"van Zuiden M.","year":"2013","unstructured":"van Zuiden M.; Kavelaars A.; Geuze E.; Olff M.; Heijnen C.J.; Predicting PTSD: Pre-existing vulnerabilities in glucocorticoid-signaling and implications for preventive interventions. Brain Behav Immun  2013,30,12-21","journal-title":"Brain Behav Immun"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"e1002379","DOI":"10.1371\/journal.pcbi.1002379","volume":"8","author":"Sriram K.","year":"2012","unstructured":"Sriram K.; Rodriguez-Fernandez M.; Doyle F.J.; Modeling cortisol dynamics in the neuro-endocrine axis distinguishes normal, depression, and post-traumatic stress disorder (PTSD) in humans. PLOS Comput Biol  2012,8(2),e1002379","journal-title":"PLOS Comput Biol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1023\/A:1015055711424","volume":"73","author":"Yehuda R.","year":"2002","unstructured":"Yehuda R.; Clinical relevance of biologic findings in PTSD. Psychiatr Q  2002,73(2),123-133","journal-title":"Psychiatr Q"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1176\/ajp.150.1.83","volume":"150","author":"Yehuda R.","year":"1993","unstructured":"Yehuda R.; Southwick S.M.; Krystal J.H.; Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am J Psychiatry  1993,150(1),83-86","journal-title":"Am J Psychiatry"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.psyneuen.2011.04.008","volume":"36","author":"Jovanovic T.","year":"2011","unstructured":"Jovanovic T.; Phifer J.E.; Sicking K.; Weiss T.; Norrholm S.D.; Bradley B.; Ressler K.J.; Cortisol suppression by dexamethasone reduces exaggerated fear responses in posttraumatic stress disorder. Psychoneuroendocrinology  2011,36(10),1540-1552","journal-title":"Psychoneuroendocrinology"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.psyneuen.2017.12.002","volume":"88","author":"Inslicht S.S.","year":"2018","unstructured":"Inslicht S.S.; Rao M.N.; Richards A.; O\u2019Donovan A.; Gibson C.J.; Baum T.; Metzler T.J.; Neylan T.C.; Sleep and hypothalamic pituitary adrenal axis responses to metyrapone in posttraumatic stress disorder. Psychoneuroendocrinology  2018,88,136-143","journal-title":"Psychoneuroendocrinology"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/sj.npp.1300215","volume":"28","author":"Neylan T.C.","year":"2003","unstructured":"Neylan T.C.; Lenoci M.; Maglione M.L.; Rosenlicht N.Z.; Metzler T.J.; Otte C.; Schoenfeld F.B.; Yehuda R.; Marmar C.R.; Delta sleep response to metyrapone in post-traumatic stress disorder. Neuropsychopharmacology  2003,28(9),1666-1676","journal-title":"Neuropsychopharmacology"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41398-019-0539-x","volume":"9","author":"Breen M.S.","year":"2019","unstructured":"Breen M.S.; Bierer L.M.; Daskalakis N.P.; Bader H.N.; Makotkine I.; Chattopadhyay M.; Xu C.; Buxbaum Grice A.; Tocheva A.S.; Flory J.D.; Buxbaum J.D.; Meaney M.J.; Brennand K.; Yehuda R.; Differential transcriptional response following glucocorticoid activation in cultured blood immune cells: A novel approach to PTSD biomarker development. Transl Psychiatry  2019,9(1),201","journal-title":"Transl Psychiatry"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41593-022-01161-y","volume":"25","author":"Seah C.","year":"2022","unstructured":"Seah C.; Breen M.S.; Rusielewicz T.; Bader H.N.; Xu C.; Hunter C.J.; McCarthy B.; Deans P.J.M.; Chattopadhyay M.; Goldberg J.; Desarnaud F.; Makotkine I.; Flory J.D.; Bierer L.M.; Staniskyte M.; Bauer L.; Brenner K.; Buckley-Herd G.; DesMarteau S.; Fenton P.; Ferrarotto P.; Hall J.; Jacob S.; Kroeker T.; Lallos G.; Martinez H.; McCoy P.; Monsma F.J.; Moroziewicz D.; Otto R.; Reggio K.; Sun B.; Tibbets R.; Shin D.W.; Zhou H.; Zimmer M.; Noggle S.A.; Huckins L.M.; Paull D.; Brennand K.J.; Yehuda R.; Modeling gene \u00d7 environment interactions in PTSD using human neurons reveals diagnosis-specific glucocorticoid-induced gene expression. Nat Neurosci  2022,25(11),1434-1445","journal-title":"Nat Neurosci"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"678548","DOI":"10.3389\/fnins.2021.678548","volume":"15","author":"Garrett M.E.","year":"2021","unstructured":"Garrett M.E.; Qin X.J.; Mehta D.; Dennis M.F.; Marx C.E.; Grant G.A.; Stein M.B.; Kimbrel N.A.; Beckham J.C.; Hauser M.A.; Ashley-Koch A.E.; Gene expression analysis in three posttraumatic stress disorder cohorts implicates inflammation and innate immunity pathways and uncovers shared genetic risk with major depressive disorder. Front Neurosci  2021,15,678548","journal-title":"Front Neurosci"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2215-0366(15)00309-0","volume":"2","author":"Passos I.C.","year":"2015","unstructured":"Passos I.C.; Vasconcelos-Moreno M.P.; Costa L.G.; Kunz M.; Brietzke E.; Quevedo J.; Salum G.; Magalh\u00e3es P.V.; Kapczinski F.; Kauer-Sant\u2019Anna M.; Inflammatory markers in post-traumatic stress disorder: A systematic review, meta-analysis, and meta-regression. Lancet Psychiatry  2015,2(11),1002-1012","journal-title":"Lancet Psychiatry"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bbi.2016.10.014","volume":"60","author":"O\u2019Donovan A.","year":"2017","unstructured":"O\u2019Donovan A.; Ahmadian A.J.; Neylan T.C.; Pacult M.A.; Edmondson D.; Cohen B.E.; Current posttraumatic stress disorder and exaggerated threat sensitivity associated with elevated inflammation in the Mind Your Heart Study. Brain Behav Immun  2017,60,198-205","journal-title":"Brain Behav Immun"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/antiox9020107","volume":"9","author":"Kim T.D.","year":"2020","unstructured":"Kim T.D.; Lee S.; Yoon S.; Inflammation in post-traumatic stress disorder (PTSD): A review of potential correlates of PTSD with a neurological perspective. Antioxidants  2020,9(2),107","journal-title":"Antioxidants"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fpsyt.2013.00118","volume":"4","author":"Yehuda R.","year":"2013","unstructured":"Yehuda R.; Daskalakis N.P.; Desarnaud F.; Makotkine I.; Lehrner A.L.; Koch E.; Flory J.D.; Buxbaum J.D.; Meaney M.J.; Bierer L.M.; Epigenetic biomarkers as predictors and correlates of symptom improvement following psychotherapy in combat veterans with PTSD. Front Psychiatry  2013,4,118","journal-title":"Front Psychiatry"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.biopsych.2014.02.006","volume":"77","author":"Yehuda R.","year":"2015","unstructured":"Yehuda R.; Flory J.D.; Bierer L.M.; Henn-Haase C.; Lehrner A.; Desarnaud F.; Makotkine I.; Daskalakis N.P.; Marmar C.R.; Meaney M.J.; Lower methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of veterans with posttraumatic stress disorder. Biol Psychiatry  2015,77(4),356-364","journal-title":"Biol Psychiatry"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"31","DOI":"10.12703\/r\/11-31","volume":"11","author":"Carvalho V.S.","year":"2022","unstructured":"Carvalho V.S.; Gomes W.R.; Calado R.T.; Recent advances in understanding telomere diseases. Fac Rev  2022,11,31","journal-title":"Fac Rev"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1038\/s41598-017-04682-w","volume":"7","author":"Kim T.Y.","year":"2017","unstructured":"Kim T.Y.; Kim S.J.; Choi J.R.; Lee S-T.; Kim J.; Hwang I.S.; Chung H.G.; Choi J.H.; Kim H.W.; Kim S.H.; Kang J.I.; The effect of trauma and PTSD on telomere length: An exploratory study in people exposed to combat trauma. Sci Rep  2017,7(1),4375","journal-title":"Sci Rep"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.biopsych.2018.02.007","volume":"83","author":"Mellon S.H.","year":"2018","unstructured":"Mellon S.H.; Gautam A.; Hammamieh R.; Jett M.; Wolkowitz O.M.; Metabolism, metabolomics, and inflammation in posttraumatic stress disorder. Biol Psychiatry  2018,83(10),866-875","journal-title":"Biol Psychiatry"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1038\/s41380-019-0496-z","volume":"25","author":"Dean K.R.","year":"2020","unstructured":"Dean K.R.; Hammamieh R.; Mellon S.H.; Abu-Amara D.; Flory J.D.; Guffanti G.; Wang K.; Daigle B.J.; Gautam A.; Lee I.; Yang R.; Almli L.M.; Bersani F.S.; Chakraborty N.; Donohue D.; Kerley K.; Kim T-K.; Laska E.; Young Lee M.; Lindqvist D.; Lori A.; Lu L.; Misganaw B.; Muhie S.; Newman J.; Price N.D.; Qin S.; Reus V.I.; Siegel C.; Somvanshi P.R.; Thakur G.S.; Zhou Y.; Hood L.; Ressler K.J.; Wolkowitz O.M.; Yehuda R.; Jett M.; Doyle F.J.; Marmar C.; Multi-omic biomarker identification and validation for diagnosing warzone-related post-traumatic stress disorder. Mol Psychiatry  2020,25(12),3337-3349","journal-title":"Mol Psychiatry"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.euroneuro.2021.11.009","volume":"56","author":"Malan-Muller S.","year":"2022","unstructured":"Malan-Muller S.; Valles-Colomer M.; Foxx C.L.; Vieira-Silva S.; van den Heuvel L.L.; Raes J.; Seedat S.; Lowry C.A.; Hemmings S.M.J.; Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls. Eur Neuropsychopharmacol  2022,56,24-38","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1038\/s41380-020-00966-2","volume":"26","author":"Yang R.","year":"2021","unstructured":"Yang R.; Gautam A.; Getnet D.; Daigle B.J.; Miller S.; Misganaw B.; Dean K.R.; Kumar R.; Muhie S.; Wang K.; Lee I.; Abu-Amara D.; Flory J.D.; Hoke A.; Chakraborty N.; Petzold L.; Wu G.; Guffanti G.; Kim T-K.; Lee M.Y.; Bierer L.; Hood L.; Wolkowitz O.M.; Mellon S.H.; Doyle F.J.; Yehuda R.; Marmar C.R.; Ressler K.J.; Hammamieh R.; Jett M.; Epigenetic biotypes of post-traumatic stress disorder in war-zone exposed veteran and active duty males. Mol Psychiatry  2021,26(8),4300-4314","journal-title":"Mol Psychiatry"},{"key":"ref=179","first-page":"429","author":"Friedman M.J.","year":"1995","unstructured":"Friedman M.J.; Yehuda R.;  Post-traumatic stress disorder and comorbidity: Psychobiological approaches to differential diagnosis Neurobiological and clinical consequences of stress: From normal adaptation to post-traumatic stress disorder  1995,429-445","journal-title":"Post-traumatic stress disorder and comorbidity: Psychobiological approaches to differential diagnosis Neurobiological and clinical consequences of stress: From normal adaptation to post-traumatic stress disorder"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"1729633","DOI":"10.1080\/20008198.2020.1729633","volume":"11","author":"Lewis C.","year":"2020","unstructured":"Lewis C.; Roberts N.P.; Andrew M.; Starling E.; Bisson J.I.; Psychological therapies for post-traumatic stress disorder in adults: Systematic review and meta-analysis. Eur J Psychotraumatol  2020,11(1),1729633","journal-title":"Eur J Psychotraumatol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1176\/appi.ajp.2009.09050617","volume":"167","author":"Bryant R.A.","year":"2010","unstructured":"Bryant R.A.; O\u2019Donnell M.L.; Creamer M.; McFarlane A.C.; Clark C.R.; Silove D.; The psychiatric sequelae of traumatic injury. Am J Psychiatry  2010,167(3),312-320","journal-title":"Am J Psychiatry"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"19979","DOI":"10.3402\/ejpt.v4i0.19979","volume":"4","author":"Nijdam M.J.","year":"2013","unstructured":"Nijdam M.J.; Gersons B.P.R.; Olff M.; The role of major depression in neurocognitive functioning in patients with posttraumatic stress disorder. Eur J Psychotraumatol  2013,4(1),19979","journal-title":"Eur J Psychotraumatol"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jclp.20279","volume":"62","author":"Green B.L.","year":"2006","unstructured":"Green B.L.; Krupnick J.L.; Chung J.; Siddique J.; Krause E.D.; Revicki D.; Frank L.; Miranda J.; Impact of PTSD comorbidity on one-year outcomes in a depression trial. J Clin Psychol  2006,62(7),815-835","journal-title":"J Clin Psychol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jad.2014.03.016","volume":"161","author":"Ramsawh H.J.","year":"2014","unstructured":"Ramsawh H.J.; Fullerton C.S.; Mash H.B.H.; Ng T.H.H.; Kessler R.C.; Stein M.B.; Ursano R.J.; Risk for suicidal behaviors associated with PTSD, depression, and their comorbidity in the U.S. Army. J Affect Disord  2014,161,116-122","journal-title":"J Affect Disord"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cpr.2015.02.007","volume":"38","author":"Roberts N.P.","year":"2015","unstructured":"Roberts N.P.; Roberts P.A.; Jones N.; Bisson J.I.; Psychological interventions for post-traumatic stress disorder and comorbid substance use disorder: A systematic review and meta-analysis. Clin Psychol Rev  2015,38,25-38","journal-title":"Clin Psychol Rev"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1037\/adb0000486","volume":"33","author":"Goldberg S.B.","year":"2019","unstructured":"Goldberg S.B.; Livingston W.S.; Blais R.K.; Brignone E.; Suo Y.; Lehavot K.; Simpson T.L.; Fargo J.; Gundlapalli A.V.; A positive screen for military sexual trauma is associated with greater risk for substance use disorders in women veterans. Psychol Addict Behav  2019,33(5),477-483","journal-title":"Psychol Addict Behav"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/add.14565","volume":"114","author":"Simpson T.L.","year":"2019","unstructured":"Simpson T.L.; Rise P.; Browne K.C.; Lehavot K.; Kaysen D.; Clinical presentations, social functioning, and treatment receipt among individuals with comorbid life-time PTSD and alcohol use disorders versus drug use disorders: Findings from NESARC-III. Addiction  2019,114(6),983-993","journal-title":"Addiction"},{"key":"ref=188","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/jts.20482","volume":"23","author":"McDevitt-Murphy M.E.","year":"2010","unstructured":"McDevitt-Murphy M.E.; Williams J.L.; Bracken K.L.; PTSD symptoms, hazardous drinking, and health functioning among U.S. OEF and OIF veterans presenting to primary care. J Traumat Stress  2010,23(1),108-111","journal-title":"J Traumat Stress"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jad.2009.08.006","volume":"123","author":"Ginzburg K.","year":"2010","unstructured":"Ginzburg K.; Ein-Dor T.; Solomon Z.; Comorbidity of posttraumatic stress disorder, anxiety and depression: A 20-year longitudinal study of war veterans. J Affect Disord  2010,123(1-3),249-257","journal-title":"J Affect Disord"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"20442","DOI":"10.1038\/s41598-020-75706-1","volume":"10","author":"Wolfson P.E.","year":"2020","unstructured":"Wolfson P.E.; Andries J.; Feduccia A.A.; Jerome L.; Wang J.B.; Williams E.; Carlin S.C.; Sola E.; Hamilton S.; Yazar-Klosinski B.; Emerson A.; Mithoefer M.C.; Doblin R.; MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: A randomized pilot study. Sci Rep  2020,10(1),20442","journal-title":"Sci Rep"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1177\/070674370204701004","volume":"47","author":"Asmundson G.J.G.","year":"2002","unstructured":"Asmundson G.J.G.; Coons M.J.; Taylor S.; Katz J.; PTSD and the experience of pain: Research and clinical implications of shared vulnerability and mutual maintenance models. Can J Psychiatry  2002,47(10),930-937","journal-title":"Can J Psychiatry"},{"key":"ref=192","first-page":"711","volume":"18","author":"Fishbain D.A.","year":"2017","unstructured":"Fishbain D.A.; Pulikal A.; Lewis J.E.; Gao J.; Chronic pain types differ in their reported prevalence of post -traumatic stress disorder (PTSD) and there is consistent evidence that chronic pain is associated with PTSD: An evidence-based structured systematic review. Pain Med  2017,18(4),711-735","journal-title":"Pain Med"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11916-019-0828-3","volume":"23","author":"Kind S.","year":"2019","unstructured":"Kind S.; Otis J.D.; The interaction between chronic pain and PTSD. Curr Pain Headache Rep  2019,23(12),91","journal-title":"Curr Pain Headache Rep"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.chest.2018.04.007","volume":"154","author":"El-Solh A.A.","year":"2018","unstructured":"El-Solh A.A.; Riaz U.; Roberts J.; Sleep disorders in patients with posttraumatic stress disorder. Chest  2018,154(2),427-439","journal-title":"Chest"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1053\/comp.2000.16568","volume":"41","author":"Ohayon M.M.","year":"2000","unstructured":"Ohayon M.M.; Shapiro C.M.; Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population. Compr Psychiatry  2000,41(6),469-478","journal-title":"Compr Psychiatry"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijchp.2014.11.002","volume":"15","author":"Britvi\u0107 D.","year":"2015","unstructured":"Britvi\u0107 D.; Anti\u010devi\u0107 V.; Kaliterna M.; Lu\u0161i\u0107 L.; Beg A.; Brajevi\u0107-Gizdi\u0107 I.; Kudri\u0107 M.; Stupalo \u017d.; Krolo V.; Pivac N.; Comorbidities with posttraumatic stress disorder (PTSD) among combat veterans: 15 years postwar analysis. Int J Clin Health Psychol  2015,15(2),81-92","journal-title":"Int J Clin Health Psychol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.janxdis.2012.08.004","volume":"27","author":"Pacella M.L.","year":"2013","unstructured":"Pacella M.L.; Hruska B.; Delahanty D.L.; The physical health consequences of PTSD and PTSD symptoms: A meta-analytic review. J Anxiety Disord  2013,27(1),33-46","journal-title":"J Anxiety Disord"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11920-018-0977-9","volume":"20","author":"Ryder A.L.","year":"2018","unstructured":"Ryder A.L.; Azcarate P.M.; Cohen B.E.; PTSD and physical health. Curr Psychiatry Rep  2018,20(12),116","journal-title":"Curr Psychiatry Rep"},{"key":"ref=199","author":"Foa E.B.","year":"2010","unstructured":"Foa E.B.; Keane T.M.; Friedman M.J.; Cohen J.A.;  Effective treatments for PTSD: practice guidelines from the International Society for Traumatic Stress Studies  2010","journal-title":"Effective treatments for PTSD: practice guidelines from the International Society for Traumatic Stress Studies"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11920-017-0757-y","volume":"19","author":"Krause-Utz A.","year":"2017","unstructured":"Krause-Utz A.; Frost R.; Winter D.; Elzinga B.M.; Dissociation and alterations in brain function and structure: implications for borderline personality disorder. Curr Psychiatry Rep  2017,19(1),6","journal-title":"Curr Psychiatry Rep"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jaac.2017.09.425","volume":"56","author":"Choi K.R.","year":"2017","unstructured":"Choi K.R.; Seng J.S.; Briggs E.C.; Munro-Kramer M.L.; Graham-Bermann S.A.; Lee R.C.; Ford J.D.; The dissociative subtype of post-traumatic stress disorder (PTSD) among adolescents: Co-occurring PTSD, depersonalization\/derealization, and other dissociation symptoms. J Am Acad Child Adolesc Psychiatry  2017,56(12),1062-1072","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/da.21920","volume":"29","author":"Cloitre M.","year":"2012","unstructured":"Cloitre M.; Petkova E.; Wang J.; Lu L.F.; An examination of the influence of a sequential treatment on the course and impact of dissociation among women with PTSD related to childhood abuse. Depress Anxiety  2012,29(8),709-717","journal-title":"Depress Anxiety"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1176\/appi.ajp.2009.09081168","volume":"167","author":"Lanius R.A.","year":"2010","unstructured":"Lanius R.A.; Vermetten E.; Loewenstein R.J.; Brand B.; Schmahl C.; Bremner J.D.; Spiegel D.; Emotion modulation in PTSD: Clinical and neurobiological evidence for a dissociative subtype. Am J Psychiatry  2010,167(6),640-647","journal-title":"Am J Psychiatry"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"Berman R.M.","year":"2000","unstructured":"Berman R.M.; Cappiello A.; Anand A.; Oren D.A.; Heninger G.R.; Charney D.S.; Krystal J.H.; Antidepressant effects of ketamine in depressed patients. Biol Psychiatry  2000,47(4),351-354","journal-title":"Biol Psychiatry"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jad.2018.02.049","volume":"232","author":"Niciu M.J.","year":"2018","unstructured":"Niciu M.J.; Shovestul B.J.; Jaso B.A.; Farmer C.; Luckenbaugh D.A.; Brutsche N.E.; Park L.T.; Ballard E.D.; Zarate C.A.; Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord  2018,232,310-315","journal-title":"J Affect Disord"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2174\/1570159X21666230428091433","volume":"22","author":"Burback L.","year":"2023","unstructured":"Burback L.; Br\u00e9mault-Phillips S.; Nijdam M.J.; McFarlane A.; Vermetten E.; Treatment of posttraumatic stress disorder: A state-of-the-art review. Curr Neuropharmacol  2023,22,627-705","journal-title":"Curr Neuropharmacol"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/da.21997","volume":"29","author":"Kearns M.C.","year":"2012","unstructured":"Kearns M.C.; Ressler K.J.; Zatzick D.; Rothbaum B.O.; Early interventions for PTSD: A review. Depress Anxiety  2012,29(10),833-842","journal-title":"Depress Anxiety"},{"key":"ref=208","first-page":"2401","volume":"68","author":"Grinage B.D.","year":"2003","unstructured":"Grinage B.D.; Diagnosis and management of post-traumatic stress disorder. Am Fam Physician  2003,68(12),2401-2408","journal-title":"Am Fam Physician"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.3390\/jcm9092951","volume":"9","author":"Aliev G.","year":"2020","unstructured":"Aliev G.; Beeraka N.M.; Nikolenko V.N.; Svistunov A.A.; Rozhnova T.; Kostyuk S.; Cherkesov I.; Gavryushova L.V.; Chekhonatsky A.A.; Mikhaleva L.M.; Somasundaram S.G.; Avila-Rodriguez M.F.; Kirkland C.E.; Neurophysiology and psychopathology underlying PTSD and recent insights into the PTSD therapies: A comprehensive review. J Clin Med  2020,9(9),2951","journal-title":"J Clin Med"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s11136-018-1833-4","volume":"27","author":"Le Q.A.","year":"2018","unstructured":"Le Q.A.; Doctor J.N.; Zoellner L.A.; Feeny N.C.; Effects of treatment, choice, and preference on health-related quality-of-life outcomes in patients with posttraumatic stress disorder (PTSD). Qual Life Res  2018,27(6),1555-1562","journal-title":"Qual Life Res"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/wps.20656","volume":"18","author":"Bryant R.A.","year":"2019","unstructured":"Bryant R.A.; Post-traumatic stress disorder: A state-of-the-art review of evidence and challenges. World Psychiatry  2019,18(3),259-269","journal-title":"World Psychiatry"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"101769","DOI":"10.1016\/j.jbtep.2022.101769","volume":"77","author":"Raabe S.","year":"2022","unstructured":"Raabe S.; Ehring T.; Marquenie L.; Arntz A.; Kindt M.; Imagery rescripting as a stand-alone treatment for posttraumatic stress disorder related to childhood abuse: A randomized controlled trial. J Behav Ther Exp Psychiatry  2022,77,101769","journal-title":"J Behav Ther Exp Psychiatry"},{"key":"ref=213","doi-asserted-by":"publisher","DOI":"10.1093\/med:psych\/9780199342211.003.0018","author":"Najavits L.M.","year":"2015","unstructured":"Najavits L.M.; Anderson M.L.;  Psychosocial treatments for posttraumatic stress disorder  2015","journal-title":"Psychosocial treatments for posttraumatic stress disorder"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1037\/a0030600","volume":"80","author":"Galovski T.E.","year":"2012","unstructured":"Galovski T.E.; Blain L.M.; Mott J.M.; Elwood L.; Houle T.; Manualized therapy for PTSD: Flexing the structure of cognitive processing therapy. J Consult Clin Psychol  2012,80(6),968-981","journal-title":"J Consult Clin Psychol"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cpr.2010.04.007","volume":"30","author":"Powers M.B.","year":"2010","unstructured":"Powers M.B.; Halpern J.M.; Ferenschak M.P.; Gillihan S.J.; Foa E.B.; A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev  2010,30(6),635-641","journal-title":"Clin Psychol Rev"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1017\/S1352465812000793","volume":"41","author":"Jeffries F.W.","year":"2013","unstructured":"Jeffries F.W.; Davis P.; What is the role of eye movements in eye movement desensitization and reprocessing (EMDR) for post-traumatic stress disorder (PTSD)? A review. Behav Cogn Psychother  2013,41(3),290-300","journal-title":"Behav Cogn Psychother"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/10503307.2020.1847345","volume":"31","author":"Siehl S.","year":"2021","unstructured":"Siehl S.; Robjant K.; Crombach A.; Systematic review and meta-analyses of the long-term efficacy of narrative exposure therapy for adults, children and perpetrators. Psychother Res  2021,31(6),695-710","journal-title":"Psychother Res"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"1550344","DOI":"10.1080\/20008198.2018.1550344","volume":"10","author":"Lely J.C.","year":"2019","unstructured":"Lely J.C.; Smid G.E.; Jongedijk R.A.W.; Knipscheer J.; Kleber R.J.; The effectiveness of narrative exposure therapy: A review, meta-analysis and meta-regression analysis. Eur J Psychotraumatol  2019,10(1),1550344","journal-title":"Eur J Psychotraumatol"},{"key":"ref=219","first-page":"281","author":"Nijdam M.J.","year":"2022","unstructured":"Nijdam M.J.; Meewisse M-L.; Smid G.E.; Gersons B.P.;  Brief Eclectic Psychotherapy for PTSD Evidence based treatments for trauma-related psychological disorders: A practical guide for clinicians  2022,281-306","journal-title":"Brief Eclectic Psychotherapy for PTSD Evidence based treatments for trauma-related psychological disorders: A practical guide for clinicians"},{"key":"ref=220","doi-asserted-by":"publisher","DOI":"10.1037\/0000196-000","author":"Bufka L.F.","year":"2020","unstructured":"Bufka L.F.; Wright C.V.E.; Halfond R.W.;  Casebook to the APA Clinical Practice Guideline for the treatment of PTSD  2020","journal-title":"Casebook to the APA Clinical Practice Guideline for the treatment of PTSD"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"1929026","DOI":"10.1080\/20008198.2021.1929026","volume":"12","author":"de la Rie S.M.","year":"2021","unstructured":"de la Rie S.M.; van Sint Fiet A.; Bos J.B.A.; Mooren N.; Smid G.; Gersons B.P.R.; Brief Eclectic Psychotherapy for Moral Trauma (BEP-MT): treatment protocol description and a case study. Eur J Psychotraumatol  2021,12(1),1929026","journal-title":"Eur J Psychotraumatol"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/acps.13366","volume":"145","author":"Jericho B.","year":"2022","unstructured":"Jericho B.; Luo A.; Berle D.; Trauma-focused psychotherapies for post-traumatic stress disorder: A systematic review and network meta-analysis. Acta Psychiatr Scand  2022,145(2),132-155","journal-title":"Acta Psychiatr Scand"},{"key":"ref=223","author":"Weber M.","year":"2021","unstructured":"Weber M.; Schumacher S.; Hannig W.;  Long-term outcomes of psychological treatment for posttraumatic stress disorder: A systematic review and meta-analysis  2021","journal-title":"Long-term outcomes of psychological treatment for posttraumatic stress disorder: A systematic review and meta-analysis"},{"key":"ref=224","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rpsm.2015.12.002","volume":"11","author":"Navarro P.N.","year":"2018","unstructured":"Navarro P.N.; Landin-Romero R.; Guardiola-Wanden-Berghe R.; 25 years of Eye Movement Desensitization and Reprocessing (EMDR): The EMDR therapy protocol, hypotheses of its mechanism of action and a systematic review of its efficacy in the treatment of post-traumatic stress disorder. Rev Psiquiatr Salud Ment  2018,11(2),101-114","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"25982","DOI":"10.4088\/PCC.19nr02572","volume":"23","author":"Pary R.","year":"2021","unstructured":"Pary R.; Micchelli A.N.; Lippmann S.; How we treat posttraumatic stress disorder. Prim Care Companion CNS Disord  2021,23(1),25982","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref=226","first-page":"11","author":"Belsher B.E.","year":"2019","unstructured":"Belsher B.E.; Beech E.; Evatt D.; Present-centered therapy (PCT) for post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev  2019,11","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jad.2019.12.021","volume":"264","author":"Althobaiti S.","year":"2020","unstructured":"Althobaiti S.; Kazantzis N.; Ofori-Asenso R.; Romero L.; Fisher J.; Mills K.E.; Liew D.; Efficacy of interpersonal psychotherapy for post-traumatic stress disorder: A systematic review and meta-analysis. J Affect Disord  2020,264,286-294","journal-title":"J Affect Disord"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1037\/int0000113","volume":"29","author":"Bleiberg K.L.","year":"2019","unstructured":"Bleiberg K.L.; Markowitz J.C.; Interpersonal psychotherapy for PTSD: Treating trauma without exposure. J Psychother Integration  2019,29(1),15-22","journal-title":"J Psychother Integration"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1037\/tra0000432","volume":"11","author":"Jackson S.","year":"2019","unstructured":"Jackson S.; Baity M.R.; Bobb K.; Swick D.; Giorgio J.; Stress inoculation training outcomes among veterans with PTSD and TBI. Psychol Trauma  2019,11(8),842-850","journal-title":"Psychol Trauma"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1001\/jama.2015.8370","volume":"314","author":"Steenkamp M.M.","year":"2015","unstructured":"Steenkamp M.M.; Litz B.T.; Hoge C.W.; Marmar C.R.; Psychotherapy for Military-Related PTSD. JAMA  2015,314(5),489-500","journal-title":"JAMA"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"31858","DOI":"10.3402\/ejpt.v7.31858","volume":"7","author":"Kelmendi B.","year":"2016","unstructured":"Kelmendi B.; Adams T.G.; Yarnell S.; Southwick S.; Abdallah C.G.; Krystal J.H.; PTSD: from neurobiology to pharmacological treatments. Eur J Psychotraumatol  2016,7(1),31858","journal-title":"Eur J Psychotraumatol"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pnpbp.2008.12.004","volume":"33","author":"Berger W.","year":"2009","unstructured":"Berger W.; Mendlowicz M.V.; Marques-Portella C.; Kinrys G.; Fontenelle L.F.; Marmar C.R.; Figueira I.; Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry  2009,33(2),169-180","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/da.22511","volume":"33","author":"Lee D.J.","year":"2016","unstructured":"Lee D.J.; Schnitzlein C.W.; Wolf J.P.; Vythilingam M.; Rasmusson A.M.; Hoge C.W.; Psychotherapy versus pharmacotherapy for post-traumatic stress disorder: Systemic review and meta-analyses to determine first-line treatments. Depress Anxiety  2016,33(9),792-806","journal-title":"Depress Anxiety"},{"key":"ref=234","first-page":"CD002795","volume":"3","author":"Williams T.","year":"2022","unstructured":"Williams T.; Phillips N.J.; Stein D.J.; Ipser J.C.; Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev  2022,3,CD002795","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=235","first-page":"609","author":"Friedman M.J.","year":"2007","unstructured":"Friedman M.J.; Keane T.M.; Resick P.A.;  Handbook of PTSD, 1st  2007,609","journal-title":"Handbook of PTSD, 1st"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/da.10021","volume":"15","author":"Davidson J.R.T.","year":"2002","unstructured":"Davidson J.R.T.; Tharwani H.M.; Connor K.M.; Davidson Trauma Scale (DTS): Normative scores in the general population and effect sizes in placebo-controlled SSRI trials. Depress Anxiety  2002,15(2),75-78","journal-title":"Depress Anxiety"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1176\/appi.ajp.158.12.1982","volume":"158","author":"Marshall R.D.","year":"2001","unstructured":"Marshall R.D.; Beebe K.L.; Oldham M.; Zaninelli R.; Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. Am J Psychiatry  2001,158(12),1982-1988","journal-title":"Am J Psychiatry"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"860","DOI":"10.4088\/JCP.v62n1105","volume":"62","author":"Tucker P.","year":"2001","unstructured":"Tucker P.; Zaninelli R.; Yehuda R.; Ruggiero L.; Dillingham K.; Pitts C.D.; Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry  2001,62(11),860-868","journal-title":"J Clin Psychiatry"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1517\/14656566.2.5.883","volume":"2","author":"McRae A.L.","year":"2001","unstructured":"McRae A.L.; Brady K.T.; Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin Pharmacother  2001,2(5),883-892","journal-title":"Expert Opin Pharmacother"},{"key":"ref=240","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.07.21260166","author":"Duek O.","year":"2021","unstructured":"Duek O.; Li Y.; Kelmendi B.; Modulating amygdala activation to traumatic memories with a single ketamine infusion. Medrxiv  2021","journal-title":"Medrxiv"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1055\/s-2001-15871","volume":"34","author":"Warner M.D.","year":"2001","unstructured":"Warner M.D.; Dorn M.R.; Peabody C.A.; Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry  2001,34(4),128-131","journal-title":"Pharmacopsychiatry"},{"key":"ref=242","first-page":"1309","volume":"80","author":"Akiki T.J.","year":"2019","unstructured":"Akiki T.J.; Abdallah C.G.; Are there effective psychopharmacologic treatments for PTSD? J Clin Psychiatry  2019,80(3),1309","journal-title":"J Clin Psychiatry"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1037\/pst0000231","volume":"56","author":"Hamblen J.L.","year":"2019","unstructured":"Hamblen J.L.; Norman S.B.; Sonis J.H.; Phelps A.J.; Bisson J.I.; Nunes V.D.; Megnin-Viggars O.; Forbes D.; Riggs D.S.; Schnurr P.P.; A guide to guidelines for the treatment of posttraumatic stress disorder in adults: An update. Psychotherapy  2019,56(3),359-373","journal-title":"Psychotherapy"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"114840","DOI":"10.1016\/j.psychres.2022.114840","volume":"317","author":"Bajor L.A.","year":"2022","unstructured":"Bajor L.A.; Balsara C.; Osser D.N.; An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD): 2022 update. Psychiatry Res  2022,317,114840","journal-title":"Psychiatry Res"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"26306","DOI":"10.4088\/PCC.16r01943","volume":"18","author":"Singh B.","year":"2016","unstructured":"Singh B.; Hughes A.J.; Mehta G.; Erwin P.J.; Parsaik A.K.; Efficacy of prazosin in posttraumatic stress disorder: A systematic review and meta-analysis. Prim Care Companion CNS Disord  2016,18(4),26306","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1176\/appi.ajp.2013.12081133","volume":"170","author":"Raskind M.A.","year":"2013","unstructured":"Raskind M.A.; Peterson K.; Williams T.; Hoff D.J.; Hart K.; Holmes H.; Homas D.; Hill J.; Daniels C.; Calohan J.; Millard S.P.; Rohde K.; O\u2019Connell J.; Pritzl D.; Feiszli K.; Petrie E.C.; Gross C.; Mayer C.L.; Freed M.C.; Engel C.; Peskind E.R.; A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry  2013,170(9),1003-1010","journal-title":"Am J Psychiatry"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"101285","DOI":"10.1016\/j.smrv.2020.101285","volume":"51","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y.; Ren R.; Sanford L.D.; Tang X.; Commentary on Y\u00fccel DE et al. Downgrading recommendation level of prazosin for treating trauma-related nightmares: Should decision be based on a single study? Sleep Med Rev  2020,51,101285","journal-title":"Sleep Med Rev"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"1853379","DOI":"10.1080\/20008198.2020.1853379","volume":"12","author":"Hoskins M.D.","year":"2021","unstructured":"Hoskins M.D.; Sinnerton R.; Nakamura A.; Underwood J.F.G.; Slater A.; Lewis C.; Roberts N.P.; Bisson J.I.; Lee M.; Clarke L.; Pharmacological-assisted psychotherapy for post traumatic stress disorder: A systematic review and meta-analysis. Eur J Psychotraumatol  2021,12(1),1853379","journal-title":"Eur J Psychotraumatol"},{"key":"ref=249","first-page":"CD007316","volume":"7","author":"Hetrick S.E.","year":"2010","unstructured":"Hetrick S.E.; Purcell R.; Garner B.; Parslow R.; Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev  2010,7,CD007316","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamapsychiatry.2018.3412","volume":"76","author":"Rauch S.A.M.","year":"2019","unstructured":"Rauch S.A.M.; Kim H.M.; Powell C.; Tuerk P.W.; Simon N.M.; Acierno R.; Allard C.B.; Norman S.B.; Venners M.R.; Rothbaum B.O.; Stein M.B.; Porter K.; Martis B.; King A.P.; Liberzon I.; Phan K.L.; Hoge C.W.; Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry  2019,76(2),117-126","journal-title":"JAMA Psychiatry"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/13543784.2022.2035358","volume":"31","author":"Averill L.A.","year":"2022","unstructured":"Averill L.A.; Abdallah C.G.; Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): Emerging approaches and shifting paradigms in the era of psychedelic medicine. Expert Opin Investig Drugs  2022,31(2),133-137","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/jclp.22634","volume":"74","author":"Niles B.L.","year":"2018","unstructured":"Niles B.L.; Mori D.L.; Polizzi C.; Pless Kaiser A.; Weinstein E.S.; Gershkovich M.; Wang C.; A systematic review of randomized trials of mind-body interventions for PTSD. J Clin Psychol  2018,74(9),1485-1508","journal-title":"J Clin Psychol"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"1795361","DOI":"10.1080\/20008198.2020.1795361","volume":"11","author":"Bisson J.I.","year":"2020","unstructured":"Bisson J.I.; van Gelderen M.; Roberts N.P.; Lewis C.; Non-pharmacological and non-psychological approaches to the treatment of PTSD: Results of a systematic review and meta-analyses. Eur J Psychotraumatol  2020,11(1),1795361","journal-title":"Eur J Psychotraumatol"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.janxdis.2019.02.001","volume":"63","author":"Sripada R.K.","year":"2019","unstructured":"Sripada R.K.; Blow F.C.; Rauch S.A.M.; Ganoczy D.; Hoff R.; Harpaz-Rotem I.; Bohnert K.M.; Examining the nonresponse phenomenon: Factors associated with treatment response in a national sample of veterans undergoing residential PTSD treatment. J Anxiety Disord  2019,63,18-25","journal-title":"J Anxiety Disord"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/jts.22653","volume":"34","author":"Edwards-Stewart A.","year":"2021","unstructured":"Edwards-Stewart A.; Smolenski D.J.; Bush N.E.; Cyr B-A.; Beech E.H.; Skopp N.A.; Belsher B.E.; Posttraumatic stress disorder treatment dropout among military and veteran populations: A systematic review and meta-analysis. J Trauma Stress  2021,34(4),808-818","journal-title":"J Trauma Stress"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"100093","DOI":"10.1016\/j.jadr.2021.100093","volume":"4","author":"Varker T.","year":"2021","unstructured":"Varker T.; Jones K.A.; Arjmand H.A.; Hinton M.; Hiles S.A.; Freijah I.; Forbes D.; Kartal D.; Phelps A.; Bryant R.A.; McFarlane A.; Hopwood M.; O\u2019Donnell M.; Dropout from guideline-recommended psychological treatments for posttraumatic stress disorder: A systematic review and meta-analysis. J Affect Disord Rep  2021,4,100093","journal-title":"J Affect Disord Rep"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"1774240","DOI":"10.1080\/20008198.2020.1774240","volume":"11","author":"Barawi K.S.","year":"2020","unstructured":"Barawi K.S.; Lewis C.; Simon N.; Bisson J.I.; A systematic review of factors associated with outcome of psychological treatments for post-traumatic stress disorder. Eur J Psychotraumatol  2020,11(1),1774240","journal-title":"Eur J Psychotraumatol"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1037\/ser0000139","volume":"15","author":"Fleming C.J.E.","year":"2018","unstructured":"Fleming C.J.E.; Kholodkov T.; Dillon K.H.; Belvet B.; Crawford E.F.; Actuarial prediction of psychotherapy retention among Iraq-Afghanistan veterans with posttraumatic stress disorder. Psychol Serv  2018,15(2),172-180","journal-title":"Psychol Serv"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/jts.21768","volume":"26","author":"Jakupcak M.","year":"2013","unstructured":"Jakupcak M.; Hoerster K.D.; Blais R.K.; Malte C.A.; Hunt S.; Seal K.; Readiness for change predicts VA mental healthcare utilization among Iraq and Afghanistan war veterans. J Trauma Stress  2013,26(1),165-168","journal-title":"J Trauma Stress"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"710004","DOI":"10.3389\/fnins.2021.710004","volume":"15","author":"Lepow L.","year":"2021","unstructured":"Lepow L.; Morishita H.; Yehuda R.; Critical period plasticity as a framework for psychedelic-assisted psychotherapy. Front Neurosci  2021,15,710004","journal-title":"Front Neurosci"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fphar.2018.00733","volume":"9","author":"Schenberg E.E.","year":"2018","unstructured":"Schenberg E.E.; Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Front Pharmacol  2018,9,733","journal-title":"Front Pharmacol"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"116715","DOI":"10.1016\/j.jns.2020.116715","volume":"411","author":"Chi T.","year":"2020","unstructured":"Chi T.; Gold J.A.; A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci  2020,411,116715","journal-title":"J Neurol Sci"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","volume":"23","author":"Krediet E.","year":"2020","unstructured":"Krediet E.; Bostoen T.; Breeksema J.; van Schagen A.; Passie T.; Vermetten E.; Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol  2020,23(6),385-400","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=264","author":"Bourguignon E.","year":"1973","unstructured":"Bourguignon E.;  Religion, altered states of consciousness, and social change  1973","journal-title":"Religion, altered states of consciousness, and social change"},{"key":"ref=265","author":"Hofmann A.","year":"1980","unstructured":"Hofmann A.;  LSD, my problem child  1980","journal-title":"LSD, my problem child"},{"key":"ref=266","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fphar.2018.00172","volume":"9","author":"Swanson L.R.","year":"2018","unstructured":"Swanson L.R.; Unifying theories of psychedelic drug effects. Front Pharmacol  2018,9,172","journal-title":"Front Pharmacol"},{"key":"ref=267","author":"Passie T.","year":"1997","unstructured":"Passie T.;  Psycholytic and psychedelic therapy research 1931-\n1995: A complete international bibliography  1997","journal-title":"Psycholytic and psychedelic therapy research 1931-\n1995: A complete international bibliography"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF02159243","volume":"14","author":"Hofmann A.","year":"1958","unstructured":"Hofmann A.; Heim R.; Brack A.; Kobel H.; Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim. Experientia  1958,14(3),107-109","journal-title":"Experientia"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1055\/a-1310-3990","volume":"54","author":"Nichols D.E.","year":"2021","unstructured":"Nichols D.E.; Walter H.; The history of psychedelics in psychiatry. Pharmacopsychiatry  2021,54(4),151-166","journal-title":"Pharmacopsychiatry"},{"key":"ref=270","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"Moreno F.","year":"2006","unstructured":"Moreno F.; Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry  2006,67(11),1735-1740","journal-title":"J Clin Psychiatry"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","volume":"80","author":"Siegel J.S.","year":"2023","unstructured":"Siegel J.S.; Daily J.E.; Perry D.A.; Nicol G.E.; Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry  2023,80(1),77-83","journal-title":"JAMA Psychiatry"},{"key":"ref=272","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","volume":"78","author":"Nutt D.","year":"2021","unstructured":"Nutt D.; Carhart-Harris R.; The current status of psychedelics in psychiatry. JAMA Psychiatry  2021,78(2),121-122","journal-title":"JAMA Psychiatry"},{"key":"ref=273","doi-asserted-by":"crossref","first-page":"661233","DOI":"10.3389\/fpsyt.2021.661233","volume":"12","author":"Ko\u010d\u00e1rov\u00e1 R.","year":"2021","unstructured":"Ko\u010d\u00e1rov\u00e1 R.; Hor\u00e1\u010dek J.; Carhart-Harris R.; Does psychedelic therapy have a transdiagnostic action and prophylactic potential? Front Psychiatry  2021,12,661233","journal-title":"Front Psychiatry"},{"key":"ref=274","year":"2017","unstructured":"MAPS Psychotherapy Manual; Santa Cruz, CA: U.S,  2017"},{"key":"ref=275","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0269881112456611","volume":"27","author":"Mithoefer M.C.","year":"2013","unstructured":"Mithoefer M.C.; Wagner M.T.; Mithoefer A.T.; Jerome L.; Martin S.F.; Yazar-Klosinski B.; Michel Y.; Brewerton T.D.; Doblin R.; Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. J Psychopharmacol  2013,27(1),28-39","journal-title":"J Psychopharmacol"},{"key":"ref=276","first-page":"677","author":"Grinspoon L.","year":"2001","unstructured":"Grinspoon L.; Doblin R.; Psychedelics as catalysts of insight-oriented psychotherapy. Soc Res  2001,677-695","journal-title":"Soc Res"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/0022167816670996","volume":"57","author":"Richards W.A.","year":"2017","unstructured":"Richards W.A.; Psychedelic psychotherapy: Insights from 25 years of research. J Humanist Psychol  2017,57(4),323-337","journal-title":"J Humanist Psychol"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1176\/appi.psychotherapy.20200055","volume":"74","author":"Horton D.M.","year":"2021","unstructured":"Horton D.M.; Morrison B.; Schmidt J.; Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy. Am J Psychother  2021,74(4),140-149","journal-title":"Am J Psychother"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10879-017-9379-2","volume":"48","author":"Thal S.B.","year":"2018","unstructured":"Thal S.B.; Lommen M.J.J.; Current perspective on MDMA-assisted psychotherapy for posttraumatic stress disorder. J Contemp Psychother  2018,48(2),99-108","journal-title":"J Contemp Psychother"},{"key":"ref=280","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/a-1721-2914","volume":"55","author":"Vollenweider F.X.","year":"2022","unstructured":"Vollenweider F.X.; Smallridge J.W.; Classic psychedelic drugs: Update on biological mechanisms. Pharmacopsychiatry  2022,55(3),121-138","journal-title":"Pharmacopsychiatry"},{"key":"ref=281","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/02698811211015221","volume":"36","author":"de Wit H.","year":"2022","unstructured":"de Wit H.; Bershad A.K.; Grob C.; Challenges in translational research: MDMA in the laboratory versus therapeutic settings. J Psychopharmacol  2022,36(3),252-257","journal-title":"J Psychopharmacol"},{"key":"ref=282","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"Mithoefer M.C.","year":"2019","unstructured":"Mithoefer M.C.; Feduccia A.A.; Jerome L.; Mithoefer A.; Wagner M.; Walsh Z.; Hamilton S.; Yazar-Klosinski B.; Emerson A.; Doblin R.; MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology  2019,236(9),2735-2745","journal-title":"Psychopharmacology"},{"key":"ref=283","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/j.1360-0443.2006.01511.x","volume":"101","author":"Freudenmann R.W.","year":"2006","unstructured":"Freudenmann R.W.; \u00d6xler F.; Bernschneider-Reif S.; The origin of MDMA (ecstasy) revisited: The true story reconstructed from the original documents. Addiction  2006,101(9),1241-1245","journal-title":"Addiction"},{"key":"ref=284","author":"Shulgin A.T.","year":"1991","unstructured":"Shulgin A.T.; Shulgin A.;  PIHKAL: A chemical love story  1991","journal-title":"PIHKAL: A chemical love story"},{"key":"ref=285","author":"Holland J.","year":"2001","unstructured":"Holland J.;  Ecstasy: The complete guide: A comprehensive look at the risks and benefits of MDMA  2001","journal-title":"Ecstasy: The complete guide: A comprehensive look at the risks and benefits of MDMA"},{"key":"ref=286","first-page":"59","volume":"10","author":"Adamson S.","year":"1988","unstructured":"Adamson S.; Metzner R.; The nature of the MDMA experience and its role in healing, psychotherapy and spiritual practice. ReVision  1988,10(4),59-72","journal-title":"ReVision"},{"key":"ref=287","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","volume":"18","author":"Nichols D.E.","year":"1986","unstructured":"Nichols D.E.; Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. identification of a new therapeutic class. Entactogens J Psychoactive Drugs  1986,18(4),305-313","journal-title":"Entactogens J Psychoactive Drugs"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"863088","DOI":"10.3389\/fpsyt.2022.863088","volume":"13","author":"Nichols D.E.","year":"2022","unstructured":"Nichols D.E.; Entactogens: How the name for a novel class of psychoactive agents originated. Front Psychiatry  2022,13,863088","journal-title":"Front Psychiatry"},{"key":"ref=289","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2190\/DCRP-U22M-AUMD-D84H","volume":"16","author":"Climko R.P.","year":"1987","unstructured":"Climko R.P.; Roehrich H.; Sweeney D.R.; Al-Razi J.; ECSTACY: A review of MDMA and MDA. Int J Psychiatry Med  1987,16(4),359-372","journal-title":"Int J Psychiatry Med"},{"key":"ref=290","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1053\/j.ajkd.2008.03.004","volume":"52","author":"Liamis G.","year":"2008","unstructured":"Liamis G.; Milionis H.; Elisaf M.; A review of drug-induced hyponatremia. Am J Kidney Dis  2008,52(1),144-153","journal-title":"Am J Kidney Dis"},{"key":"ref=291","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0091-3057(01)00711-0","volume":"71","author":"Parrott A.C.","year":"2002","unstructured":"Parrott A.C.; Recreational Ecstasy\/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav  2002,71(4),837-844","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=292","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.npp.1395197","volume":"19","author":"Vollenweider F.X.","year":"1998","unstructured":"Vollenweider F.X.; Gamma A.; Liechti M.; Huber T.; Psychological and cardiovascular effects and short-term sequelae of MDMA (\u201cEcstasy\u201d) in MDMA-na\u00efve healthy volunteers. Neuropsychopharmacology  1998,19(4),241-251","journal-title":"Neuropsychopharmacology"},{"key":"ref=293","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/09595230220119363","volume":"21","author":"Gowing L.R.","year":"2002","unstructured":"Gowing L.R.; Henry-Edwards S.M.; Irvine R.J.; Ali R.L.; The health effects of ecstasy: A literature review. Drug Alcohol Rev  2002,21(1),53-63","journal-title":"Drug Alcohol Rev"},{"key":"ref=294","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/jmt\/9.2.64","volume":"9","author":"Bonny H.L.","year":"1972","unstructured":"Bonny H.L.; Pahnke W.N.; The use of music in psychedelic (LSD) psychotherapy. J Music Ther  1972,9(2),64-87","journal-title":"J Music Ther"},{"key":"ref=295","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","volume":"235","author":"Kaelen M.","year":"2018","unstructured":"Kaelen M.; Giribaldi B.; Raine J.; Evans L.; Timmerman C.; Rodriguez N.; Roseman L.; Feilding A.; Nutt D.; Carhart-Harris R.; The hidden therapist: Evidence for a central role of music in psychedelic therapy. Psychopharmacology  2018,235(2),505-519","journal-title":"Psychopharmacology"},{"key":"ref=296","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00213-017-4779-2","volume":"235","author":"Feduccia A.A.","year":"2018","unstructured":"Feduccia A.A.; Holland J.; Mithoefer M.C.; Progress and promise for the MDMA drug development program. Psychopharmacology  2018,235(2),561-571","journal-title":"Psychopharmacology"},{"key":"ref=297","first-page":"2","volume":"71","author":"Carhart-Harris R.","year":"2014","unstructured":"Carhart-Harris R.; Leech R.; Tagliazucchi E.; How do hallucinogens work on the brain. J Psychophysiol  2014,71(1),2-8","journal-title":"J Psychophysiol"},{"key":"ref=298","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1007\/s00213-014-3570-x","volume":"231","author":"Wardle M.C.","year":"2014","unstructured":"Wardle M.C.; de Wit H.; MDMA alters emotional processing and facilitates positive social interaction. Psychopharmacology  2014,231(21),4219-4229","journal-title":"Psychopharmacology"},{"key":"ref=299","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/scan\/nsu035","volume":"9","author":"Wardle M.C.","year":"2014","unstructured":"Wardle M.C.; Kirkpatrick M.G.; de Wit H.; \u2018Ecstasy\u2019 as a social drug: MDMA preferentially affects responses to emotional stimuli with social content. Soc Cogn Affect Neurosci  2014,9(8),1076-1081","journal-title":"Soc Cogn Affect Neurosci"},{"key":"ref=300","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1177\/0269881116663120","volume":"30","author":"Bershad A.K.","year":"2016","unstructured":"Bershad A.K.; Miller M.A.; Baggott M.J.; de Wit H.; The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants? J Psychopharmacol  2016,30(12),1248-1258","journal-title":"J Psychopharmacol"},{"key":"ref=301","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.neubiorev.2015.08.016","volume":"57","author":"Kamilar-Britt P.","year":"2015","unstructured":"Kamilar-Britt P.; Bedi G.; The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals. Neurosci Biobehav Rev  2015,57,433-446","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=302","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1360-0443.2006.01423.x","volume":"101","author":"Baylen C.A.","year":"2006","unstructured":"Baylen C.A.; Rosenberg H.; A review of the acute subjective effects of MDMA\/ecstasy. Addiction  2006,101(7),933-947","journal-title":"Addiction"},{"key":"ref=303","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/00004714-200008000-00010","volume":"20","author":"Cam\u00ed J.","year":"2000","unstructured":"Cam\u00ed J.; Farr\u00e9 M.; Mas M.; Roset P.N.; Poudevida S.; Mas A.; San L.; de la Torre R.; Human pharmacology of 3,4-methylenedioxymeth-amphetamine (\u201cEcstasy\u201d): Psychomotor performance and subjective effects. J Clin Psychopharmacol  2000,20(4),455-466","journal-title":"J Clin Psychopharmacol"},{"key":"ref=304","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1177\/0269881121998322","volume":"35","author":"Studerus E.","year":"2021","unstructured":"Studerus E.; Vizeli P.; Harder S.; Ley L.; Liechti M.E.; Prediction of MDMA response in healthy humans: A pooled analysis of placebo-controlled studies. J Psychopharmacol  2021,35(5),556-565","journal-title":"J Psychopharmacol"},{"key":"ref=305","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hup.529","volume":"18","author":"Verheyden S.L.","year":"2003","unstructured":"Verheyden S.L.; Henry J.A.; Curran H.V.; Acute, sub-acute and long-term subjective consequences of ecstasy? (MDMA) consumption in 430 regular users. Hum Psychopharmacol  2003,18(7),507-517","journal-title":"Hum Psychopharmacol"},{"key":"ref=306","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/10673220216223","volume":"10","author":"Montoya A.G.","year":"2002","unstructured":"Montoya A.G.; Sorrentino R.; Lukas S.E.; Price B.H.; Long-term neuropsychiatric consequences of \u201cEcstasy\u201d (MDMA): A review. Harv Rev Psychiatry  2002,10(4),212-220","journal-title":"Harv Rev Psychiatry"},{"key":"ref=307","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drugpo.2018.11.002","volume":"64","author":"Amoroso T.","year":"2019","unstructured":"Amoroso T.; The spurious relationship between ecstasy use and neurocognitive deficits: A bradford hill review. Int J Drug Policy  2019,64,47-53","journal-title":"Int J Drug Policy"},{"key":"ref=308","doi-asserted-by":"publisher","first-page":"iii-iv-ix-xii, 1-315","DOI":"10.3310\/hta13060","volume":"136","author":"Rogers G","year":"2009","unstructured":"Rogers G; Elston J; Garside R; The harmful health effects of recreational ecstasy: A systematic review of observational evidence. HealTechnolAssess  2009,136,iii-iv-ix-xii, 1-315","journal-title":"HealTechnolAssess"},{"key":"ref=309","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/hup.873","volume":"22","author":"Zakzanis K.K.","year":"2007","unstructured":"Zakzanis K.K.; Campbell Z.; Jovanovski D.; The neuropsychology of ecstasy (MDMA) use: A quantitative review. Hum Psychopharmacol  2007,22(7),427-435","journal-title":"Hum Psychopharmacol"},{"key":"ref=310","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s002130000545","volume":"152","author":"Morgan M.J.","year":"2000","unstructured":"Morgan M.J.; Ecstasy (MDMA): A review of its possible persistent psychological effects. Psychopharmacology  2000,152(3),230-248","journal-title":"Psychopharmacology"},{"key":"ref=311","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s002130050803","volume":"141","author":"Morgan M.J.","year":"1999","unstructured":"Morgan M.J.; Memory deficits associated with recreational use of \u201cecstasy\u201d (MDMA). Psychopharmacology  1999,141(1),30-36","journal-title":"Psychopharmacology"},{"key":"ref=312","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1177\/0269881117715596","volume":"31","author":"Saleemi S.","year":"2017","unstructured":"Saleemi S.; Pennybaker S.J.; Wooldridge M.; Johnson M.W.; Who is \u2018Molly\u2019? MDMA adulterants by product name and the impact of harm-reduction services at raves. J Psychopharmacol  2017,31(8),1056-1060","journal-title":"J Psychopharmacol"},{"key":"ref=313","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/j.1360-0443.2011.03399.x","volume":"106","author":"Morefield K.M.","year":"2011","unstructured":"Morefield K.M.; Keane M.; Felgate P.; White J.M.; Irvine R.J.; Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational \u2018ecstasy\u2019 users. Addiction  2011,106(7),1293-1300","journal-title":"Addiction"},{"key":"ref=314","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/0269881106059939","volume":"20","author":"Gouzoulis-Mayfrank E.","year":"2006","unstructured":"Gouzoulis-Mayfrank E.; Daumann J.; The confounding problem of polydrug use in recreational ecstasy\/MDMA users: A brief overview. J Psychopharmacol  2006,20(2),188-193","journal-title":"J Psychopharmacol"},{"key":"ref=315","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"Randolph C.","year":"1998","unstructured":"Randolph C.; Tierney M.C.; Mohr E.; Chase T.N.; The repeatable battery for the assessment of neuropsychological status (RBANS): Preliminary clinical validity. J Clin Exp Neuropsychol  1998,20(3),310-319","journal-title":"J Clin Exp Neuropsychol"},{"key":"ref=316","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2466\/pms.1977.44.2.367","volume":"44","author":"Gronwall D.M.A.","year":"1977","unstructured":"Gronwall D.M.A.; Paced auditory serial-addition task: A measure of recovery from concussion. Percept Mot Skills  1977,44(2),367-373","journal-title":"Percept Mot Skills"},{"key":"ref=317","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/13854049108401840","volume":"5","author":"Roman D.D.","year":"1991","unstructured":"Roman D.D.; Edwall G.E.; Buchanan R.J.; Patton J.H.; Extended norms for the paced auditory serial addition task. Clin Neuropsychol  1991,5(1),33-40","journal-title":"Clin Neuropsychol"},{"key":"ref=318","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00213-011-2383-4","volume":"219","author":"Kirkpatrick M.G.","year":"2012","unstructured":"Kirkpatrick M.G.; Gunderson E.W.; Perez A.Y.; Haney M.; Foltin R.W.; Hart C.L.; A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology  2012,219(1),109-122","journal-title":"Psychopharmacology"},{"key":"ref=319","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/JCP.0b013e31817ef470","volume":"28","author":"Kolbrich E.A.","year":"2008","unstructured":"Kolbrich E.A.; Goodwin R.S.; Gorelick D.A.; Hayes R.J.; Stein E.A.; Huestis M.A.; Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol  2008,28(4),432-440","journal-title":"J Clin Psychopharmacol"},{"key":"ref=320","doi-asserted-by":"publisher","first-page":"969","DOI":"10.7326\/0003-4819-133-12-200012190-00012","volume":"133","author":"Lester S.J.","year":"2000","unstructured":"Lester S.J.; Baggott M.; Welm S.; Cardiovascular effects of 3, 4-methylenedioxymethamphetamine: A double-blind, placebo-controlled trial. Ann Intern Med  2000,133(12),969-973","journal-title":"Ann Intern Med"},{"key":"ref=321","first-page":"136","volume":"290","author":"Mas M.","year":"1999","unstructured":"Mas M.; Farr\u00e9 M.; de la Torre R.; Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxy-methamphetamine in humans. J Pharmacol Exp Ther  1999,290(1),136-145","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=322","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/0269881117691569","volume":"31","author":"Vizeli P.","year":"2017","unstructured":"Vizeli P.; Liechti M.E.; Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol  2017,31(5),576-588","journal-title":"J Psychopharmacol"},{"key":"ref=323","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","volume":"5","author":"Mithoefer M.C.","year":"2018","unstructured":"Mithoefer M.C.; Mithoefer A.T.; Feduccia A.A.; Jerome L.; Wagner M.; Wymer J.; Holland J.; Hamilton S.; Yazar-Klosinski B.; Emerson A.; Doblin R.; 3,4-methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry  2018,5(6),486-497","journal-title":"Lancet Psychiatry"},{"key":"ref=324","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1749-6632.2000.tb05199.x","volume":"914","author":"De La Torre R.","year":"2000","unstructured":"De La Torre R.; Farr\u00e9 M.; Roset P.N.; L\u00f3pez C.H.; Mas M.; Ortu\u00f1o J.; Menoyo E.; Pizarro N.; Segura J.; Cam\u00ed J.; Pharmacology of MDMA in Humans. Ann N Y Acad Sci  2000,914(1),225-237","journal-title":"Ann N Y Acad Sci"},{"key":"ref=325","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00213-020-05710-w","volume":"238","author":"Feduccia A.A.","year":"2021","unstructured":"Feduccia A.A.; Jerome L.; Mithoefer M.C.; Holland J.; Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. Psychopharmacology  2021,238(2),581-588","journal-title":"Psychopharmacology"},{"key":"ref=326","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/0269881120920420","volume":"35","author":"Oeri H.E.","year":"2021","unstructured":"Oeri H.E.; Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. J Psychopharmacol  2021,35(5),512-536","journal-title":"J Psychopharmacol"},{"key":"ref=327","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/17425255.2020.1749262","volume":"16","author":"Papaseit E.","year":"2020","unstructured":"Papaseit E.; P\u00e9rez-Ma\u00f1\u00e1 C.; Torrens M.; Farr\u00e9 A.; Poyatos L.; Hladun O.; Sanvisens A.; Muga R.; Farr\u00e9 M.; MDMA interactions with pharmaceuticals and drugs of abuse. Expert Opin Drug Metab Toxicol  2020,16(5),357-369","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=328","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","volume":"168","author":"Simmler L.D.","year":"2013","unstructured":"Simmler L.D.; Buser T.A.; Donzelli M.; Schramm Y.; Dieu L-H.; Huwyler J.; Chaboz S.; Hoener M.C.; Liechti M.E.; Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol  2013,168(2),458-470","journal-title":"Br J Pharmacol"},{"key":"ref=329","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-019-1075-9","volume":"569","author":"Nardou R.","year":"2019","unstructured":"Nardou R.; Lewis E.M.; Rothhaas R.; Xu R.; Yang A.; Boyden E.; D\u00f6len G.; Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature  2019,569(7754),116-120","journal-title":"Nature"},{"key":"ref=330","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/jne.12284","volume":"27","author":"D\u00f6len G.","year":"2015","unstructured":"D\u00f6len G.; Oxytocin: Parallel processing in the social brain? J Neuroendocrinol  2015,27(6),516-535","journal-title":"J Neuroendocrinol"},{"key":"ref=331","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.neuroscience.2007.02.032","volume":"146","author":"Thompson M.R.","year":"2007","unstructured":"Thompson M.R.; Callaghan P.D.; Hunt G.E.; Cornish J.L.; McGregor I.S.; A role for oxytocin and 5-HT receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (\u201cecstasy\u201d). Neuroscience  2007,146(2),509-514","journal-title":"Neuroscience"},{"key":"ref=332","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/medicina58070923","volume":"58","author":"Florea T.","year":"2022","unstructured":"Florea T.; Palimariciuc M.; Cristofor A.C.; Dobrin I.; Chiri\u021b\u0103 R.; B\u00eersan M.; Dobrin R.P.; P\u0103durariu M.; Oxytocin: Narrative expert review of current perspectives on the relationship with other neurotransmitters and the impact on the main psychiatric disorders. Medicina  2022,58(7),923","journal-title":"Medicina"},{"key":"ref=333","first-page":"13","year":"2022","unstructured":"MAPS Investigators Brochure, 14th  2022,13-253","journal-title":"MAPS Investigators Brochure, 14th"},{"key":"ref=334","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/17470910802649470","volume":"4","author":"Dumont G.J.H.","year":"2009","unstructured":"Dumont G.J.H.; Sweep F.C.G.J.; van der Steen R.; Hermsen R.; Donders A.R.T.; Touw D.J.; van Gerven J.M.A.; Buitelaar J.K.; Verkes R.J.; Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci  2009,4(4),359-366","journal-title":"Soc Neurosci"},{"key":"ref=335","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","volume":"189","author":"Tancer M.","year":"2006","unstructured":"Tancer M.; Johanson C.E.; The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology  2006,189(4),565-573","journal-title":"Psychopharmacology"},{"key":"ref=336","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.107.129056","volume":"323","author":"Farr\u00e9 M.","year":"2007","unstructured":"Farr\u00e9 M.; Abanades S.; Roset P.N.; Peir\u00f3 A.M.; Torrens M.; O\u2019Math\u00fana B.; Segura M.; de la Torre R.; Pharmacological interaction between 3,4-methylenedioxymethamphetamine (Ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther  2007,323(3),954-962","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=337","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s002130000648","volume":"154","author":"Liechti M.E.","year":"2001","unstructured":"Liechti M.E.; Gamma A.; Vollenweider F.X.; Gender differences in the subjective effects of MDMA. Psychopharmacology  2001,154(2),161-168","journal-title":"Psychopharmacology"},{"key":"ref=338","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00213-017-4699-1","volume":"235","author":"Kuypers K.P.C.","year":"2018","unstructured":"Kuypers K.P.C.; de la Torre R.; Farre M.; Pizarro N.; Xicota L.; Ramaekers J.G.; MDMA-induced indifference to negative sounds is mediated by the 5-HT receptor. Psychopharmacology  2018,235(2),481-490","journal-title":"Psychopharmacology"},{"key":"ref=339","doi-asserted-by":"publisher","first-page":"e100719","DOI":"10.1371\/journal.pone.0100719","volume":"9","author":"Kuypers K.P.C.","year":"2014","unstructured":"Kuypers K.P.C.; de la Torre R.; Farre M.; Yubero-Lahoz S.; Dziobek I.; Van den Bos W.; Ramaekers J.G.; No Evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS One  2014,9(6),e100719","journal-title":"PLoS One"},{"key":"ref=340","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/hup.348","volume":"16","author":"Liechti M.E.","year":"2001","unstructured":"Liechti M.E.; Vollenweider F.X.; Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol  2001,16(8),589-598","journal-title":"Hum Psychopharmacol"},{"key":"ref=341","doi-asserted-by":"publisher","first-page":"115028","DOI":"10.1016\/j.bcp.2022.115028","volume":"200","author":"Casey A.B.","year":"2022","unstructured":"Casey A.B.; Cui M.; Booth R.G.; Canal C.E.; \u201cSelective\u201d serotonin 5-HT receptor antagonists. Biochem Pharmacol  2022,200,115028","journal-title":"Biochem Pharmacol"},{"key":"ref=342","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/JCP.0000000000001595","volume":"42","author":"Price C.M.","year":"2022","unstructured":"Price C.M.; Feduccia A.F.; DeBonis K.; Effects of selective serotonin reuptake inhibitor use on 3,4-methylenedioxy-methamphetamine-assisted therapy for posttraumatic stress disorder a review of the evidence, neurobiological plausibility, and clinical significance. J Clin Psychopharmacol  2022,42(5),464-469","journal-title":"J Clin Psychopharmacol"},{"key":"ref=343","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00213-012-2645-9","volume":"222","author":"Hysek C.M.","year":"2012","unstructured":"Hysek C.M.; Domes G.; Liechti M.E.; MDMA enhances \u201cmind reading\u201d of positive emotions and impairs \u201cmind reading\u201d of negative emotions. Psychopharmacology  2012,222(2),293-302","journal-title":"Psychopharmacology"},{"key":"ref=344","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/clpt.2011.78","volume":"90","author":"Hysek C.M.","year":"2011","unstructured":"Hysek C.M.; Simmler L.D.; Ineichen M.; Grouzmann E.; Hoener M.C.; Brenneisen R.; Huwyler J.; Liechti M.E.; The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cEcstasy\u201d) in humans. Clin Pharmacol Ther  2011,90(2),246-255","journal-title":"Clin Pharmacol Ther"},{"key":"ref=345","doi-asserted-by":"publisher","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","volume":"7","author":"Hysek C.M.","year":"2012","unstructured":"Hysek C.M.; Simmler L.D.; Nicola V.G.; Vischer N.; Donzelli M.; Kr\u00e4henb\u00fchl S.; Grouzmann E.; Huwyler J.; Hoener M.C.; Liechti M.E.; Duloxetine inhibits effects of MDMA (\u201cecstasy\u201d) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One  2012,7(5),e36476","journal-title":"PLoS One"},{"key":"ref=346","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/jnc.15348","volume":"157","author":"Schenk S.","year":"2021","unstructured":"Schenk S.; Highgate Q.; Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse. J Neurochem  2021,157(5),1714-1724","journal-title":"J Neurochem"},{"key":"ref=347","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.pbb.2016.10.002","volume":"150-151","author":"Ramos L.","year":"2016","unstructured":"Ramos L.; Hicks C.; Caminer A.; Couto K.; Narlawar R.; Kassiou M.; McGregor I.S.; MDMA (\u2018Ecstasy\u2019), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. Pharmacol Biochem Behav  2016,150-151,115-123","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=348","doi-asserted-by":"publisher","first-page":"e0199384","DOI":"10.1371\/journal.pone.0199384","volume":"13","author":"Vizeli P.","year":"2018","unstructured":"Vizeli P.; Liechti M.E.; Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects. PLoS One  2018,13(6),e0199384","journal-title":"PLoS One"},{"key":"ref=349","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1177\/0269881114542454","volume":"28","author":"Schmid Y.","year":"2014","unstructured":"Schmid Y.; Hysek C.M.; Simmler L.D.; Crockett M.J.; Quednow B.B.; Liechti M.E.; Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol  2014,28(9),847-856","journal-title":"J Psychopharmacol"},{"key":"ref=350","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/0269881117699617","volume":"31","author":"Kuypers K.P.C.","year":"2017","unstructured":"Kuypers K.P.C.; Dolder P.C.; Ramaekers J.G.; Liechti M.E.; Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies. J Psychopharmacol  2017,31(5),589-598","journal-title":"J Psychopharmacol"},{"key":"ref=351","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/scan\/nst161","volume":"9","author":"Hysek C.M.","year":"2014","unstructured":"Hysek C.M.; Schmid Y.; Simmler L.D.; Domes G.; Heinrichs M.; Eisenegger C.; Preller K.H.; Quednow B.B.; Liechti M.E.; MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci  2014,9(11),1645-1652","journal-title":"Soc Cogn Affect Neurosci"},{"key":"ref=352","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.psyneuen.2014.04.006","volume":"46","author":"Kirkpatrick M.G.","year":"2014","unstructured":"Kirkpatrick M.G.; Francis S.M.; Lee R.; de Wit H.; Jacob S.; Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans. Psychoneuroendocrinology  2014,46,23-31","journal-title":"Psychoneuroendocrinology"},{"key":"ref=353","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/17470919.2016.1143026","volume":"11","author":"Bershad A.K.","year":"2016","unstructured":"Bershad A.K.; Weafer J.J.; Kirkpatrick M.G.; Wardle M.C.; Miller M.A.; de Wit H.; Oxytocin receptor gene variation predicts subjective responses to MDMA. Soc Neurosci  2016,11(6),592-599","journal-title":"Soc Neurosci"},{"key":"ref=354","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1021\/acs.jproteome.8b00438","volume":"17","author":"Boxler M.I.","year":"2018","unstructured":"Boxler M.I.; Streun G.L.; Liechti M.E.; Schmid Y.; Kraemer T.; Steuer A.E.; Human metabolome changes after a single dose of 3,4-methylenedioxymethamphetamine (MDMA) with special focus on steroid metabolism and inflammation processes. J Proteome Res  2018,17(8),2900-2907","journal-title":"J Proteome Res"},{"key":"ref=355","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000364879","volume":"100","author":"Seibert J.","year":"2014","unstructured":"Seibert J.; Hysek C.M.; Penno C.A.; Schmid Y.; Kratschmar D.V.; Liechti M.E.; Odermatt A.; Acute effects of 3,4-methylenedioxymethamphetamine and methylphenidate on circulating steroid levels in healthy subjects. Neuroendocrinology  2014,100(1),17-25","journal-title":"Neuroendocrinology"},{"key":"ref=356","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00213-004-1789-7","volume":"173","author":"Farr\u00e9 M.","year":"2004","unstructured":"Farr\u00e9 M.; de la Torre R.; \u00d3 Math\u00fana B.; Roset P.N.; Peir\u00f3 A.M.; Torrens M.; Ortu\u00f1o J.; Pujadas M.; Cam\u00ed J.; Repeated doses administration of MDMA in humans: Pharmacological effects and pharmacokinetics. Psychopharmacology  2004,173(3-4),364-375","journal-title":"Psychopharmacology"},{"key":"ref=357","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00213-002-1131-1","volume":"162","author":"Harris D.S.","year":"2002","unstructured":"Harris D.S.; Baggott M.; Mendelson J.H.; Mendelson J.E.; Jones R.T.; Subjective and hormonal effects of 3,4-methylenedioxy-methamphetamine (MDMA) in humans. Psychopharmacology  2002,162(4),396-405","journal-title":"Psychopharmacology"},{"key":"ref=358","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1211\/0022357011777855","volume":"53","author":"Forsling M.","year":"2010","unstructured":"Forsling M.; Fallon J.K.; Kicman A.T.; Hutt A.J.; Cowan D.A.; Henry J.A.; Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): Is metabolism a contributory factor? J Pharm Pharmacol  2010,53(10),1357-1363","journal-title":"J Pharm Pharmacol"},{"key":"ref=359","first-page":"026988112211169","author":"Breeksema J.J.","year":"2022","unstructured":"Breeksema J.J.; Kuin B.W.; Kamphuis J.; Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharm  2022,026988112211169","journal-title":"J Psychopharm"},{"key":"ref=360","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","volume":"80","author":"McNamee S.","year":"2023","unstructured":"McNamee S.; Devenot N.; Buisson M.; Studying harms is key to improving psychedelic-assisted therapy\u2014participants call for changes to research landscape. JAMA Psychiatry  2023,80(5),411","journal-title":"JAMA Psychiatry"},{"key":"ref=361","doi-asserted-by":"publisher","first-page":"e0258849","DOI":"10.1371\/journal.pone.0258849","volume":"16","author":"Regan A.","year":"2021","unstructured":"Regan A.; Margolis S.; de Wit H.; Lyubomirsky S.; Does \u00b13,4-methylenedioxymethamphetamine (ecstasy) induce subjective feelings of social connection in humans? A multilevel meta-analysis. PLoS One  2021,16(10),e0258849","journal-title":"PLoS One"},{"key":"ref=362","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/npp.2014.12","volume":"39","author":"Kirkpatrick M.G.","year":"2014","unstructured":"Kirkpatrick M.G.; Lee R.; Wardle M.C.; Jacob S.; de Wit H.; Effects of MDMA and intranasal oxytocin on social and emotional processing. Neuropsychopharmacology  2014,39(7),1654-1663","journal-title":"Neuropsychopharmacology"},{"key":"ref=363","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.biopsych.2010.08.003","volume":"68","author":"Bedi G.","year":"2010","unstructured":"Bedi G.; Hyman D.; de Wit H.; Is Ecstasy an \u201cEmpathogen\u201d? effects of \u00b13,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry  2010,68(12),1134-1140","journal-title":"Biol Psychiatry"},{"key":"ref=364","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1017\/S1461145713001132","volume":"17","author":"Hysek C.M.","year":"2014","unstructured":"Hysek C.M.; Simmler L.D.; Schillinger N.; Meyer N.; Schmid Y.; Donzelli M.; Grouzmann E.; Liechti M.E.; Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol  2014,17(3),371-381","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=365","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00213-009-1635-z","volume":"207","author":"Bedi G.","year":"2009","unstructured":"Bedi G.; Phan K.L.; Angstadt M.; de Wit H.; Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology  2009,207(1),73-83","journal-title":"Psychopharmacology"},{"key":"ref=366","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"Mithoefer M.C.","year":"2011","unstructured":"Mithoefer M.C.; Wagner M.T.; Mithoefer A.T.; Jerome L.; Doblin R.; The safety and efficacy of \u00b13,4-methylenedioxy-methamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. J Psychopharmacol  2011,25(4),439-452","journal-title":"J Psychopharmacol"},{"key":"ref=367","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/02791072.2008.10400637","volume":"40","author":"Bouso J.C.","year":"2008","unstructured":"Bouso J.C.; Doblin R.; Farr\u00e9 M.; Alc\u00e1zar M.\u00c1.; G\u00f3mez-Jarabo G.; MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs  2008,40(3),225-236","journal-title":"J Psychoactive Drugs"},{"key":"ref=368","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/0269881115626348","volume":"30","author":"Baggott M.J.","year":"2016","unstructured":"Baggott M.J.; Coyle J.R.; Siegrist J.D.; Garrison K.J.; Galloway G.P.; Mendelson J.E.; Effects of 3,4-methylenedioxy-methamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol  2016,30(4),378-387","journal-title":"J Psychopharmacol"},{"key":"ref=369","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/0269881115581962","volume":"29","author":"Baggott M.J.","year":"2015","unstructured":"Baggott M.J.; Kirkpatrick M.G.; Bedi G.; de Wit H.; Intimate insight: MDMA changes how people talk about significant others. J Psychopharmacol  2015,29(6),669-677","journal-title":"J Psychopharmacol"},{"key":"ref=370","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbb.2013.11.030","volume":"117","author":"Frye C.G.","year":"2014","unstructured":"Frye C.G.; Wardle M.C.; Norman G.J.; de Wit H.; MDMA decreases the effects of simulated social rejection. Pharmacol Biochem Behav  2014,117,1-6","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=371","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/cpp.2642","volume":"29","author":"Howard R.","year":"2022","unstructured":"Howard R.; Berry K.; Haddock G.; Therapeutic alliance in psychological therapy for posttraumatic stress disorder: A systematic review and meta-analysis. Clin Psychol Psychother  2022,29(2),373-399","journal-title":"Clin Psychol Psychother"},{"key":"ref=372","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0269881120926673","volume":"35","author":"Borissova A.","year":"2021","unstructured":"Borissova A.; Ferguson B.; Wall M.B.; Morgan C.J.A.; Carhart-Harris R.L.; Bolstridge M.; Bloomfield M.A.P.; Williams T.M.; Feilding A.; Murphy K.; Tyacke R.J.; Erritzoe D.; Stewart L.; Wolff K.; Nutt D.; Curran H.V.; Lawn W.; Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. J Psychopharmacol  2021,35(5),547-555","journal-title":"J Psychopharmacol"},{"key":"ref=373","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1523\/JNEUROSCI.1276-18.2018","volume":"39","author":"Gabay A.S.","year":"2019","unstructured":"Gabay A.S.; Kempton M.J.; Gilleen J.; Mehta M.A.; MDMA increases cooperation and recruitment of social brain areas when playing trustworthy players in an iterated prisoner\u2019s dilemma. J Neurosci  2019,39(2),307-320","journal-title":"J Neurosci"},{"key":"ref=374","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0893-133X(00)00130-5","volume":"23","author":"Gamma A.","year":"2000","unstructured":"Gamma A.; 3,4-methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H215O]-PET in healthy humans. Neuropsychopharmacology  2000,23(4),388-395","journal-title":"Neuropsychopharmacology"},{"key":"ref=375","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1600-0447.2011.01755.x","volume":"124","author":"Lanius R.A.","year":"2011","unstructured":"Lanius R.A.; Bluhm R.L.; Frewen P.A.; How understanding the neurobiology of complex post-traumatic stress disorder can inform clinical practice: A social cognitive and affective neuroscience approach. Acta Psychiatr Scand  2011,124(5),331-348","journal-title":"Acta Psychiatr Scand"},{"key":"ref=376","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.biopsych.2013.12.015","volume":"78","author":"Carhart-Harris R.L.","year":"2015","unstructured":"Carhart-Harris R.L.; Murphy K.; Leech R.; Erritzoe D.; Wall M.B.; Ferguson B.; Williams L.T.J.; Roseman L.; Brugger S.; De Meer I.; Tanner M.; Tyacke R.; Wolff K.; Sethi A.; Bloomfield M.A.P.; Williams T.M.; Bolstridge M.; Stewart L.; Morgan C.; Newbould R.D.; Feilding A.; Curran H.V.; Nutt D.J.; The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. Biol Psychiatry  2015,78(8),554-562","journal-title":"Biol Psychiatry"},{"key":"ref=377","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1017\/S1461145713001405","volume":"17","author":"Carhart-Harris R.L.","year":"2014","unstructured":"Carhart-Harris R.L.; Wall M.B.; Erritzoe D.; Kaelen M.; Ferguson B.; De Meer I.; Tanner M.; Bloomfield M.; Williams T.M.; Bolstridge M.; Stewart L.; Morgan C.J.; Newbould R.D.; Feilding A.; Curran H.V.; Nutt D.J.; The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol  2014,17(4),527-540","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=378","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"Carhart-Harris R.L.","year":"2012","unstructured":"Carhart-Harris R.L.; Erritzoe D.; Williams T.; Stone J.M.; Reed L.J.; Colasanti A.; Tyacke R.J.; Leech R.; Malizia A.L.; Murphy K.; Hobden P.; Evans J.; Feilding A.; Wise R.G.; Nutt D.J.; Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci  2012,109(6),2138-2143","journal-title":"Proc Natl Acad Sci"},{"key":"ref=379","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/scan\/nsq080","volume":"6","author":"Berman M.G.","year":"2011","unstructured":"Berman M.G.; Peltier S.; Nee D.E.; Kross E.; Deldin P.J.; Jonides J.; Depression, rumination and the default network. Soc Cogn Affect Neurosci  2011,6(5),548-555","journal-title":"Soc Cogn Affect Neurosci"},{"key":"ref=380","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/npp.2017.35","volume":"42","author":"Walpola I.C.","year":"2017","unstructured":"Walpola I.C.; Nest T.; Roseman L.; Erritzoe D.; Feilding A.; Nutt D.J.; Carhart-Harris R.L.; Altered insula connectivity under MDMA. Neuropsychopharmacology  2017,42(11),2152-2162","journal-title":"Neuropsychopharmacology"},{"key":"ref=381","doi-asserted-by":"publisher","first-page":"20160002","DOI":"10.1098\/rstb.2016.0002","volume":"371","author":"Tsakiris M","year":"2016","unstructured":"Tsakiris M; Critchley H.; Interoception beyond homeostasis: Affect,\ncognition and mental health. Biol Sci  2016,371(1708),20160002","journal-title":"Biol Sci"},{"key":"ref=382","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/tp.2015.84","volume":"5","author":"Alvarez R.P.","year":"2015","unstructured":"Alvarez R.P.; Kirlic N.; Misaki M.; Increased anterior insula activity in anxious individuals is linked to diminished perceived control. Transl Psychiat  2015,5,591","journal-title":"Transl Psychiat"},{"key":"ref=383","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1176\/appi.ajp.2007.07030504","volume":"164","author":"Etkin A.","year":"2007","unstructured":"Etkin A.; Wager T.D.; Functional neuroimaging of anxiety: A meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry  2007,164(10),1476-1488","journal-title":"Am J Psychiatry"},{"key":"ref=384","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1523\/JNEUROSCI.5587-06.2007","volume":"27","author":"Seeley W.W.","year":"2007","unstructured":"Seeley W.W.; Menon V.; Schatzberg A.F.; Keller J.; Glover G.H.; Kenna H.; Reiss A.L.; Greicius M.D.; Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci  2007,27(9),2349-2356","journal-title":"J Neurosci"},{"key":"ref=385","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/070674371405900602","volume":"59","author":"Peterson A.","year":"2014","unstructured":"Peterson A.; Thome J.; Frewen P.; Lanius R.A.; Resting state neuroimaging studies: A new way of identifying differences and similarities among the anxiety disorders? Can J Psychiatry  2014,59(6),294-300","journal-title":"Can J Psychiatry"},{"key":"ref=386","doi-asserted-by":"publisher","first-page":"959590","DOI":"10.3389\/fpsyt.2023.959590","volume":"14","author":"Lewis C.R.","year":"2023","unstructured":"Lewis C.R.; Tafur J.; Spencer S.; Green J.M.; Harrison C.; Kelmendi B.; Rabin D.M.; Yehuda R.; Yazar-Klosinski B.; Cahn B.R.; Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD. Front Psychiatry  2023,14,959590","journal-title":"Front Psychiatry"},{"key":"ref=387","author":"Siegel D.J.","year":"1999","unstructured":"Siegel D.J.;  The developing mind: Toward a neurobiology of interpersonal experience  1999","journal-title":"The developing mind: Toward a neurobiology of interpersonal experience"},{"key":"ref=388","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/0269881109354930","volume":"25","author":"Corrigan F.M.","year":"2011","unstructured":"Corrigan F.M.; Fisher J.J.; Nutt D.J.; Autonomic dysregulation and the Window of Tolerance model of the effects of complex emotional trauma. J Psychopharmacol  2011,25(1),17-25","journal-title":"J Psychopharmacol"},{"key":"ref=389","author":"Wilbarger PaJ.W.","year":"1997","unstructured":"Wilbarger PaJ.W.;  Sensory defensiveness and related social\/\nemotional and neurological problems  1997","journal-title":"Sensory defensiveness and related social\/\nemotional and neurological problems"},{"key":"ref=390","doi-asserted-by":"publisher","first-page":"906639","DOI":"10.3389\/fphar.2022.906639","volume":"13","author":"Vizeli P.","year":"2022","unstructured":"Vizeli P.; Straumann I.; Duthaler U.; Varghese N.; Eckert A.; Paulus M.P.; Risbrough V.; Liechti M.E.; Effects of 3, 4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects. Front Pharmacol  2022,13,906639","journal-title":"Front Pharmacol"},{"key":"ref=391","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/jnr.25017","volume":"100","author":"Glavonic E.","year":"2022","unstructured":"Glavonic E.; Mitic M.; Adzic M.; Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction. J Neurosci Res  2022,100(4),947-969","journal-title":"J Neurosci Res"},{"key":"ref=392","doi-asserted-by":"publisher","first-page":"108195","DOI":"10.1016\/j.pharmthera.2022.108195","volume":"239","author":"Raut S.B.","year":"2022","unstructured":"Raut S.B.; Marathe P.A.; van Eijk L.; Eri R.; Ravindran M.; Benedek D.M.; Ursano R.J.; Canales J.J.; Johnson L.R.; Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. Pharmacol Ther  2022,239,108195","journal-title":"Pharmacol Ther"},{"key":"ref=393","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/02698811211069124","volume":"36","author":"Maples-Keller J.L.","year":"2022","unstructured":"Maples-Keller J.L.; Norrholm S.D.; Burton M.; Reiff C.; Coghlan C.; Jovanovic T.; Yasinski C.; Jarboe K.; Rakofsky J.; Rauch S.; Dunlop B.W.; Rothbaum B.O.; A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J Psychopharmacol  2022,36(3),368-377","journal-title":"J Psychopharmacol"},{"key":"ref=394","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","volume":"84","author":"Feduccia A.A.","year":"2018","unstructured":"Feduccia A.A.; Mithoefer M.C.; MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry  2018,84,221-228","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=395","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1038\/tp.2015.138","volume":"5","author":"Young M.B.","year":"2015","unstructured":"Young M.B.; Andero R.; Ressler K.J.; Howell L.L.; 3,4-\nmethylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry  2015,5(9),e634-e","journal-title":"Transl Psychiatry"},{"key":"ref=396","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1007\/s00213-017-4684-8","volume":"234","author":"Young M.B.","year":"2017","unstructured":"Young M.B.; Norrholm S.D.; Khoury L.M.; Jovanovic T.; Rauch S.A.M.; Reiff C.M.; Dunlop B.W.; Rothbaum B.O.; Howell L.L.; Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxy-methamphetamine (MDMA). Psychopharmacology  2017,234(19),2883-2895","journal-title":"Psychopharmacology"},{"key":"ref=397","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jts.2490090305","volume":"9","author":"Calhoun Ta.","year":"1996","unstructured":"Calhoun Ta.; The posttraumatic growth inventory: Measuring the positive legacy of trauma. J Trauma Stress  1996,9(3),455-471","journal-title":"J Trauma Stress"},{"key":"ref=398","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3389\/fpsyt.2019.00650","volume":"10","author":"Feduccia A.A.","year":"2019","unstructured":"Feduccia A.A.; Jerome L.; Yazar-Klosinski B.; Emerson A.; Mithoefer M.C.; Doblin R.; Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry  2019,10,650","journal-title":"Front Psychiatry"},{"key":"ref=399","doi-asserted-by":"publisher","first-page":"1840123","DOI":"10.1080\/20008198.2020.1840123","volume":"11","author":"Monson C.M.","year":"2020","unstructured":"Monson C.M.; Wagner A.C.; Mithoefer A.T.; Liebman R.E.; Feduccia A.A.; Jerome L.; Yazar-Klosinski B.; Emerson A.; Doblin R.; Mithoefer M.C.; MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: An uncontrolled trial. Eur J Psychotraumatol  2020,11(1),1840123","journal-title":"Eur J Psychotraumatol"},{"key":"ref=400","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"Johnson M.W.","year":"2019","unstructured":"Johnson M.W.; Hendricks P.S.; Barrett F.S.; Griffiths R.R.; Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther  2019,197,83-102","journal-title":"Pharmacol Ther"},{"key":"ref=401","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fnint.2018.00054","volume":"12","author":"Zamberlan F.","year":"2018","unstructured":"Zamberlan F.; Sanz C.; Mart\u00ednez V.R.; Pallavicini C.; Erowid F.; Erowid E.; Tagliazucchi E.; The varieties of the psychedelic experience: a preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines. Front Integr Nuerosci  2018,12,54","journal-title":"Front Integr Nuerosci"},{"key":"ref=402","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1073\/pnas.40.4.228","volume":"40","author":"Woolley D.W.","year":"1954","unstructured":"Woolley D.W.; Shaw E.; A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci  1954,40(4),228-231","journal-title":"Proc Natl Acad Sci"},{"key":"ref=403","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nrl.2011.07.003","volume":"30","author":"Carod-Artal F.J.","year":"2015","unstructured":"Carod-Artal F.J.; Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia  2015,30(1),42-49","journal-title":"Neurologia"},{"key":"ref=404","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","volume":"73","author":"Nichols D.E.","year":"2020","unstructured":"Nichols D.E.; Psilocybin: From ancient magic to modern medicine. J Antibiot  2020,73(10),679-686","journal-title":"J Antibiot"},{"key":"ref=405","first-page":"9","volume":"100","author":"Wasson R.G.","year":"1957","unstructured":"Wasson R.G.; Life magazine: Seeking the magic mushroom. Time Inc Magaz Comp  1957,100(2),9-20","journal-title":"Time Inc Magaz Comp"},{"key":"ref=406","first-page":"241","volume":"11","author":"Busch A.K.","year":"1950","unstructured":"Busch A.K.; Johnson W.C.L.S.D.; 25 as an aid in psychotherapy: Preliminary report of a new drug. Dis Nerv Syst  1950,11(8),241-243","journal-title":"Dis Nerv Syst"},{"key":"ref=407","author":"Bastiaans J.","year":"1984","unstructured":"Bastiaans J.;  Mental Liberation Facilitated by the Use of Hallucinogenic Drugs  1984","journal-title":"Mental Liberation Facilitated by the Use of Hallucinogenic Drugs"},{"key":"ref=408","author":"Luna L.E.","unstructured":"Luna L.E.;   The Ethnopharmacology of Ayahuasca: Indigenous and\nmestizo use of ayahuasca. An overview: In: Transworl.Res. Netw;\n2011, pp. 1-21."},{"key":"ref=409","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/02791072.1984.10472305","volume":"16","author":"McKenna D.J.","year":"1984","unstructured":"McKenna D.J.; Towers G.H.N.; Biochemistry and pharmacology of tryptamines and \u03b2-carbolines a minireview. J Psychoactive Drugs  1984,16(4),347-358","journal-title":"J Psychoactive Drugs"},{"key":"ref=410","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0378-8741(79)90003-5","volume":"1","author":"Naranjo P.","year":"1979","unstructured":"Naranjo P.; Hallucinogenic plant use and related indigenous belief systems in the ecuadorian amazon. J Ethnopharmacol  1979,1(2),121-145","journal-title":"J Ethnopharmacol"},{"key":"ref=411","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0378-8741(84)90036-9","volume":"11","author":"Luna L.E.","year":"1984","unstructured":"Luna L.E.; The concept of plants as teachers among four mestizo shamans of iquitos. Northeastern Peru J Ethnopharmacol  1984,11(2),135-156","journal-title":"Northeastern Peru J Ethnopharmacol"},{"key":"ref=412","author":"Villavicencio M.","year":"1858","unstructured":"Villavicencio M.;  Geography of the Republic of Ecuador; R  1858","journal-title":"Geography of the Republic of Ecuador; R"},{"key":"ref=413","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pharmthera.2004.03.002","volume":"102","author":"McKenna D.J.","year":"2004","unstructured":"McKenna D.J.; Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges. Pharmacol Ther  2004,102(2),111-129","journal-title":"Pharmacol Ther"},{"key":"ref=414","unstructured":"Veteran Psychedelic Group Therapy Fellowship Available from:  https:\/\/www.veteransofwar.org\/how (updated 07-2019)."},{"key":"ref=415","unstructured":""},{"key":"ref=416","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0022167816673493","volume":"57","author":"Bogenschutz M.P.","year":"2017","unstructured":"Bogenschutz M.P.; Forcehimes A.A.; Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. J Humanist Psychol  2017,57(4),389-414","journal-title":"J Humanist Psychol"},{"key":"ref=417","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"Johnson M.W.","year":"2008","unstructured":"Johnson M.W.; Richards W.A.; Griffiths R.R.; Human hallucinogen research: Guidelines for safety. J Psychopharmacol  2008,22(6),603-620","journal-title":"J Psychopharmacol"},{"key":"ref=418","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/acsptsci.0c00187","volume":"4","author":"Strickland J.C.","year":"2021","unstructured":"Strickland J.C.; Garcia-Romeu A.; Johnson M.W.; Set and setting: A randomized study of different musical genres in supporting psychedelic therapy. ACS Pharmacol Transl Sci  2021,4(2),472-478","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref=419","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1007\/s00213-015-4014-y","volume":"232","author":"Kaelen M.","year":"2015","unstructured":"Kaelen M.; Barrett F.S.; Roseman L.; Lorenz R.; Family N.; Bolstridge M.; Curran H.V.; Feilding A.; Nutt D.J.; Carhart-Harris R.L.; LSD enhances the emotional response to music. Psychopharmacology  2015,232(19),3607-3614","journal-title":"Psychopharmacology"},{"key":"ref=420","doi-asserted-by":"publisher","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","volume":"7","author":"Studerus E.","year":"2012","unstructured":"Studerus E.; Gamma A.; Kometer M.; Vollenweider F.X.; Prediction of psilocybin response in healthy volunteers. PLoS One  2012,7(2),e30800","journal-title":"PLoS One"},{"key":"ref=421","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"Griffiths R.R.","year":"2006","unstructured":"Griffiths R.R.; Richards W.A.; McCann U.; Jesse R.; Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology  2006,187(3),268-283","journal-title":"Psychopharmacology"},{"key":"ref=422","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","volume":"3","author":"Mithoefer M.C.","year":"2016","unstructured":"Mithoefer M.C.; Grob C.S.; Brewerton T.D.; Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA. Lancet Psychiatry  2016,3(5),481-488","journal-title":"Lancet Psychiatry"},{"key":"ref=423","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fpsyt.2019.00943","volume":"21","author":"Fuentes J.","year":"2020","unstructured":"Fuentes J.; Fuentes J.J.; Fonseca F.; Ellices M.; Farr\u00e9 M.; Torrens M.; Therapeutic use of lsd in psychiatry: A systematic review of randomized controlled clinical trials. Front Psychiatry  2020,21,10-943","journal-title":"Front Psychiatry"},{"key":"ref=424","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","volume":"212","author":"Pahnke W.N.","year":"1970","unstructured":"Pahnke W.N.; Kurland A.A.; Unger S.; Savage C.; Grof S.; The experimental use of psychedelic (LSD) psychotherapy. JAMA  1970,212(11),1856-1863","journal-title":"JAMA"},{"key":"ref=425","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-40426-9","author":"Labate B.","year":"2014","unstructured":"Labate B.;  The therapeutic use of ayahuasca  2014","journal-title":"The therapeutic use of ayahuasca"},{"key":"ref=426","doi-asserted-by":"publisher","DOI":"10.1177\/00221678211008331","author":"Bathje G.J.","year":"2021","unstructured":"Bathje G.J.; Fenton J.; Pillersdorf D.; Hill L.C.; A qualitative study of intention and impact of ayahuasca use by westerners. J Humanist Psychol  2021","journal-title":"J Humanist Psychol"},{"key":"ref=427","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s00213-021-05817-8","volume":"238","author":"Uthaug M.V.","year":"2021","unstructured":"Uthaug M.V.; Mason N.L.; Toennes S.W.; Reckweg J.T.; de Sousa F.P.E.B.; Kuypers K.P.C.; van Oorsouw K.; Riba J.; Ramaekers J.G.; A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology  2021,238(7),1899-1910","journal-title":"Psychopharmacology"},{"key":"ref=428","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/02791072.2005.10399799","volume":"37","author":"Baker J.R.","year":"2005","unstructured":"Baker J.R.; Psychedelic sacraments. J Psychoactive Drugs  2005,37(2),179-187","journal-title":"J Psychoactive Drugs"},{"key":"ref=429","doi-asserted-by":"publisher","DOI":"10.1177\/00221678211043300","author":"Callon C.","year":"2021","unstructured":"Callon C.; Williams M.; Lafrance A.; \u201cMeeting the medicine halfway\u201d: Ayahuasca ceremony leaders\u2019 perspectives on preparation and integration practices for participants. J Humanist Psychol  2021","journal-title":"J Humanist Psychol"},{"key":"ref=430","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1176\/appi.psychotherapy.1965.19.3.417","volume":"19","author":"Ludwig A.M.","year":"1965","unstructured":"Ludwig A.M.; Levine J.; A controlled comparison of five brief treatment techniques employing LSD, hypnosis, and psychotherapy. Am J Psychother  1965,19(3),417-435","journal-title":"Am J Psychother"},{"key":"ref=431","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/7854_2016_459","volume":"36","author":"Preller K.H.","year":"2016","unstructured":"Preller K.H.; Vollenweider F.X.; Phenomenology, structure, and dynamic of psychedelic states. Curr Top Behav Neurosci  2016,36,221-256","journal-title":"Curr Top Behav Neurosci"},{"key":"ref=432","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11097-010-9157-z","volume":"9","author":"D\u00edaz J.L.","year":"2010","unstructured":"D\u00edaz J.L.; Sacred plants and visionary consciousness. Phenomenol Cogn Sci  2010,9(2),159-170","journal-title":"Phenomenol Cogn Sci"},{"key":"ref=433","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.brainresbull.2016.03.002","volume":"126","author":"Dom\u00ednguez-Clav\u00e9 E.","year":"2016","unstructured":"Dom\u00ednguez-Clav\u00e9 E.; Soler J.; Elices M.; Pascual J.C.; \u00c1lvarez E.; de la Fuente Revenga M.; Friedlander P.; Feilding A.; Riba J.; Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Res Bull  2016,126,89-101","journal-title":"Brain Res Bull"},{"key":"ref=434","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/hbm.21381","volume":"33","author":"de Araujo D.B.","year":"2012","unstructured":"de Araujo D.B.; Ribeiro S.; Cecchi G.A.; Carvalho F.M.; Sanchez T.A.; Pinto J.P.; de Martinis B.S.; Crippa J.A.; Hallak J.E.C.; Santos A.C.; Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion. Hum Brain Mapp  2012,33(11),2550-2560","journal-title":"Hum Brain Mapp"},{"key":"ref=435","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biopsych.2010.10.002","volume":"69","author":"Kometer M.","year":"2011","unstructured":"Kometer M.; Cahn B.R.; Andel D.; Carter O.L.; Vollenweider F.X.; The 5-HT\/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry  2011,69(5),399-406","journal-title":"Biol Psychiatry"},{"key":"ref=436","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"Studerus E.","year":"2011","unstructured":"Studerus E.; Kometer M.; Hasler F.; Vollenweider F.X.; Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J Psychopharmacol  2011,25(11),1434-1452","journal-title":"J Psychopharmacol"},{"key":"ref=437","first-page":"3","volume":"9","author":"Shanon B.","year":"2002","unstructured":"Shanon B.; Ayahuasca visualizations: A structural typology. J Conscious Stud  2002,9,3-30","journal-title":"J Conscious Stud"},{"key":"ref=438","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"Dittrich A.","year":"1998","unstructured":"Dittrich A.; The standardized psychometric assessment of altered\nstates of consciousness (ASCs) in humans. Pharmacopsychiatry,  1998,31(S 2)(2),80-84","journal-title":"Pharmacopsychiatry,"},{"key":"ref=439","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fphar.2016.00211","volume":"7","author":"Gallimore A.R.","year":"2016","unstructured":"Gallimore A.R.; Strassman R.J.; A model for the application of target-controlled intravenous infusion for a prolonged immersive DMT psychedelic experience. Front Pharmacol  2016,7,211","journal-title":"Front Pharmacol"},{"key":"ref=440","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","volume":"51","author":"Strassman R.J.","year":"1994","unstructured":"Strassman R.J.; Qualls C.R.; Uhlenhuth E.H.; Kellner R.; Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry  1994,51(2),98-108","journal-title":"Arch Gen Psychiatry"},{"key":"ref=441","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fpsyg.2017.01238","volume":"8","author":"Barrett F.S.","year":"2017","unstructured":"Barrett F.S.; Robbins H.; Smooke D.; Brown J.L.; Griffiths R.R.; Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions. Front Psychol  2017,8,1238","journal-title":"Front Psychol"},{"key":"ref=442","first-page":"286","author":"Leuner H.","year":"2013","unstructured":"Leuner H.;  In: Versuch Einer Konditonal-Genetischen und Funktionalen Psychopathologie der Psychose  2013,286","journal-title":"In: Versuch Einer Konditonal-Genetischen und Funktionalen Psychopathologie der Psychose"},{"key":"ref=443","first-page":"837","volume":"81","author":"Fischer R.","year":"1951","unstructured":"Fischer R.; Georgi F.; Weber R.; Psychophysical correlations. VIII. Experimental tests in schizophrenia; lysergic acid diethylamide and mescaline. Schweiz Med Wochenschr  1951,81(35),837-840","journal-title":"Schweiz Med Wochenschr"},{"key":"ref=444","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/2071049a0","volume":"207","author":"Fischer R.","year":"1965","unstructured":"Fischer R.; Griffin F.; Archer R.C.; Zinsmeister S.C.; Jastram P.S.; Weber ratio in gustatory chemoreception; an indicator of systemic (Drug) reactivity. Nature  1965,207(5001),1049-1053","journal-title":"Nature"},{"key":"ref=445","first-page":"183","volume":"9","author":"Fischer R.","year":"1966","unstructured":"Fischer R.; Kaelbling R.; Increase in taste acuity with sympathetic stimulation: The relation of a justnoticeable taste difference to systemic psychotropic drug dose. Recent Adv Biol Psychiatry  1966,9,183-195","journal-title":"Recent Adv Biol Psychiatry"},{"key":"ref=446","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/0269881121992676","volume":"35","author":"Hirschfeld T.","year":"2021","unstructured":"Hirschfeld T.; Schmidt T.T.; Doseresponse relationships of psilocybininduced subjective experiences in humans. J Psychopharmacol  2021,35(4),384-397","journal-title":"J Psychopharmacol"},{"key":"ref=447","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"Hasler F.","year":"2004","unstructured":"Hasler F.; Grimberg U.; Benz M.A.; Huber T.; Vollenweider F.X.; Acute psychological and physiological effects of psilocybin in healthy humans: A doubleblind, placebocontrolled dose?effect study. Psychopharmacology  2004,172(2),145-156","journal-title":"Psychopharmacology"},{"key":"ref=448","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/00005053-196001000-00005","volume":"130","author":"Cohen S.","year":"1960","unstructured":"Cohen S.; Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis  1960,130(1),30-40","journal-title":"J Nerv Ment Dis"},{"key":"ref=449","doi-asserted-by":"publisher","first-page":"109214","DOI":"10.1016\/j.neuropharm.2022.109214","volume":"219","author":"Belouin S.J.","year":"2022","unstructured":"Belouin S.J.; Averill L.A.; Henningfield J.E.; Xenakis S.N.; Donato I.; Grob C.S.; Berger A.; Magar V.; Danforth A.L.; Anderson B.T.; Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. Neuropharmacology  2022,219,109214","journal-title":"Neuropharmacology"},{"key":"ref=450","doi-asserted-by":"publisher","first-page":"102997","DOI":"10.1016\/j.drugpo.2020.102997","volume":"87","author":"Gashi L.","year":"2021","unstructured":"Gashi L.; Sandberg S.; Pedersen W.; Making \u201cbad trips\u201d good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int J Drug Policy  2021,87,102997","journal-title":"Int J Drug Policy"},{"key":"ref=451","doi-asserted-by":"publisher","first-page":"879221","DOI":"10.3389\/fnins.2022.879221","volume":"16","author":"Perkins D.","year":"2023","unstructured":"Perkins D.; Ruffell S.G.D.; Day K.; Pinzon Rubiano D.; Sarris J.; Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use. Front Neurosci  2023,16,879221","journal-title":"Front Neurosci"},{"key":"ref=452","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"Griffiths R.R.","year":"2008","unstructured":"Griffiths R.R.; Richards W.A.; Johnson M.W.; McCann U.D.; Jesse R.; Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol  2008,22(6),621-632","journal-title":"J Psychopharmacol"},{"key":"ref=453","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"Palhano-Fontes F.","year":"2019","unstructured":"Palhano-Fontes F.; Barreto D.; Onias H.; Andrade K.C.; Novaes M.M.; Pessoa J.A.; Mota-Rolim S.A.; Os\u00f3rio F.L.; Sanches R.; dos Santos R.G.; T\u00f3foli L.F.; de Oliveira Silveira G.; Yonamine M.; Riba J.; Santos F.R.; Silva-Junior A.A.; Alchieri J.C.; Galv\u00e3o-Coelho N.L.; Lob\u00e3o-Soares B.; Hallak J.E.C.; Arcoverde E.; Maia-de-Oliveira J.P.; Ara\u00fajo D.B.; Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychol Med  2019,49(4),655-663","journal-title":"Psychol Med"},{"key":"ref=454","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00213-016-4453-0","volume":"234","author":"Liechti M.E.","year":"2017","unstructured":"Liechti M.E.; Dolder P.C.; Schmid Y.; Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology  2017,234(9-10),1499-1510","journal-title":"Psychopharmacology"},{"key":"ref=455","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","volume":"47","author":"Holze F.","year":"2022","unstructured":"Holze F.; Ley L.; M\u00fcller F.; Becker A.M.; Straumann I.; Vizeli P.; Kuehne S.S.; Roder M.A.; Duthaler U.; Kolaczynska K.E.; Varghese N.; Eckert A.; Liechti M.E.; Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology  2022,47(6),1180-1187","journal-title":"Neuropsychopharmacology"},{"key":"ref=456","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1556\/2054.2022.00198","volume":"6","author":"Gandy S.","year":"2022","unstructured":"Gandy S.; Predictors and potentiators of psychedelic-occasioned mystical experiences. J Psychedelic Stud  2022,6(1),31-47","journal-title":"J Psychedelic Stud"},{"key":"ref=457","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"Roseman L.","year":"2018","unstructured":"Roseman L.; Nutt D.J.; Carhart-Harris R.L.; Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol  2018,8,974","journal-title":"Front Pharmacol"},{"key":"ref=458","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/09687637.2020.1854688","volume":"28","author":"Williams M.T.","year":"2021","unstructured":"Williams M.T.; Davis A.K.; Xin Y.; Sepeda N.D.; Grigas P.C.; Sinnott S.; Haeny A.M.; People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs Educ Prev Policy  2021,28(3),215-226","journal-title":"Drugs Educ Prev Policy"},{"key":"ref=459","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00213-020-05756-w","volume":"238","author":"Healy C.J.","year":"2021","unstructured":"Healy C.J.; The acute effects of classic psychedelics on memory in humans. Psychopharmacology  2021,238(3),639-653","journal-title":"Psychopharmacology"},{"key":"ref=460","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1162\/089892905774597191","volume":"17","author":"Carter O.L.","year":"2005","unstructured":"Carter O.L.; Burr D.C.; Pettigrew J.D.; Wallis G.M.; Hasler F.; Vollenweider F.X.; Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci  2005,17(10),1497-1508","journal-title":"J Cogn Neurosci"},{"key":"ref=461","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/0269881106065859","volume":"21","author":"Wittmann M.","year":"2007","unstructured":"Wittmann M.; Carter O.; Hasler F.; Cahn B.R.; Grimberg U.; Spring P.; Hell D.; Flohr H.; Vollenweider F.X.; Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol  2007,21(1),50-64","journal-title":"J Psychopharmacol"},{"key":"ref=462","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","volume":"237","author":"Family N.","year":"2020","unstructured":"Family N.; Maillet E.L.; Williams L.T.J.; Krediet E.; Carhart-Harris R.L.; Williams T.M.; Nichols C.D.; Goble D.J.; Raz S.; Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology  2020,237(3),841-853","journal-title":"Psychopharmacology"},{"key":"ref=463","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","volume":"86","author":"Bershad A.K.","year":"2019","unstructured":"Bershad A.K.; Schepers S.T.; Bremmer M.P.; Lee R.; de Wit H.; Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry  2019,86(10),792-800","journal-title":"Biol Psychiatry"},{"key":"ref=464","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-013-3167-9","volume":"230","author":"Bouso J.C.","year":"2013","unstructured":"Bouso J.C.; F\u00e1bregas J.M.; Antonijoan R.M.; Rodr\u00edguez-Fornells A.; Riba J.; Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. Psychopharmacology  2013,230(3),415-424","journal-title":"Psychopharmacology"},{"key":"ref=465","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/ijnp\/pyx047","volume":"20","author":"Pokorny T.","year":"2017","unstructured":"Pokorny T.; Preller K.H.; Kometer M.; Dziobek I.; Vollenweider F.X.; Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol  2017,20(9),747-757","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=466","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1038\/npp.2016.82","volume":"41","author":"Dolder P.C.","year":"2016","unstructured":"Dolder P.C.; Schmid Y.; M\u00fcller F.; Borgwardt S.; Liechti M.E.; LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology  2016,41(11),2638-2646","journal-title":"Neuropsychopharmacology"},{"key":"ref=467","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","volume":"72","author":"Kometer M.","year":"2012","unstructured":"Kometer M.; Schmidt A.; Bachmann R.; Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry  2012,72(11),898-906","journal-title":"Biol Psychiatry"},{"key":"ref=468","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"Watts R.","year":"2017","unstructured":"Watts R.; Day C.; Krzanowski J.; Nutt D.; Carhart-Harris R.; Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol  2017,57(5),520-564","journal-title":"J Humanist Psychol"},{"key":"ref=469","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1093\/cercor\/bht178","volume":"24","author":"Bernasconi F.","year":"2014","unstructured":"Bernasconi F.; Schmidt A.; Pokorny T.; Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A\/2A receptor agonist psilocybin. Cerebral cortex  2014,24(12),3221-3231","journal-title":"Cerebral cortex"},{"key":"ref=470","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00213-012-2811-0","volume":"225","author":"Schmidt A.","year":"2013","unstructured":"Schmidt A.; Kometer M.; Bachmann R.; Seifritz E.; Vollenweider F.; The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology  2013,225(1),227-239","journal-title":"Psychopharmacology"},{"key":"ref=471","doi-asserted-by":"publisher","first-page":"e1084","DOI":"10.1038\/tp.2017.54","volume":"7","author":"Mueller F.","year":"2017","unstructured":"Mueller F.; Lenz C.; Dolder P.C.; Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Translational Psychiatry  2017,7(4),e1084-e","journal-title":"Translational Psychiatry"},{"key":"ref=472","doi-asserted-by":"publisher","first-page":"721537","DOI":"10.3389\/fphar.2021.721537","volume":"12","author":"Kiraga M.K.","year":"2021","unstructured":"Kiraga M.K.; Mason N.L.; Uthaug M.V.; van Oorsouw K.I.M.; Toennes S.W.; Ramaekers J.G.; Kuypers K.P.C.; Persisting effects of ayahuasca on empathy, creative thinking, decentering, personality, and well-being. Front Pharmacol  2021,12,721537","journal-title":"Front Pharmacol"},{"key":"ref=473","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/JCP.0000000000001396","volume":"41","author":"Rocha J.M.","year":"2021","unstructured":"Rocha J.M.; Rossi G.N.; de Lima Os\u00f3rio F.; Bouso J.C.; de Oliveira Silveira G.; Yonamine M.; Campos A.C.; Bertozi G.; Cec\u00edlio Hallak J.E.; dos Santos R.G.; Effects of ayahuasca on the recognition of facial expressions of emotions in naive healthy volunteers. J Clin Psychopharmacol  2021,41(3),267-274","journal-title":"J Clin Psychopharmacol"},{"key":"ref=474","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ijnp\/pyx036","volume":"20","author":"Sampedro F.","year":"2017","unstructured":"Sampedro F.; de la Fuente Revenga M.; Valle M.; Roberto N.; Dom\u00ednguez-Clav\u00e9 E.; Elices M.; Luna L.E.; Crippa J.A.S.; Hallak J.E.C.; de Araujo D.B.; Friedlander P.; Barker S.A.; \u00c1lvarez E.; Soler J.; Pascual J.C.; Feilding A.; Riba J.; Assessing the psychedelic \u201cafter-glow\u201d in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. Int J Neuropsychopharmacol  2017,20(9),698-711","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=475","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00213-015-4162-0","volume":"233","author":"Soler J.","year":"2016","unstructured":"Soler J.; Elices M.; Franquesa A.; Barker S.; Friedlander P.; Feilding A.; Pascual J.C.; Riba J.; Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. Psychopharmacology  2016,233(5),823-829","journal-title":"Psychopharmacology"},{"key":"ref=476","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00213-015-4026-7","volume":"232","author":"Kometer M.","year":"2015","unstructured":"Kometer M.; Pokorny T.; Seifritz E.; Volleinweider F.X.; Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology  2015,232(19),3663-3676","journal-title":"Psychopharmacology"},{"key":"ref=477","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/02791072.2012.703099","volume":"44","author":"Frecska E.","year":"2012","unstructured":"Frecska E.; M\u00f3r\u00e9 C.E.; Vargha A.; Luna L.E.; Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. J Psychoactive Drugs  2012,44(3),191-199","journal-title":"J Psychoactive Drugs"},{"key":"ref=478","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euroneuro.2020.02.001","volume":"33","author":"Madsen M.K.","year":"2020","unstructured":"Madsen M.K.; Fisher P.M.; Stenb\u00e6k D.S.; Kristiansen S.; Burmester D.; Lehel S.; P\u00e1len\u00ed\u010dek T.; Kucha\u0159 M.; Svarer C.; Ozenne B.; Knudsen G.M.; A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neo-cortical 5-HT receptor binding. Eur Neuropsychopharmacol  2020,33,71-80","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=479","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuroimage.2019.04.009","volume":"196","author":"Smigielski L.","year":"2019","unstructured":"Smigielski L.; Scheidegger M.; Kometer M.; Vollenweider F.X.; Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage  2019,196,207-215","journal-title":"Neuroimage"},{"key":"ref=480","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1017\/S0033291721002531","volume":"53","author":"Wie\u00dfner I.","year":"2023","unstructured":"Wie\u00dfner I.; Falchi M.; Palhano-Fontes F.; Feilding A.; Ribeiro S.; T\u00f3foli L.F.; LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Psychol Med  2023,53(4),1151-1165","journal-title":"Psychol Med"},{"key":"ref=481","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s00213-019-05236-w","volume":"236","author":"Uthaug M.V.","year":"2019","unstructured":"Uthaug M.V.; Lancelotta R.; van Oorsouw K.; Kuypers K.P.C.; Mason N.; Rak J.; \u0160ul\u00e1kov\u00e1 A.; Jurok R.; Mary\u0161ka M.; Kucha\u0159 M.; P\u00e1len\u00ed\u010dek T.; Riba J.; Ramaekers J.G.; A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology  2019,236(9),2653-2666","journal-title":"Psychopharmacology"},{"key":"ref=482","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1007\/s00213-018-4988-3","volume":"235","author":"Uthaug M.V.","year":"2018","unstructured":"Uthaug M.V.; van Oorsouw K.; Kuypers K.P.C.; van Boxtel M.; Broers N.J.; Mason N.L.; Toennes S.W.; Riba J.; Ramaekers J.G.; Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology  2018,235(10),2979-2989","journal-title":"Psychopharmacology"},{"key":"ref=483","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00213-019-05414-w","volume":"237","author":"Uthaug M.V.","year":"2020","unstructured":"Uthaug M.V.; Lancelotta R.; Szabo A.; Davis A.K.; Riba J.; Ramaekers J.G.; Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology  2020,237(3),773-785","journal-title":"Psychopharmacology"},{"key":"ref=484","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00213-018-5085-3","volume":"236","author":"Dom\u00ednguez-Clav\u00e9 E.","year":"2019","unstructured":"Dom\u00ednguez-Clav\u00e9 E.; Soler J.; Pascual J.C.; Elices M.; Franquesa A.; Valle M.; Alvarez E.; Riba J.; Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. Psychopharmacology  2019,236(2),573-580","journal-title":"Psychopharmacology"},{"key":"ref=485","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fphar.2018.00224","volume":"9","author":"Soler J.","year":"2018","unstructured":"Soler J.; Elices M.; Dominguez-Clav\u00e9 E.; Pascual J.C.; Feilding A.; Navarro-Gil M.; Garc\u00eda-Campayo J.; Riba J.; Four weekly ayahuasca sessions lead to increases in \u201cacceptance\u201d capacities: A comparison study with a standard 8-week mindfulness training program. Front Pharmacol  2018,9,224","journal-title":"Front Pharmacol"},{"key":"ref=486","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.psychres.2018.04.012","volume":"264","author":"Franquesa A.","year":"2018","unstructured":"Franquesa A.; Sainz-Cort A.; Gandy S.; Soler J.; Alc\u00e1zar-C\u00f3rcoles M.\u00c1.; Bouso J.C.; Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach. Psychiatry Res  2018,264,334-339","journal-title":"Psychiatry Res"},{"key":"ref=487","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.beth.2006.08.003","volume":"38","author":"Fresco D.M.","year":"2007","unstructured":"Fresco D.M.; Moore M.T.; van Dulmen M.H.M.; Segal Z.V.; Ma S.H.; Teasdale J.D.; Williams J.M.G.; Initial psychometric properties of the experiences questionnaire: Validation of a self-report measure of decentering. Behav Ther  2007,38(3),234-246","journal-title":"Behav Ther"},{"key":"ref=488","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00213-019-05446-2","volume":"237","author":"Gonz\u00e1lez D.","year":"2020","unstructured":"Gonz\u00e1lez D.; Cantillo J.; P\u00e9rez I.; Farr\u00e9 M.; Feilding A.; Obiols J.E.; Bouso J.C.; Therapeutic potential of ayahuasca in grief: A prospective, observational study. Psychopharmacology  2020,237(4),1171-1182","journal-title":"Psychopharmacology"},{"key":"ref=489","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1007\/s00213-016-4377-8","volume":"233","author":"Kuypers K.P.C.","year":"2016","unstructured":"Kuypers K.P.C.; Riba J.; de la Fuente Revenga M.; Barker S.; Theunissen E.L.; Ramaekers J.G.; Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology  2016,233(18),3395-3403","journal-title":"Psychopharmacology"},{"key":"ref=490","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-3-642-40426-9_8","author":"Loizaga-Velder A.","year":"2014","unstructured":"Loizaga-Velder A.; Pazzi A.L.;  The Therapeutic Use of Ayahuasca  2014,133-152","journal-title":"The Therapeutic Use of Ayahuasca"},{"key":"ref=491","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00213-014-3714-z","volume":"232","author":"Carhart-Harris R.L.","year":"2015","unstructured":"Carhart-Harris R.L.; Kaelen M.; Whalley M.G.; Bolstridge M.; Feilding A.; Nutt D.J.; LSD enhances suggestibility in healthy volunteers. Psychopharmacology  2015,232(4),785-794","journal-title":"Psychopharmacology"},{"key":"ref=492","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fpsyg.2014.00613","volume":"5","author":"Forgeard M.J.C.","year":"2014","unstructured":"Forgeard M.J.C.; Elstein J.G.; Advancing the clinical science of creativity. Front Psychol  2014,5,613","journal-title":"Front Psychol"},{"key":"ref=493","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41398-021-01335-5","volume":"11","author":"Mason N.L.","year":"2021","unstructured":"Mason N.L.; Kuypers K.P.C.; Reckweg J.T.; M\u00fcller F.; Tse D.H.Y.; Da Rios B.; Toennes S.W.; Stiers P.; Feilding A.; Ramaekers J.G.; Spontaneous and deliberate creative cognition during and after psilocybin exposure. Transl Psychiatry  2021,11(1),209","journal-title":"Transl Psychiatry"},{"key":"ref=494","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/02698811211069113","volume":"36","author":"Wie\u00dfner I.","year":"2022","unstructured":"Wie\u00dfner I.; Falchi M.; Maia L.O.; Daldegan-Bueno D.; Palhano-Fontes F.; Mason N.L.; Ramaekers J.G.; Gross M.E.; Schooler J.W.; Feilding A.; Ribeiro S.; Araujo D.B.; T\u00f3foli L.F.; LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking. J Psychopharmacol  2022,36(3),348-359","journal-title":"J Psychopharmacol"},{"key":"ref=495","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/j.2162-6057.1968.tb00104.x","volume":"2","author":"Mednick S.A.","year":"1968","unstructured":"Mednick S.A.; The remote associates test. J Creat Behav  1968,2(3),213-214","journal-title":"J Creat Behav"},{"key":"ref=496","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/02791072.2009.10399767","volume":"41","author":"Kjellgren A.","year":"2009","unstructured":"Kjellgren A.; Eriksson A.; Norlander T.; Experiences of encounters with ayahuasca\u2014\u201cthe vine of the soul\u201d. J Psychoactive Drugs  2009,41(4),309-315","journal-title":"J Psychoactive Drugs"},{"key":"ref=497","doi-asserted-by":"publisher","first-page":"12181","DOI":"10.1038\/s41598-020-68899-y","volume":"10","author":"Duerler P.","year":"2020","unstructured":"Duerler P.; Schilbach L.; St\u00e4mpfli P.; Vollenweider F.X.; Preller K.H.; LSD-induced increases in social adaptation to opinions similar to one\u2019s own are associated with stimulation of serotonin receptors. Sci Rep  2020,10(1),12181","journal-title":"Sci Rep"},{"key":"ref=498","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"Bogenschutz M.P.","year":"2022","unstructured":"Bogenschutz M.P.; Ross S.; Bhatt S.; Baron T.; Forcehimes A.A.; Laska E.; Mennenga S.E.; O\u2019Donnell K.; Owens L.T.; Podrebarac S.; Rotrosen J.; Tonigan J.S.; Worth L.; Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry  2022,79(10),953","journal-title":"JAMA Psychiatry"},{"key":"ref=499","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"Carhart-Harris R.","year":"2021","unstructured":"Carhart-Harris R.; Giribaldi B.; Watts R.; Baker-Jones M.; Murphy-Beiner A.; Murphy R.; Martell J.; Blemings A.; Erritzoe D.; Nutt D.J.; Trial of psilocybin versus escitalopram for depression. N Engl J Med  2021,384(15),1402-1411","journal-title":"N Engl J Med"},{"key":"ref=500","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"Davis A.K.","year":"2021","unstructured":"Davis A.K.; Barrett F.S.; May D.G.; Cosimano M.P.; Sepeda N.D.; Johnson M.W.; Finan P.H.; Griffiths R.R.; Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry  2021,78(5),481-489","journal-title":"JAMA Psychiatry"},{"key":"ref=501","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/jpet.103.049882","volume":"306","author":"Riba J.","year":"2003","unstructured":"Riba J.; Valle M.; Urbano G.; Yritia M.; Morte A.; Barbanoj M.J.; Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther  2003,306(1),73-83","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=502","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1590\/1516-4446-2020-0913","volume":"43","author":"Durante \u00cd.","year":"2021","unstructured":"Durante \u00cd.; dos Santos R.G.; Bouso J.C.; Hallak J.E.; Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects. Br J Psychiatry  2021,43(4),362-369","journal-title":"Br J Psychiatry"},{"key":"ref=503","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/JCP.0b013e31823607f6","volume":"31","author":"dos Santos R.G.","year":"2011","unstructured":"dos Santos R.G.; Valle M.; Bouso J.C.; Nomded\u00e9u J.F.; Rodr\u00edguez-Espinosa J.; McIlhenny E.H.; Barker S.A.; Barbanoj M.J.; Riba J.; Autonomic, neuroendocrine, and immunological effects of ayahuasca. J Clin Psychopharmacol  2011,31(6),717-726","journal-title":"J Clin Psychopharmacol"},{"key":"ref=504","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/02791072.2005.10399804","volume":"37","author":"Riba J.","year":"2005","unstructured":"Riba J.; Barbanoj M.J.; Bringing ayahuasca to the clinical research laboratory. J Psychoactive Drugs  2005,37(2),219-230","journal-title":"J Psychoactive Drugs"},{"key":"ref=505","doi-asserted-by":"publisher","first-page":"12374","DOI":"10.1111\/jne.12374","volume":"28","author":"Strajhar P.","year":"2016","unstructured":"Strajhar P.; Schmid Y.; Liakoni E.; Dolder P.C.; Rentsch K.M.; Kratschmar D.V.; Odermatt A.; Liechti M.E.; Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. J Neuroendocrinol  2016,28(3),12374","journal-title":"J Neuroendocrinol"},{"key":"ref=506","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/08923979409029898","volume":"16","author":"House R.V.","year":"1994","unstructured":"House R.V.; Thomas P.T.; Bhargava H.N.; Immunological consequences of in vitro exposure to lysergic acid diethylamide (LSD). Immunopharmacol Immunotoxicol  1994,16(1),23-40","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref=507","first-page":"9","author":"Galv\u00e3o ACdM","year":"2018","unstructured":"Galv\u00e3o ACdM; Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front Psychiatry  2018,9","journal-title":"Front Psychiatry"},{"key":"ref=508","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1177\/0269881120936486","volume":"34","author":"Galv\u00e3o-Coelho N.L.","year":"2020","unstructured":"Galv\u00e3o-Coelho N.L.; de Menezes Galv\u00e3o A.C.; de Almeida R.N.; Palhano-Fontes F.; Campos Braga I.; Lob\u00e3o Soares B.; Maia-de-Oliveira J.P.; Perkins D.; Sarris J.; de Araujo D.B.; Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J Psychopharmacol  2020,34(10),1125-1133","journal-title":"J Psychopharmacol"},{"key":"ref=509","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","volume":"30","author":"Flanagan T.W.","year":"2018","unstructured":"Flanagan T.W.; Nichols C.D.; Psychedelics as anti-inflammatory agents. Int Rev Psychiatry  2018,30(4),363-375","journal-title":"Int Rev Psychiatry"},{"key":"ref=510","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","volume":"14","author":"Passie T.","year":"2008","unstructured":"Passie T.; Halpern J.H.; Stichtenoth D.O.; Emrich H.M.; Hintzen A.; The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci Ther  2008,14(4),295-314","journal-title":"CNS Neurosci Ther"},{"key":"ref=511","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","volume":"49","author":"Dinis-Oliveira R.J.","year":"2017","unstructured":"Dinis-Oliveira R.J.; Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev  2017,49(1),84-91","journal-title":"Drug Metab Rev"},{"key":"ref=512","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","volume":"73","author":"Inserra A.","year":"2021","unstructured":"Inserra A.; De Gregorio D.; Gobbi G.; Psychedelics in psychiatry: Neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev  2021,73(1),202-277","journal-title":"Pharmacol Rev"},{"key":"ref=513","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/0269881116677104","volume":"31","author":"Canal C.E.","year":"2017","unstructured":"Canal C.E.; Murnane K.S.; The serotonin 5-HT 2C receptor and the non-addictive nature of classic hallucinogens. J Psychopharmacol  2017,31(1),127-143","journal-title":"J Psychopharmacol"},{"key":"ref=514","year":"2023","unstructured":"National Center for Biotechnology Information. (NIH) NIoH Available from:  https:\/\/ncbi.nlm.nih.gov\/2023"},{"key":"ref=515","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3389\/fnins.2018.00536","volume":"12","author":"Barker S.A.","year":"2018","unstructured":"Barker S.A.; N,N-Dimethyltryptamine (DMT), an endogenous hallucinogen: Past, present, and future research to determine its role and function. Front Neurosci  2018,12,536","journal-title":"Front Neurosci"},{"key":"ref=516","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fphar.2016.00035","volume":"7","author":"Frecska E.","year":"2016","unstructured":"Frecska E.; Bokor P.; Winkelman M.; The therapeutic potentials of ayahuasca: Possible effects against various diseases of civilization. Front Pharmacol  2016,7,35","journal-title":"Front Pharmacol"},{"key":"ref=517","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/ph13110334","volume":"13","author":"Brito-da-Costa A.M.","year":"2020","unstructured":"Brito-da-Costa A.M.; Dias-da-Silva D.; Gomes N.G.M.; Dinis-Oliveira R.J.; Madureira-Carvalho \u00c1.; Toxicokinetics and toxicodynamics of ayahuasca alkaloids N,N-dimethyltryptamine (DMT), Harmine, harmaline and tetrahydroharmine: clinical and forensic impact. Pharmaceuticals (Basel)  2020,13(11),334","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=518","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1360-0443.2006.01652.x","volume":"102","author":"Gable R.S.","year":"2007","unstructured":"Gable R.S.; Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction  2007,102(1),24-34","journal-title":"Addiction"},{"key":"ref=519","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00213-011-2434-x","volume":"219","author":"dos Santos R.G.","year":"2012","unstructured":"dos Santos R.G.; Grasa E.; Valle M.; Ballester M.R.; Bouso J.C.; Nomded\u00e9u J.F.; Homs R.; Barbanoj M.J.; Riba J.; Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology  2012,219(4),1039-1053","journal-title":"Psychopharmacology"},{"key":"ref=520","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/dta.1344","volume":"4","author":"Riba J.","year":"2012","unstructured":"Riba J.; McIlhenny E.H.; Valle M.; Bouso J.C.; Barker S.A.; Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Test Anal  2012,4(7-8),610-616","journal-title":"Drug Test Anal"},{"key":"ref=521","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1590\/1516-4446-2020-0884","volume":"42","author":"Ruffell S.","year":"2020","unstructured":"Ruffell S.; Netzband N.; Bird C.; Young A.H.; Juruena M.F.; The pharmacological interaction of compounds in ayahuasca: A systematic review. Br J Psychiatry  2020,42(6),646-656","journal-title":"Br J Psychiatry"},{"key":"ref=522","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"Nichols D.E.","year":"2004","unstructured":"Nichols D.E.; Hallucinogens. Pharmacol Ther  2004,101(2),131-181","journal-title":"Pharmacol Ther"},{"key":"ref=523","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"Rickli A.","year":"2016","unstructured":"Rickli A.; Moning O.D.; Hoener M.C.; Liechti M.E.; Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol  2016,26(8),1327-1337","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=524","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bcp.2019.04.013","volume":"164","author":"Luethi D.","year":"2019","unstructured":"Luethi D.; Hoener M.C.; Kr\u00e4henb\u00fchl S.; Liechti M.E.; Duthaler U.; Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. Biochem Pharmacol  2019,164,129-138","journal-title":"Biochem Pharmacol"},{"key":"ref=525","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"Vollenweider F.X.","year":"2020","unstructured":"Vollenweider F.X.; Preller K.H.; Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci  2020,21(11),611-624","journal-title":"Nat Rev Neurosci"},{"key":"ref=526","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"Glennon R.A.","year":"1984","unstructured":"Glennon R.A.; Titeler M.; McKenney J.D.; Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci  1984,35(25),2505-2511","journal-title":"Life Sci"},{"key":"ref=527","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/jnc.15536","volume":"162","author":"Jaster A.M.","year":"2022","unstructured":"Jaster A.M.; de la Fuente Revenga M.; Gonz\u00e1lez-Maeso J.; Molecular targets of psychedelic-induced plasticity. J Neurochem  2022,162(1),80-88","journal-title":"J Neurochem"},{"key":"ref=528","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","volume":"126","author":"Carbonaro T.M.","year":"2016","unstructured":"Carbonaro T.M.; Gatch M.B.; Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull  2016,126,74-88","journal-title":"Brain Res Bull"},{"key":"ref=529","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0028-3908(90)90001-8","volume":"29","author":"Mckenna D.J.","year":"1990","unstructured":"Mckenna D.J.; Repke D.B.; Lo L.; Peroutka S.J.; Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology  1990,29(3),193-198","journal-title":"Neuropharmacology"},{"key":"ref=530","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/ijnp\/pyaa087","volume":"24","author":"Kadriu B.","year":"2021","unstructured":"Kadriu B.; Greenwald M.; Henter I.D.; Gilbert J.R.; Kraus C.; Park L.T.; Zarate C.A.; Ketamine and serotonergic psychedelics: Common mechanisms underlying the effects of rapid-acting antidepressants. Int J Neuropsychopharmacol  2021,24(1),8-21","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=531","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1091\/mbc.E20-05-0340","volume":"32","author":"Banks M.I.","year":"2021","unstructured":"Banks M.I.; Zahid Z.; Jones N.T.; Sultan Z.W.; Wenthur C.J.; Catalysts for change: The cellular neurobiology of psychedelics. Mol Biol Cell  2021,32(12),1135-1144","journal-title":"Mol Biol Cell"},{"key":"ref=532","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"Reiff C.M.","year":"2020","unstructured":"Reiff C.M.; Richman E.E.; Nemeroff C.B.; Carpenter L.L.; Widge A.S.; Rodriguez C.I.; Kalin N.H.; McDonald W.M.; Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry  2020,177(5),391-410","journal-title":"Am J Psychiatry"},{"key":"ref=533","doi-asserted-by":"publisher","first-page":"e9019","DOI":"10.1371\/journal.pone.0009019","volume":"5","author":"Ray T.S.","year":"2010","unstructured":"Ray T.S.; Psychedelics and the human receptorome. PLoS One  2010,5(2),e9019","journal-title":"PLoS One"},{"key":"ref=534","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0091-3057(98)00110-5","volume":"61","author":"Smith R.","year":"1998","unstructured":"Smith R.; Canton H.; Barrett R.J.; Sanders-Bush E.; Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT and 5-HT receptors. Pharmacol Biochem Behav  1998,61(3),323-330","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=535","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1021\/acschemneuro.8b00101","volume":"9","author":"Cameron L.P.","year":"2018","unstructured":"Cameron L.P.; Olson D.E.; Dark classics in chemical neuroscience: N, N -Dimethyltryptamine (DMT). ACS Chem Neurosci  2018,9(10),2344-2357","journal-title":"ACS Chem Neurosci"},{"key":"ref=536","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF02245347","volume":"116","author":"Callaway J.C.","year":"1994","unstructured":"Callaway J.C.; Airaksinen M.M.; Mckenna D.J.; Brito G.S.; Grob C.S.; Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacology  1994,116(3),385-387","journal-title":"Psychopharmacology"},{"key":"ref=537","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","volume":"73","author":"Strassman R.J.","year":"1995","unstructured":"Strassman R.J.; Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res  1995,73(1-2),121-124","journal-title":"Behav Brain Res"},{"key":"ref=538","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/0006-2952(77)90007-7","volume":"26","author":"Buckholtz N.S.","year":"1977","unstructured":"Buckholtz N.S.; Boggan W.O.; Monoamine oxidase inhibition in brain and liver produced by \u03b2-carbolines: structure-activity relationships and substrate specificity. Biochem Pharmacol  1977,26(21),1991-1996","journal-title":"Biochem Pharmacol"},{"key":"ref=539","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0376-8716(99)00148-9","volume":"60","author":"Glennon R.A.","year":"2000","unstructured":"Glennon R.A.; Dukat M.; Grella B.; Hong S-S.; Costantino L.; Teitler M.; Smith C.; Egan C.; Davis K.; Mattson M.V.; Binding of \u03b2-carbolines and related agents at serotonin (5-HT2 and 5-HT), dopamine (D2) and benzodiazepine receptors. Drug Alcohol Depend  2000,60(2),121-132","journal-title":"Drug Alcohol Depend"},{"key":"ref=540","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00213-005-2183-9","volume":"180","author":"Marona-Lewicka D.","year":"2005","unstructured":"Marona-Lewicka D.; Thisted R.A.; Nichols D.E.; Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology  2005,180(3),427-435","journal-title":"Psychopharmacology"},{"key":"ref=541","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","volume":"61","author":"Halberstadt A.L.","year":"2011","unstructured":"Halberstadt A.L.; Geyer M.A.; Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology  2011,61(3),364-381","journal-title":"Neuropharmacology"},{"key":"ref=542","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1124\/pr.118.016311","volume":"72","author":"Bousquet P.","year":"2020","unstructured":"Bousquet P.; Hudson A.; Garc\u00eda-Sevilla J.A.; Li J.X.; Imidazoline receptor system: The past, the present, and the future. Pharmacol Rev  2020,72(1),50-79","journal-title":"Pharmacol Rev"},{"key":"ref=543","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neulet.2011.01.046","volume":"493","author":"Moreno J.L.","year":"2011","unstructured":"Moreno J.L.; Holloway T.; Albizu L.; Sealfon S.C.; Gonz\u00e1lez-Maeso J.; Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT receptor agonists. Neurosci Lett  2011,493(3),76-79","journal-title":"Neurosci Lett"},{"key":"ref=544","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1126\/science.1166127","volume":"323","author":"Fontanilla D.","year":"2009","unstructured":"Fontanilla D.; Johannessen M.; Hajipour A.R.; Cozzi N.V.; Jackson M.B.; Ruoho A.E.; The Hallucinogen N,N-dimethyl-tryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science  2009,323(5916),934-937","journal-title":"Science"},{"key":"ref=545","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fphar.2018.00330","volume":"9","author":"Inserra A.","year":"2018","unstructured":"Inserra A.; Hypothesis: The psychedelic ayahuasca heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process. Front Pharmacol  2018,9,330","journal-title":"Front Pharmacol"},{"key":"ref=546","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fncel.2014.00213","volume":"8","author":"Chaudhari N.","year":"2014","unstructured":"Chaudhari N.; Talwar P.; Parimisetty A.; Lefebvre d\u2019Hellencourt C.; Ravanan P.; A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. Front Cell Neurosci  2014,8(1),213","journal-title":"Front Cell Neurosci"},{"key":"ref=547","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2012.01.030","volume":"682","author":"Pal A.","year":"2012","unstructured":"Pal A.; Fontanilla D.; Gopalakrishnan A.; Chae Y-K.; Markley J.L.; Ruoho A.E.; The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol  2012,682(1-3),12-20","journal-title":"Eur J Pharmacol"},{"key":"ref=548","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.13249","volume":"143","author":"Andersen K.A.A.","year":"2021","unstructured":"Andersen K.A.A.; Carhart-Harris R.; Nutt D.J.; Erritzoe D.; Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatr Scand  2021,143(2),101-118","journal-title":"Acta Psychiatr Scand"},{"key":"ref=549","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","volume":"11","author":"dos Santos R.G.","year":"2018","unstructured":"dos Santos R.G.; Bouso J.C.; Alc\u00e1zar-C\u00f3rcoles M.\u00c1.; Hallak J.E.C.; Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews. Expert Rev Clin Pharmacol  2018,11(9),889-902","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=550","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","volume":"56","author":"Brown R.T.","year":"2017","unstructured":"Brown R.T.; Nicholas C.R.; Cozzi N.V.; Gassman M.C.; Cooper K.M.; Muller D.; Thomas C.D.; Hetzel S.J.; Henriquez K.M.; Ribaudo A.S.; Hutson P.R.; Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet  2017,56(12),1543-1554","journal-title":"Clin Pharmacokinet"},{"key":"ref=551","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"Gukasyan N.","year":"2022","unstructured":"Gukasyan N.; Davis A.K.; Barrett F.S.; Cosimano M.P.; Sepeda N.D.; Johnson M.W.; Griffiths R.R.; Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol  2022,36(2),151-158","journal-title":"J Psychopharmacol"},{"key":"ref=552","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"Goodwin G.M.","year":"2022","unstructured":"Goodwin G.M.; Aaronson S.T.; Alvarez O.; Arden P.C.; Baker A.; Bennett J.C.; Bird C.; Blom R.E.; Brennan C.; Brusch D.; Burke L.; Campbell-Coker K.; Carhart-Harris R.; Cattell J.; Daniel A.; DeBattista C.; Dunlop B.W.; Eisen K.; Feifel D.; Forbes M.K.; Haumann H.M.; Hellerstein D.J.; Hoppe A.I.; Husain M.I.; Jelen L.A.; Kamphuis J.; Kawasaki J.; Kelly J.R.; Key R.E.; Kishon R.; Knatz Peck S.; Knight G.; Koolen M.H.B.; Lean M.; Licht R.W.; Maples-Keller J.L.; Mars J.; Marwood L.; McElhiney M.C.; Miller T.L.; Mirow A.; Mistry S.; Mletzko-Crowe T.; Modlin L.N.; Nielsen R.E.; Nielson E.M.; Offerhaus S.R.; O\u2019Keane V.; P\u00e1len\u00ed\u010dek T.; Printz D.; Rademaker M.C.; van Reemst A.; Reinholdt F.; Repantis D.; Rucker J.; Rudow S.; Ruffell S.; Rush A.J.; Schoevers R.A.; Seynaeve M.; Shao S.; Soares J.C.; Somers M.; Stansfield S.C.; Sterling D.; Strockis A.; Tsai J.; Visser L.; Wahba M.; Williams S.; Young A.H.; Ywema P.; Zisook S.; Malievskaia E.; Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med  2022,387(18),1637-1648","journal-title":"N Engl J Med"},{"key":"ref=553","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1001\/archpsyc.1960.03590090042008","volume":"2","author":"Chandler A.L.","year":"1960","unstructured":"Chandler A.L.; Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy. Arch Gen Psychiatry  1960,2(3),286-299","journal-title":"Arch Gen Psychiatry"},{"key":"ref=554","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1192\/bjp.118.543.229","volume":"118","author":"Malleson N.","year":"1971","unstructured":"Malleson N.; Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry  1971,118(543),229-230","journal-title":"Br J Psychiatry"},{"key":"ref=555","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"Sanches R.F.","year":"2016","unstructured":"Sanches R.F.; de Lima Os\u00f3rio F.; dos Santos R.G.; Macedo L.R.H.; Maia-de-Oliveira J.P.; Wichert-Ana L.; de Araujo D.B.; Riba J.; Crippa J.A.S.; Hallak J.E.C.; Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression. J Clin Psychopharmacol  2016,36(1),77-81","journal-title":"J Clin Psychopharmacol"},{"key":"ref=556","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/02791072.2013.785846","volume":"45","author":"dos Santos R.G.","year":"2013","unstructured":"dos Santos R.G.; A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions. J Psychoactive Drugs  2013,45(2),179-188","journal-title":"J Psychoactive Drugs"},{"key":"ref=557","first-page":"69","author":"Frecska E.","year":"2007","unstructured":"Frecska E.; Therapeutic guidelines: Dangers and contra-indications in therapeutic applications of hallucinogens. Psychedelic medicine: new evidence for hallucinogenic substances as treatments.,  2007,69-95"},{"key":"ref=558","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/2045125316689030","volume":"7","author":"dos Santos R.G.","year":"2017","unstructured":"dos Santos R.G.; Bouso J.C.; Hallak J.E.C.; Ayahuasca, dimethyltryptamine, and psychosis: A systematic review of human studies. Ther Adv Psychopharmacol  2017,7(4),141-157","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=559","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/02791072.1998.10399712","volume":"30","author":"Callaway J.C.","year":"1998","unstructured":"Callaway J.C.; Grob C.S.; Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions. J Psychoactive Drugs  1998,30(4),367-369","journal-title":"J Psychoactive Drugs"},{"key":"ref=560","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/jat\/29.8.838","volume":"29","author":"Sklerov J.","year":"2005","unstructured":"Sklerov J.; Levine B.; Moore K.A.; King T.; Fowler D.; A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol  2005,29(8),838-841","journal-title":"J Anal Toxicol"},{"key":"ref=561","doi-asserted-by":"publisher","first-page":"17180","DOI":"10.1073\/pnas.1121254109","volume":"109","author":"McEwen B.S.","year":"2012","unstructured":"McEwen B.S.; Brain on stress: How the social environment gets under the skin. Proc Natl Acad Sci  2012,109(2),17180-17185","journal-title":"Proc Natl Acad Sci"},{"key":"ref=562","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1034\/j.1399-5618.2002.01203.x","volume":"4","author":"D\u2019Sa C.","year":"2002","unstructured":"D\u2019Sa C.; Duman R.S.; Antidepressants and neuroplasticity. Bipolar Disord  2002,4(3),183-194","journal-title":"Bipolar Disord"},{"key":"ref=563","doi-asserted-by":"publisher","first-page":"1179069518800508","DOI":"10.1177\/1179069518800508","volume":"12","author":"Olson D.E.","year":"2018","unstructured":"Olson D.E.; Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci  2018,12,1179069518800508","journal-title":"J Exp Neurosci"},{"key":"ref=564","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.tins.2010.02.002","volume":"33","author":"Russo S.J.","year":"2010","unstructured":"Russo S.J.; Dietz D.M.; Dumitriu D.; The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci  2010,33(6),267-276","journal-title":"Trends Neurosci"},{"key":"ref=565","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"Ly C.","year":"2018","unstructured":"Ly C.; Greb A.C.; Cameron L.P.; Wong J.M.; Barragan E.V.; Wilson P.C.; Burbach K.F.; Soltanzadeh Z.S.; Sood A.; Paddy M.R.; Duim W.C.; Dennis M.Y.; McAllister A.K.; Ori-McKenney K.M.; Gray J.A.; Olson D.E.; Psychedelics promote structural and functional neural plasticity. Cell Rep  2018,23(11),3170-3182","journal-title":"Cell Rep"},{"key":"ref=566","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0006-8993(02)03548-5","volume":"958","author":"Frankel P.S.","year":"2002","unstructured":"Frankel P.S.; Cunningham K.A.; The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain. Brain Res  2002,958(2),251-260","journal-title":"Brain Res"},{"key":"ref=567","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"Gonz\u00e1lez-Maeso J.","year":"2007","unstructured":"Gonz\u00e1lez-Maeso J.; Weisstaub N.V.; Zhou M.; Chan P.; Ivic L.; Ang R.; Lira A.; Bradley-Moore M.; Ge Y.; Zhou Q.; Sealfon S.C.; Gingrich J.A.; Hallucinogens recruit specific cortical 5-HT receptor-mediated signaling pathways to affect behavior. Neuron  2007,53(3),439-452","journal-title":"Neuron"},{"key":"ref=568","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0091-3057(02)00844-4","volume":"73","author":"Gewirtz J.C.","year":"2002","unstructured":"Gewirtz J.C.; Chen A.C.; Terwilliger R.; Duman R.C.; Marek G.J.; Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol Biochem Behav  2002,73(2),317-326","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=569","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/85138","volume":"4","author":"Jones M.W.","year":"2001","unstructured":"Jones M.W.; Errington M.L.; French P.J.; Fine A.; Bliss T.V.P.; Garel S.; Charnay P.; Bozon B.; Laroche S.; Davis S.; A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat Neurosci  2001,4(3),289-296","journal-title":"Nat Neurosci"},{"key":"ref=570","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.neuroscience.2008.01.012","volume":"152","author":"DeSteno D.A.","year":"2008","unstructured":"DeSteno D.A.; Schmauss C.; Induction of early growth response gene 2 expression in the forebrain of mice performing an attention-set-shifting task. Neuroscience  2008,152(2),417-428","journal-title":"Neuroscience"},{"key":"ref=571","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1523\/JNEUROSCI.4093-14.2015","volume":"35","author":"Radiske A.","year":"2015","unstructured":"Radiske A.; Rossato J.I.; K\u00f6hler C.A.; Gonzalez M.C.; Medina J.H.; Cammarota M.; Requirement for BDNF in the reconsolidation of fear extinction. J Neurosci  2015,35(16),6570-6574","journal-title":"J Neurosci"},{"key":"ref=572","doi-asserted-by":"publisher","first-page":"13993","DOI":"10.1038\/srep13993","volume":"5","author":"Su\u00e1rez-Pereira I.","year":"2015","unstructured":"Su\u00e1rez-Pereira I.; Carri\u00f3n \u00c1.M.; Updating stored memory requires adult hippocampal neurogenesis. Sci Rep  2015,5(1),13993","journal-title":"Sci Rep"},{"key":"ref=573","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3389\/fpsyg.2019.01234","volume":"10","author":"Almeida R.N.","year":"2019","unstructured":"Almeida R.N.; Galv\u00e3o A.C.M.; da Silva F.S.; Silva E.A.S.; Palhano-Fontes F.; Maia-de-Oliveira J.P.; de Ara\u00fajo L-S.B.; Lob\u00e3o-Soares B.; Galv\u00e3o-Coelho N.L.; Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: Observation from a randomized controlled trial. Front Psychol  2019,10,1234","journal-title":"Front Psychol"},{"key":"ref=574","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5498\/wjp.v6.i1.84","volume":"6","author":"Serra-Mill\u00e0s M.","year":"2016","unstructured":"Serra-Mill\u00e0s M.; Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation? World J Psychiatry  2016,6(1),84-101","journal-title":"World J Psychiatry"},{"key":"ref=575","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1097\/MLR.0000000000000221","volume":"52","author":"Kearney D.J.","year":"2014","unstructured":"Kearney D.J.; McManus C.; Malte C.A.; Martinez M.E.; Felleman B.; Simpson T.L.; Loving-kindness meditation and the broaden-and-build theory of positive emotions among veterans with posttraumatic stress disorder. Med Care  2014,52(12)(5),S32-S38","journal-title":"Med Care"},{"key":"ref=576","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.copsyc.2019.02.009","volume":"28","author":"King A.P.","year":"2019","unstructured":"King A.P.; Fresco D.M.; A neurobehavioral account for decentering as the salve for the distressed mind. Curr Opin Psychol  2019,28,285-293","journal-title":"Curr Opin Psychol"},{"key":"ref=577","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.euroneuro.2015.01.008","volume":"25","author":"Bouso J.C.","year":"2015","unstructured":"Bouso J.C.; Palhano-Fontes F.; Rodr\u00edguez-Fornells A.; Ribeiro S.; Sanches R.; Crippa J.A.S.; Hallak J.E.C.; de Araujo D.B.; Riba J.; Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol  2015,25(4),483-492","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=578","doi-asserted-by":"publisher","first-page":"e35082","DOI":"10.7554\/eLife.35082","volume":"7","author":"Preller K.H.","year":"2018","unstructured":"Preller K.H.; Burt J.B.; Ji J.L.; Schleifer C.H.; Adkinson B.D.; St\u00e4mpfli P.; Seifritz E.; Repovs G.; Krystal J.H.; Murray J.D.; Vollen-weider F.X.; Anticevic A.; Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT receptor. eLife  2018,7,e35082","journal-title":"eLife"},{"key":"ref=579","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00259-019-04360-1","volume":"46","author":"Rousseau P.F.","year":"2019","unstructured":"Rousseau P.F.; Malbos E.; Verger A.; Nicolas F.; Lan\u00e7on C.; Khalfa S.; Guedj E.; Increase of precuneus metabolism correlates with reduction of PTSD symptoms after EMDR therapy in military veterans: An 18F-FDG PET study during virtual reality exposure to war. Eur J Nucl Med Mol Imaging  2019,46(9),1817-1821","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=580","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"Carhart-Harris R.L.","year":"2016","unstructured":"Carhart-Harris R.L.; Muthukumaraswamy S.; Roseman L.; Kaelen M.; Droog W.; Murphy K.; Tagliazucchi E.; Schenberg E.E.; Nest T.; Orban C.; Leech R.; Williams L.T.; Williams T.M.; Bolstridge M.; Sessa B.; McGonigle J.; Sereno M.I.; Nichols D.; Hellyer P.J.; Hobden P.; Evans J.; Singh K.D.; Wise R.G.; Curran H.V.; Feilding A.; Nutt D.J.; Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci  2016,113(17),4853-4858","journal-title":"Proc Natl Acad Sci"},{"key":"ref=581","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1440.011","volume":"1124","author":"Buckner R.L.","year":"2008","unstructured":"Buckner R.L.; Andrews-Hanna J.R.; Schacter D.L.; The brain\u2019s default network: Anatomy, function, and relevance to disease. Ann N Y Acad Sci  2008,1124(1),1-38","journal-title":"Ann N Y Acad Sci"},{"key":"ref=582","doi-asserted-by":"publisher","first-page":"e0118143","DOI":"10.1371\/journal.pone.0118143","volume":"10","author":"Palhano-Fontes F.","year":"2015","unstructured":"Palhano-Fontes F.; Andrade K.C.; Tofoli L.F.; Santos A.C.; Crippa J.A.S.; Hallak J.E.C.; Ribeiro S.; de Araujo D.B.; The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One  2015,10(2),e0118143","journal-title":"PLoS One"},{"key":"ref=583","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ijnp\/pyac074","volume":"26","author":"Gattuso J.J.","year":"2023","unstructured":"Gattuso J.J.; Perkins D.; Ruffell S.; Lawrence A.J.; Hoyer D.; Jacobson L.H.; Timmermann C.; Castle D.; Rossell S.L.; Downey L.A.; Pagni B.A.; Galv\u00e3o-Coelho N.L.; Nutt D.; Sarris J.; Default mode network modulation by psychedelics: A systematic review. Int J Neuropsychopharmacol  2023,26(3),155-188","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=584","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/s41386-020-00946-8","volume":"46","author":"Harnett N.G.","year":"2021","unstructured":"Harnett N.G.; van Rooij S.J.H.; Ely T.D.; Lebois L.A.M.; Murty V.P.; Jovanovic T.; Hill S.B.; Dumornay N.M.; Merker J.B.; Bruce S.E.; House S.L.; Beaudoin F.L.; An X.; Zeng D.; Neylan T.C.; Clifford G.D.; Linnstaedt S.D.; Germine L.T.; Bollen K.A.; Rauch S.L.; Lewandowski C.; Hendry P.L.; Sheikh S.; Storrow A.B.; Musey P.I.; Haran J.P.; Jones C.W.; Punches B.E.; Swor R.A.; McGrath M.E.; Pascual J.L.; Seamon M.J.; Mohiuddin K.; Chang A.M.; Pearson C.; Peak D.A.; Domeier R.M.; Rathlev N.K.; Sanchez L.D.; Pietrzak R.H.; Joormann J.; Barch D.M.; Pizzagalli D.A.; Sheridan J.F.; Harte S.E.; Elliott J.M.; Kessler R.C.; Koenen K.C.; Mclean S.; Ressler K.J.; Stevens J.S.; Prognostic neuroimaging biomarkers of trauma-related psychopathology: resting-state fMRI shortly after trauma predicts future PTSD and depression symptoms in the AURORA study. Neuropsychopharmacology  2021,46(7),1263-1271","journal-title":"Neuropsychopharmacology"},{"key":"ref=585","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.bpsc.2016.12.006","volume":"2","author":"Miller D.R.","year":"2017","unstructured":"Miller D.R.; Hayes S.M.; Hayes J.P.; Spielberg J.M.; Lafleche G.; Verfaellie M.; Default mode network subsystems are differentially disrupted in posttraumatic stress disorder. Biol Psychiatry Cogn Neurosci Neuroimaging  2017,2(4),363-371","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"ref=586","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","volume":"10","author":"Barrett F.S.","year":"2020","unstructured":"Barrett F.S.; Doss M.K.; Sepeda N.D.; Pekar J.J.; Griffiths R.R.; Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep  2020,10(1),2214","journal-title":"Sci Rep"},{"key":"ref=587","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","volume":"7","author":"Carhart-Harris R.L.","year":"2017","unstructured":"Carhart-Harris R.L.; Roseman L.; Bolstridge M.; Demetriou L.; Pannekoek J.N.; Wall M.B.; Tanner M.; Kaelen M.; McGonigle J.; Murphy K.; Leech R.; Curran H.V.; Nutt D.J.; Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. Sci Rep  2017,7(1),13187","journal-title":"Sci Rep"},{"key":"ref=588","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11920-017-0840-4","volume":"19","author":"Akiki T.J.","year":"2017","unstructured":"Akiki T.J.; Averill C.L.; Abdallah C.G.; A network-based neurobiological model of PTSD: Evidence from structural and functional neuroimaging studies. Curr Psychiatry Rep  2017,19(11),81","journal-title":"Curr Psychiatry Rep"},{"key":"ref=589","doi-asserted-by":"publisher","first-page":"120302","DOI":"10.1016\/j.jns.2022.120302","volume":"439","author":"Henner R.L.","year":"2022","unstructured":"Henner R.L.; Keshavan M.S.; Hill K.P.; Review of otential sychedelic reatments for PTSD. J Neurol Sci  2022,439,120302","journal-title":"J Neurol Sci"},{"key":"ref=590","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1073\/pnas.1815129116","volume":"116","author":"Preller K.H.","year":"2019","unstructured":"Preller K.H.; Razi A.; Zeidman P.; St\u00e4mpfli P.; Friston K.J.; Vollenweider F.X.; Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proc Natl Acad Sci  2019,116(7),2743-2748","journal-title":"Proc Natl Acad Sci"},{"key":"ref=591","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0361-9230(01)00646-3","volume":"56","author":"Vollenweider F.X.","year":"2001","unstructured":"Vollenweider F.X.; Geyer M.A.; A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull  2001,56(5),495-507","journal-title":"Brain Res Bull"},{"key":"ref=592","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","volume":"78","author":"Kraehenmann R.","year":"2015","unstructured":"Kraehenmann R.; Preller K.H.; Scheidegger M.; Pokorny T.; Bosch O.G.; Seifritz E.; Vollenweider F.X.; Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry  2015,78(8),572-581","journal-title":"Biol Psychiatry"},{"key":"ref=593","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"Carhart-Harris R.L.","year":"2019","unstructured":"Carhart-Harris R.L.; Friston K.J.; REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacol Rev  2019,71(3),316-344","journal-title":"Pharmacol Rev"},{"key":"ref=594","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/cercor\/bhab202","volume":"32","author":"Duerler P.","year":"2021","unstructured":"Duerler P.; Brem S.; Fraga-Gonz\u00e1lez G.; Psilocybin induces aberrant prediction error processing of tactile mismatch responses: A simultaneous EEG-FMRI study. Cereb Cortex  2021,32(1),186-196","journal-title":"Cereb Cortex"},{"key":"ref=595","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyv039","volume":"18","author":"Alonso J.F.","year":"2015","unstructured":"Alonso J.F.; Romero S.; Ma\u00f1anas M.\u00c0.; Riba J.; Serotonergic psychedelics temporarily modify information transfer in humans. Int J Neuropsychopharmacol  2015,18(8),1-9","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=596","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00213-018-5086-2","volume":"236","author":"Kida S.","year":"2019","unstructured":"Kida S.; Reconsolidation\/destabilization, extinction and forgetting of fear memory as therapeutic targets for PTSD. Psychopharmacology  2019,236(1),49-57","journal-title":"Psychopharmacology"},{"key":"ref=597","doi-asserted-by":"publisher","first-page":"724606","DOI":"10.3389\/fpsyt.2021.724606","volume":"12","author":"de Vos C.M.H.","year":"2021","unstructured":"de Vos C.M.H.; Mason N.L.; Kuypers K.P.C.; Psychedelics and neuroplasticity: A systematic review unraveling the biological underpinnings of psychedelics. Front Psychiatry  2021,12,724606","journal-title":"Front Psychiatry"},{"key":"ref=598","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"Catlow B.J.","year":"2013","unstructured":"Catlow B.J.; Song S.; Paredes D.A.; Kirstein C.L.; Sanchez-Ramos J.; Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res  2013,228(4),481-491","journal-title":"Exp Brain Res"},{"key":"ref=599","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nicl.2015.08.009","volume":"11","author":"Kraehenmann R.","year":"2016","unstructured":"Kraehenmann R.; Schmidt A.; Friston K.; Preller K.H.; Seifritz E.; Vollenweider F.X.; The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage Clin  2016,11,53-60","journal-title":"Neuroimage Clin"},{"key":"ref=600","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.euroneuro.2018.03.016","volume":"28","author":"Grimm O.","year":"2018","unstructured":"Grimm O.; Kraehenmann R.; Preller K.H.; Seifritz E.; Vollenweider F.X.; Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur Neuropsychopharmacol  2018,28(6),691-700","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=601","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/B978-0-12-397025-1.00052-X","author":"Menon V.","year":"2015","unstructured":"Menon V.;  Salience Network Brain Mapping  2015,597-611","journal-title":"Salience Network Brain Mapping"},{"key":"ref=602","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-3-642-40426-9_3","author":"Nielson J.L.","year":"2014","unstructured":"Nielson J.L.; Megler J.D.;  Ayahuasca as a candidate therapy for PTSD The Therapeutic Use of Ayahuasca  2014,41-58","journal-title":"Ayahuasca as a candidate therapy for PTSD The Therapeutic Use of Ayahuasca"},{"key":"ref=603","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4331\/wjbc.v4.i4.141","volume":"4","author":"Castro-Neto E.F.","year":"2013","unstructured":"Castro-Neto E.F.; Cunha R.H.; Silveira D.X.; Yonamine M.; Gouveia T.L.F.; Cavalheiro E.A.; Amado D.; Naffah-Mazzacoratti M.G.; Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion. World J Biol Chem  2013,4(4),141-147","journal-title":"World J Biol Chem"},{"key":"ref=604","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.nlm.2013.11.007","volume":"108","author":"Abraham A.D.","year":"2014","unstructured":"Abraham A.D.; Neve K.A.; Lattal K.M.; Dopamine and extinction: A convergence of theory with fear and reward circuitry. Neurobiol Learn Mem  2014,108,65-77","journal-title":"Neurobiol Learn Mem"},{"key":"ref=605","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1213\/ANE.0b013e3181bf6ae6","volume":"109","author":"Rau V.","year":"2009","unstructured":"Rau V.; Iyer S.V.; Oh I.; Chandra D.; Harrison N.; Eger E.I.; Fanselow M.S.; Homanics G.E.; Sonner J.M.; Gamma-aminobutyric acid type A receptor alpha 4 subunit knockout mice are resistant to the amnestic effect of isoflurane. Anesth Analg  2009,109(6),1816-1822","journal-title":"Anesth Analg"},{"key":"ref=606","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/0269881119855974","volume":"33","author":"Roseman L.","year":"2019","unstructured":"Roseman L.; Haijen E.; Idialu-Ikato K.; Kaelen M.; Watts R.; Carhart-Harris R.; Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. J Psychopharmacol  2019,33(9),1076-1087","journal-title":"J Psychopharmacol"},{"key":"ref=607","doi-asserted-by":"publisher","first-page":"645246","DOI":"10.3389\/fpsyg.2021.645246","volume":"12","author":"Gorman I.","year":"2021","unstructured":"Gorman I.; Nielson E.M.; Molinar A.; Cassidy K.; Sabbagh J.; Psychedelic harm reduction and integration: A transtheoretical model for clinical practice. Front Psychol  2021,12,645246","journal-title":"Front Psychol"},{"key":"ref=608","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/15294145.2019.1689528","volume":"21","author":"Fischman L.G.","year":"2019","unstructured":"Fischman L.G.; Seeing without self: Discovering new meaning with psychedelic-assisted psychotherapy. Neuro-psychoanalysis  2019,21(2),53-78","journal-title":"Neuro-psychoanalysis"},{"key":"ref=609","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jpsychires.2022.10.050","volume":"156","author":"Janssen P.G.J.","year":"2022","unstructured":"Janssen P.G.J.; Stoltz S.; Cillessen A.H.N.; van Ee E.; Deployment-related PTSD symptomatology and social functioning: Probing the mediating roles of emotion regulation and mentalization in an outpatient veteran sample. J Psychiatr Res  2022,156,444-450","journal-title":"J Psychiatr Res"},{"key":"ref=610","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/jcm5110094","volume":"5","author":"Saraiya T.","year":"2016","unstructured":"Saraiya T.; Lopez-Castro T.; Ashamed and afraid: A scoping review of the role of shame in post-traumatic stress disorder (PTSD). J Clin Med  2016,5(11),94","journal-title":"J Clin Med"},{"key":"ref=611","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1176\/appi.ps.202000355","volume":"72","author":"Pickover A.","year":"2021","unstructured":"Pickover A.; Lowell A.; Lazarov A.; Lopez-Yianilos A.; Sanchez-Lacay A.; Ryba M.; Such S.; Arnon S.; Amsalem D.; Neria Y.; Markowitz J.C.; Interpersonal psychotherapy of posttraumatic stress disorder for veterans and family members: An open trial. Psychiatr Serv  2021,72(8),866-873","journal-title":"Psychiatr Serv"},{"key":"ref=612","doi-asserted-by":"crossref","first-page":"e2020705118","DOI":"10.1073\/pnas.2020705118","volume":"118","author":"De Gregorio D.","year":"2021","unstructured":"De Gregorio D.; Popic J.; Enns J.P.; Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc Natl Acad Sci USA  2021,118(5),e2020705118","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=613","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3389\/fpsyt.2019.00881","volume":"10","author":"Preller K.H.","year":"2019","unstructured":"Preller K.H.; Vollenweider F.X.; Modulation of social cognition via hallucinogens and \u201centactogens\u201d. Front Psychiatry  2019,10,881","journal-title":"Front Psychiatry"},{"key":"ref=614","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"Carhart-Harris R.L.","year":"2017","unstructured":"Carhart-Harris R.L.; Goodwin G.M.; The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology  2017,42(11),2105-2113","journal-title":"Neuropsychopharmacology"},{"key":"ref=615","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/0269881118780612","volume":"32","author":"Noorani T.","year":"2018","unstructured":"Noorani T.; Garcia-Romeu A.; Swift T.C.; Griffiths R.R.; Johnson M.W.; Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. J Psychopharmacol  2018,32(7),756-769","journal-title":"J Psychopharmacol"},{"key":"ref=616","doi-asserted-by":"publisher","first-page":"749788","DOI":"10.3389\/fpsyg.2021.749788","volume":"12","author":"Weiss B.","year":"2021","unstructured":"Weiss B.; Nygart V.; Pommerencke L.M.; Carhart-Harris R.L.; Erritzoe D.; Examining psychedelic-induced changes in social functioning and connectedness in a naturalistic online sample using the five-factor model of personality. Front Psychol  2021,12,749788","journal-title":"Front Psychol"},{"key":"ref=617","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","volume":"32","author":"Griffiths R.R.","year":"2018","unstructured":"Griffiths R.R.; Johnson M.W.; Richards W.A.; Richards B.D.; Jesse R.; MacLean K.A.; Barrett F.S.; Cosimano M.P.; Klinedinst M.A.; Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol  2018,32(1),49-69","journal-title":"J Psychopharmacol"},{"key":"ref=618","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","volume":"235","author":"Schmid Y.","year":"2018","unstructured":"Schmid Y.; Liechti M.E.; Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology  2018,235(2),535-545","journal-title":"Psychopharmacology"},{"key":"ref=619","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3389\/fpsyt.2020.00782","volume":"11","author":"Zeifman R.J.","year":"2020","unstructured":"Zeifman R.J.; Wagner A.C.; Watts R.; Kettner H.; Mertens L.J.; Carhart-Harris R.L.; Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Front Psychiatry  2020,11,782","journal-title":"Front Psychiatry"},{"key":"ref=620","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/7854_2022_366","volume":"56","author":"Khan A.J.","year":"2022","unstructured":"Khan A.J.; Bradley E.; O\u2019Donovan A.; Woolley J.; Psilocybin for trauma-related disorders. Curr Top Behav Neurosci  2022,56,319-322","journal-title":"Curr Top Behav Neurosci"},{"key":"ref=621","doi-asserted-by":"publisher","first-page":"100538","DOI":"10.1016\/j.eclinm.2020.100538","volume":"27","author":"Anderson B.T.","year":"2020","unstructured":"Anderson B.T.; Danforth A.; Daroff P.R.; Stauffer C.; Ekman E.; Agin-Liebes G.; Trope A.; Boden M.T.; Dilley P.J.; Mitchell J.; Woolley J.; Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClin. Med  2020,27,100538","journal-title":"Med"},{"key":"ref=622","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fphar.2018.00256","volume":"9","author":"Malone T.C.","year":"2018","unstructured":"Malone T.C.; Mennenga S.E.; Guss J.; Podrebarac S.K.; Owens L.T.; Bossis A.P.; Belser A.B.; Agin-Liebes G.; Bogenschutz M.P.; Ross S.; Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Front Pharmacol  2018,9,256","journal-title":"Front Pharmacol"},{"key":"ref=623","doi-asserted-by":"publisher","first-page":"863552","DOI":"10.3389\/fpsyt.2022.863552","volume":"13","author":"Oehen P.","year":"2022","unstructured":"Oehen P.; Gasser P.; Using a MDMA- and LSD-group therapy model in clinical practice in Switzerland and highlighting the treatment of trauma-related disorders. Front Psychiatry  2022,13,863552","journal-title":"Front Psychiatry"},{"key":"ref=624","doi-asserted-by":"publisher","first-page":"623979","DOI":"10.3389\/fphar.2021.623979","volume":"12","author":"Perkins D.","year":"2021","unstructured":"Perkins D.; Schubert V.; Simonov\u00e1 H.; T\u00f3foli L.F.; Bouso J.C.; Hor\u00e1k M.; Galv\u00e3o-Coelho N.L.; Sarris J.; Influence of context and setting on the mental health and wellbeing outcomes of ayahuasca drinkers: Results of a large international survey. Front Pharmacol  2021,12,623979","journal-title":"Front Pharmacol"},{"key":"ref=625","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1038\/s41598-020-61169-x","volume":"10","author":"Jim\u00e9nez-Garrido D.F.","year":"2020","unstructured":"Jim\u00e9nez-Garrido D.F.; G\u00f3mez-Sousa M.; Ona G.; Dos Santos R.G.; Hallak J.E.C.; Alc\u00e1zar-C\u00f3rcoles M.\u00c1.; Bouso J.C.; Effects of ayahuasca on mental health and quality of life in na\u00efve users: A longitudinal and cross-sectional study combination. Sci Rep  2020,10(1),4075","journal-title":"Sci Rep"},{"key":"ref=626","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","volume":"37","author":"Os\u00f3rio F.L.","year":"2015","unstructured":"Os\u00f3rio F.L.; Sanches R.F.; Macedo L.R.; dos Santos R.G.; Maia-de-Oliveira J.P.; Wichert-Ana L.; de Araujo D.B.; Riba J.; Crippa J.A.; Hallak J.E.; Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Rev Bras Psiquiatr  2015,37(1),13-20","journal-title":"Rev Bras Psiquiatr"},{"key":"ref=627","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/02791072.2019.1567961","volume":"51","author":"Ona G.","year":"2019","unstructured":"Ona G.; Kohek M.; Massaguer T.; Gomariz A.; Jim\u00e9nez D.F.; Dos Santos R.G.; Hallak J.E.C.; Alc\u00e1zar-C\u00f3rcoles M.\u00c1.; Bouso J.C.; Ayahuasca and public health: Health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. J Psychoactive Drugs  2019,51(2),135-145","journal-title":"J Psychoactive Drugs"},{"key":"ref=628","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jep.2007.04.012","volume":"112","author":"Santos R.G.","year":"2007","unstructured":"Santos R.G.; Landeira-Fernandez J.; Strassman R.J.; Motta V.; Cruz A.P.M.; Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol  2007,112(3),507-513","journal-title":"J Ethnopharmacol"},{"key":"ref=629","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fnhum.2016.00612","volume":"10","author":"Li L.","year":"2016","unstructured":"Li L.; Vlisides P.E.; Ketamine: 50 years of modulating the mind. Front Hum Neurosci  2016,10,612","journal-title":"Front Hum Neurosci"},{"key":"ref=630","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cpt196563279","volume":"6","author":"Domino E.F.","year":"1965","unstructured":"Domino E.F.; Chodoff P.; Corssen G.; Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther  1965,6(3),279-291","journal-title":"Clin Pharmacol Ther"},{"key":"ref=631","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/cns.12099","volume":"19","author":"Mion G.","year":"2013","unstructured":"Mion G.; Villevieille T.; Ketamine pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings). CNS Neurosci Ther  2013,19(6),370-380","journal-title":"CNS Neurosci Ther"},{"key":"ref=632","doi-asserted-by":"publisher","first-page":"172870","DOI":"10.1016\/j.pbb.2020.172870","volume":"190","author":"Wei Y.","year":"2020","unstructured":"Wei Y.; Chang L.; Hashimoto K.; A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol Biochem Behav  2020,190,172870","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=633","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s43440-021-00232-4","volume":"73","author":"Kohtala S.","year":"2021","unstructured":"Kohtala S.; Ketamine\u201450 years in use: From anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacol Rep  2021,73(2),323-345","journal-title":"Pharmacol Rep"},{"key":"ref=634","first-page":"37663","volume":"64","year":"1999","unstructured":"Administration USDE. Schedules of controlled substances: Placement of ketamine into schedule III. rules and regulations. Fed Regist U.S. Department of Justice 1999,64(133),37663-37831","journal-title":"Fed Regist"},{"key":"ref=635","doi-asserted-by":"publisher","first-page":"657714","DOI":"10.3389\/fnins.2021.657714","volume":"15","author":"Carboni E.","year":"2021","unstructured":"Carboni E.; Carta A.R.; Carboni E.; Novelli A.; Repurposing ketamine in depression and related disorders: Can this enigmatic drug achieve success? Front Neurosci  2021,15,657714","journal-title":"Front Neurosci"},{"key":"ref=636","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","volume":"126","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; Lin D.; Wu B.; Zhou W.; Ketamine abuse potential and use disorder. Brain Res Bull  2016,126,68-73","journal-title":"Brain Res Bull"},{"key":"ref=637","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1192\/bjo.2021.1061","volume":"8","author":"Walsh Z.","year":"2022","unstructured":"Walsh Z.; Mollaahmetoglu O.M.; Rootman J.; Golsof S.; Keeler J.; Marsh B.; Nutt D.J.; Morgan C.J.A.; Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review. BJPsych Open  2022,8(1),e19","journal-title":"BJPsych Open"},{"key":"ref=638","author":"Yensen R.","year":"1973","unstructured":"Yensen R.;  Ed; Group Psychotherapy with a Variety of Hallucinogens  1973","journal-title":"Ed; Group Psychotherapy with a Variety of Hallucinogens"},{"key":"ref=639","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"Zarate C.A.","year":"2006","unstructured":"Zarate C.A.; Singh J.B.; Carlson P.J.; Brutsche N.E.; Ameli R.; Luckenbaugh D.A.; Charney D.S.; Manji H.K.; A randomized trial of an n-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry  2006,63(8),856-864","journal-title":"Arch Gen Psychiatry"},{"key":"ref=640","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","volume":"175","author":"Wilkinson S.T.","year":"2018","unstructured":"Wilkinson S.T.; Ballard E.D.; Bloch M.H.; Mathew S.J.; Murrough J.W.; Feder A.; Sos P.; Wang G.; Zarate C.A.; Sanacora G.; The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. Am J Psychiatry  2018,175(2),150-158","journal-title":"Am J Psychiatry"},{"key":"ref=641","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bdi.12487","volume":"19","author":"Grunebaum M.F.","year":"2017","unstructured":"Grunebaum M.F.; Ellis S.P.; Keilp J.G.; Moitra V.K.; Cooper T.B.; Marver J.E.; Burke A.K.; Milak M.S.; Sublette M.E.; Oquendo M.A.; Mann J.J.; Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disord  2017,19(3),176-183","journal-title":"Bipolar Disord"},{"key":"ref=642","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","volume":"71","author":"Feder A.","year":"2014","unstructured":"Feder A.; Parides M.K.; Murrough J.W.; Perez A.M.; Morgan J.E.; Saxena S.; Kirkwood K.; aan het Rot, M.; Lapidus, K.A.B.; Wan, L-B.; Iosifescu, D.; Charney, D.S. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. JAMA Psychiatry  2014,71(6),681-688","journal-title":"JAMA Psychiatry"},{"key":"ref=643","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1176\/appi.ajp.2020.20121677","volume":"178","author":"Stein M.B.","year":"2021","unstructured":"Stein M.B.; Simon N.M.; Ketamine for PTSD: Well, Isn\u2019t That Special. Am J Psychiatry  2021,178(2),116-118","journal-title":"Am J Psychiatry"},{"key":"ref=644","doi-asserted-by":"publisher","first-page":"868103","DOI":"10.3389\/fpsyg.2022.868103","volume":"13","author":"Mathai D.S.","year":"2022","unstructured":"Mathai D.S.; Mora V.; Garcia-Romeu A.; Toward synergies of ketamine and psychotherapy. Front Psychol  2022,13,868103","journal-title":"Front Psychol"},{"key":"ref=645","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/JPR.S360733","volume":"15","author":"Drozdz S.J.","year":"2022","unstructured":"Drozdz S.J.; Goel A.; McGarr M.W.; Katz J.; Ritvo P.; Mattina G.; Bhat V.; Diep C.; Ladha K.S.; Ketamine assisted psychotherapy: A systematic narrative review of the literature. J Pain Res  2022,15,1691-1706","journal-title":"J Pain Res"},{"key":"ref=646","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"McIntyre R.S.","year":"2021","unstructured":"McIntyre R.S.; Rosenblat J.D.; Nemeroff C.B.; Sanacora G.; Murrough J.W.; Berk M.; Brietzke E.; Dodd S.; Gorwood P.; Ho R.; Iosifescu D.V.; Lopez Jaramillo C.; Kasper S.; Kratiuk K.; Lee J.G.; Lee Y.; Lui L.M.W.; Mansur R.B.; Papakostas G.I.; Subramaniapillai M.; Thase M.; Vieta E.; Young A.H.; Zarate C.A.; Stahl S.; Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. Am J Psychiatry  2021,178(5),383-399","journal-title":"Am J Psychiatry"},{"key":"ref=647","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.3109\/10826081003793912","volume":"45","author":"Stirling J.","year":"2010","unstructured":"Stirling J.; McCoy L.; Quantifying the psychological effects of ketamine: From euphoria to the k-hole. Subst Use Misuse  2010,45(14),2428-2443","journal-title":"Subst Use Misuse"},{"key":"ref=648","doi-asserted-by":"publisher","first-page":"6431","DOI":"10.1038\/s41467-020-20190-4","volume":"11","author":"Ballard E.D.","year":"2020","unstructured":"Ballard E.D.; Zarate C.A.; The role of dissociation in ketamine\u2019s antidepressant effects. Nat Commun  2020,11(1),6431","journal-title":"Nat Commun"},{"key":"ref=649","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","volume":"51","author":"Dore J.","year":"2019","unstructured":"Dore J.; Turnipseed B.; Dwyer S.; Turnipseed A.; Andries J.; Ascani G.; Monnette C.; Huidekoper A.; Strauss N.; Wolfson P.; Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs  2019,51(2),189-198","journal-title":"J Psychoactive Drugs"},{"key":"ref=650","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"Krystal J.H.","year":"1994","unstructured":"Krystal J.H.; Karper L.P.; Seibyl J.P.; Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry  1994,51(3),199-214","journal-title":"Arch Gen Psychiatry"},{"key":"ref=651","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/sj.npp.1300342","volume":"29","author":"Morgan C.J.A.","year":"2004","unstructured":"Morgan C.J.A.; Mofeez A.; Brandner B.; Bromley L.; Curran H.V.; Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology  2004,29(1),208-218","journal-title":"Neuropsychopharmacology"},{"key":"ref=652","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"Zanos P.","year":"2018","unstructured":"Zanos P.; Moaddel R.; Morris P.J.; Riggs L.M.; Highland J.N.; Georgiou P.; Pereira E.F.R.; Albuquerque E.X.; Thomas C.J.; Zarate C.A.; Gould T.D.; Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacol Rev  2018,70(3),621-660","journal-title":"Pharmacol Rev"},{"key":"ref=653","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2022.2066651","volume":"21","author":"Nikayin S.","year":"2022","unstructured":"Nikayin S.; Murphy E.; Krystal J.H.; Wilkinson S.T.; Long-term safety of ketamine and esketamine in treatment of depression. Expert Opin Drug Saf  2022,21(6),777-787","journal-title":"Expert Opin Drug Saf"},{"key":"ref=654","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","volume":"74","author":"Sanacora G.","year":"2017","unstructured":"Sanacora G.; Frye M.A.; McDonald W.; Mathew S.J.; Turner M.S.; Schatzberg A.F.; Summergrad P.; Nemeroff C.B.; A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry  2017,74(4),399-405","journal-title":"JAMA Psychiatry"},{"key":"ref=655","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320916657","volume":"10","author":"Matveychuk D.","year":"2020","unstructured":"Matveychuk D.; Thomas R.K.; Swainson J.; Khullar A.; MacKay M-A.; Baker G.B.; Dursun S.M.; Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers Ther Adv Psychopharmacol  ecollection 2020.2020,10","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=656","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","volume":"26","author":"Bonaventura J.","year":"2021","unstructured":"Bonaventura J.; Lam S.; Carlton M.; Boehm M.A.; Gomez J.L.; Sol\u00eds O.; S\u00e1nchez-Soto M.; Morris P.J.; Fredriksson I.; Thomas C.J.; Sibley D.R.; Shaham Y.; Zarate C.A.; Michaelides M.; Pharmacological and behavioral divergence of ketamine enantiomers: Implications for abuse liability. Mol Psychiatry  2021,26(11),6704-6722","journal-title":"Mol Psychiatry"},{"key":"ref=657","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.4088\/JCP.17f11681","volume":"78","author":"Andrade C.","year":"2017","unstructured":"Andrade C.; Ketamine for depression, 3: Does chirality matter? J Clin Psychiatry  2017,78(6),e674-e677","journal-title":"J Clin Psychiatry"},{"key":"ref=658","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/20961790.2017.1285219","volume":"2","author":"Dinis-Oliveira R.J.","year":"2017","unstructured":"Dinis-Oliveira R.J.; Metabolism and metabolomics of ketamine: A toxicological approach. Forensic Sci Res  2017,2(1),2-10","journal-title":"Forensic Sci Res"},{"key":"ref=659","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/s12888-022-04268-5","volume":"22","author":"Ahuja S.","year":"2022","unstructured":"Ahuja S.; Brendle M.; Smart L.; Moore C.; Thielking P.; Robison R.; Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: A retrospective descriptive cohort study. BMC Psychiatry  2022,22(1),634","journal-title":"BMC Psychiatry"},{"key":"ref=660","first-page":"19f12820","volume":"80","author":"Andrade C.","year":"2019","unstructured":"Andrade C.; 1: Pharmacologic considerations and clinical evidence. J Clin Psychiatry  2019,80(2),19f12820","journal-title":"J Clin Psychiatry"},{"key":"ref=661","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"Zanos P.","year":"2018","unstructured":"Zanos P.; Gould T.D.; Mechanisms of ketamine action as an antidepressant. Mol Psychiatry  2018,23(4),801-811","journal-title":"Mol Psychiatry"},{"key":"ref=662","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","volume":"36","author":"Zorumski C.F.","year":"2016","unstructured":"Zorumski C.F.; Izumi Y.; Mennerick S.; Ketamine: NMDA receptors and beyond. J Neurosci  2016,36(44),11158-11164","journal-title":"J Neurosci"},{"key":"ref=663","doi-asserted-by":"publisher","first-page":"105044","DOI":"10.1016\/j.neuint.2021.105044","volume":"146","author":"Asim M.","year":"2021","unstructured":"Asim M.; Wang B.; Hao B.; Wang X.; Ketamine for post-traumatic stress disorders and it\u2019s possible therapeutic mechanism. Neurochem Int  2021,146,105044","journal-title":"Neurochem Int"},{"key":"ref=664","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0004867419883341","volume":"54","author":"Witt K.","year":"2020","unstructured":"Witt K.; Potts J.; Hubers A.; Grunebaum M.F.; Murrough J.W.; Loo C.; Cipriani A.; Hawton K.; Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry  2020,54(1),29-45","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=665","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/0253-7176.127258","volume":"36","author":"Chilukuri H.","year":"2014","unstructured":"Chilukuri H.; Reddy N.P.; Pathapati R.M.; Manu A.N.; Jollu S.; Shaik A.B.; Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med  2014,36(1),71-76","journal-title":"Indian J Psychol Med"},{"key":"ref=666","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","volume":"76","author":"Lapidus K.A.B.","year":"2014","unstructured":"Lapidus K.A.B.; Levitch C.F.; Perez A.M.; Brallier J.W.; Parides M.K.; Soleimani L.; Feder A.; Iosifescu D.V.; Charney D.S.; Murrough J.W.; A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry  2014,76(12),970-976","journal-title":"Biol Psychiatry"},{"key":"ref=667","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","volume":"66","author":"Abdallah C.G.","year":"2015","unstructured":"Abdallah C.G.; Sanacora G.; Duman R.S.; Krystal J.H.; Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annu Rev Med  2015,66(1),509-523","journal-title":"Annu Rev Med"},{"key":"ref=668","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/7854_2022_313","volume":"56","author":"Kojic M.","year":"2022","unstructured":"Kojic M.; Saelens J.; Kadriu B.; Zarate C.A.; Kraus C.; Ketamine for depression: Advances in clinical treatment, rapid antidepressant mechanisms of action, and a contrast with serotonergic psychedelics. Curr Top Behav Neurosci  2022,56,141-167","journal-title":"Curr Top Behav Neurosci"},{"key":"ref=669","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/ijnp\/pyy094","volume":"22","author":"Kadriu B.","year":"2019","unstructured":"Kadriu B.; Musazzi L.; Henter I.D.; Graves M.; Popoli M.; Zarate C.A.; Glutamatergic neurotransmission: Pathway to developing novel rapid-acting antidepressant treatments. Int J Neuropsychopharmacol  2019,22(2),119-135","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=670","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/archgenpsychiatry.2007.37","volume":"65","author":"Deakin J.F.W.","year":"2008","unstructured":"Deakin J.F.W.; Lees J.; McKie S.; Hallak J.E.C.; Williams S.R.; Dursun S.M.; Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry  2008,65(2),154-164","journal-title":"Arch Gen Psychiatry"},{"key":"ref=671","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00429-016-1291-0","volume":"222","author":"H\u00f6flich A.","year":"2017","unstructured":"H\u00f6flich A.; Hahn A.; K\u00fcblb\u00f6ck M.; Kranz G.S.; Vanicek T.; Ganger S.; Spies M.; Windischberger C.; Kasper S.; Winkler D.; Lanzenberger R.; Ketamine-dependent neuronal activation in healthy volunteers. Brain Struct Funct  2017,222(3),1533-1542","journal-title":"Brain Struct Funct"},{"key":"ref=672","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.nicl.2018.05.037","volume":"19","author":"Mueller F.","year":"2018","unstructured":"Mueller F.; Musso F.; London M.; de Boer P.; Zacharias N.; Winterer G.; Pharmacological fMRI: Effects of subanesthetic ketamine on resting-state functional connectivity in the default mode network, salience network, dorsal attention network and executive control network. Neuroimage Clin  2018,19,745-757","journal-title":"Neuroimage Clin"},{"key":"ref=673","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hbm.24791","volume":"41","author":"Zacharias N.","year":"2020","unstructured":"Zacharias N.; Musso F.; M\u00fcller F.; Lammers F.; Saleh A.; London M.; de Boer P.; Winterer G.; Ketamine effects on default mode network activity and vigilance: A randomized, placebo-controlled crossover simultaneous fMRI\/EEG study. Hum Brain Mapp  2020,41(1),107-119","journal-title":"Hum Brain Mapp"},{"key":"ref=674","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41386-019-0591-5","volume":"45","author":"Morris L.S.","year":"2020","unstructured":"Morris L.S.; Costi S.; Tan A.; Stern E.R.; Charney D.S.; Murrough J.W.; Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacology  2020,45(6),975-981","journal-title":"Neuropsychopharmacology"},{"key":"ref=675","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.neuron.2018.11.021","volume":"101","author":"Alexander L.","year":"2019","unstructured":"Alexander L.; Gaskin P.L.R.; Sawiak S.J.; Fryer T.D.; Hong Y.T.; Cockcroft G.J.; Clarke H.F.; Roberts A.C.; Fractionating blunted reward processing characteristic of anhedonia by over-activating primate subgenual anterior cingulate cortex. Neuron  2019,101(2),307-320.e6","journal-title":"Neuron"},{"key":"ref=676","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"Zanos P.","year":"2016","unstructured":"Zanos P.; Moaddel R.; Morris P.J.; Georgiou P.; Fischell J.; Elmer G.I.; Alkondon M.; Yuan P.; Pribut H.J.; Singh N.S.; Dossou K.S.S.; Fang Y.; Huang X-P.; Mayo C.L.; Wainer I.W.; Albuquerque E.X.; Thompson S.M.; Thomas C.J.; Zarate C.A.; Gould T.D.; NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature  2016,533(7604),481-486","journal-title":"Nature"},{"key":"ref=677","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1073\/pnas.1916570117","volume":"117","author":"Klein M.E.","year":"2020","unstructured":"Klein M.E.; Chandra J.; Sheriff S.; Malinow R.; Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci  2020,117(5),2656-2662","journal-title":"Proc Natl Acad Sci"},{"key":"ref=678","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"Williams N.R.","year":"2018","unstructured":"Williams N.R.; Heifets B.D.; Blasey C.; Sudheimer K.; Pannu J.; Pankow H.; Hawkins J.; Birnbaum J.; Lyons D.M.; Rodriguez C.I.; Schatzberg A.F.; Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry  2018,175(12),1205-1215","journal-title":"Am J Psychiatry"},{"key":"ref=679","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","volume":"76","author":"Yoon G.","year":"2019","unstructured":"Yoon G.; Petrakis I.L.; Krystal J.H.; Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry  2019,76(3),337-338","journal-title":"JAMA Psychiatry"},{"key":"ref=680","doi-asserted-by":"publisher","first-page":"114892","DOI":"10.1016\/j.bcp.2021.114892","volume":"197","author":"Hess E.M.","year":"2022","unstructured":"Hess E.M.; Riggs L.M.; Michaelides M.; Gould T.D.; Mechanisms of ketamine and its metabolites as antidepressants. Biochem Pharmacol  2022,197,114892","journal-title":"Biochem Pharmacol"},{"key":"ref=681","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jfma.2011.11.010","volume":"110","author":"Chen C.H.","year":"2011","unstructured":"Chen C.H.; Lee M.H.; Chen Y.C.; Lin M.F.; Ketamine-snorting associated cystitis. J Formos Med Assoc  2011,110(12),787-791","journal-title":"J Formos Med Assoc"},{"key":"ref=682","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/archneurpsyc.1959.02340150095011","volume":"81","author":"Luby E.D.","year":"1959","unstructured":"Luby E.D.; Study of a new schizophrenomimetic drug\u2014sernyl. Arch Neurol Psychiatry  1959,81(3),363-369","journal-title":"Arch Neurol Psychiatry"},{"key":"ref=683","doi-asserted-by":"publisher","first-page":"795231","DOI":"10.3389\/fnana.2022.795231","volume":"16","author":"Strous J.F.M.","year":"2022","unstructured":"Strous J.F.M.; Weeland C.J.; van der Draai F.A.; Daams J.G.; Denys D.; Lok A.; Schoevers R.A.; Figee M.; Brain changes associated with long-term ketamine abuse, a systematic review. Front Neuroanat  2022,16,795231","journal-title":"Front Neuroanat"},{"key":"ref=684","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1360-0443.2009.02761.x","volume":"105","author":"Morgan C.J.A.","year":"2010","unstructured":"Morgan C.J.A.; Muetzelfeldt L.; Curran H.V.; Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: A 1-year longitudinal study. Addiction  2010,105(1),121-133","journal-title":"Addiction"},{"key":"ref=685","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/0897190014525754","volume":"27","author":"Bokor G.","year":"2014","unstructured":"Bokor G.; Anderson P.D.; Ketamine. J Pharm Pract  2014,27(6),582-586","journal-title":"J Pharm Pract"},{"key":"ref=686","first-page":"53","volume":"15","author":"Wong S.W.","year":"2009","unstructured":"Wong S.W.; Lee K.F.; Wong J.; Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J  2009,15(1),53-56","journal-title":"Hong Kong Med J"},{"key":"ref=687","first-page":"e52","volume":"52","author":"Lo R.S.C.","year":"2011","unstructured":"Lo R.S.C.; Krishnamoorthy R.; Freeman J.G.; Austin A.S.; Cholestasis and biliary dilatation associated with chronic ketamine abuse: A case series. Singapore Med J  2011,52(3),e52-e55","journal-title":"Singapore Med J"},{"key":"ref=688","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/j.1464-410X.2008.07920.x","volume":"102","author":"Chu P.S.K.","year":"2008","unstructured":"Chu P.S.K.; Ma W.K.; Wong S.C.W.; Chu R.W-H.; Cheng C-H.; Wong S.; Tse J.M.; Lau F-L.; Yiu M-K.; Man C-W.; The destruction of the lower urinary tract by ketamine abuse: A new syndrome? BJU Int  2008,102(11),1616-1622","journal-title":"BJU Int"},{"key":"ref=689","first-page":"311","volume":"13","author":"Chu P.S.K.","year":"2007","unstructured":"Chu P.S.K.; Kwok S.C.; Lam K.M.; \u2018Street ketamine\u2019-associated bladder dysfunction: A report of ten cases. Hong Kong Med J  2007,13(4),311-313","journal-title":"Hong Kong Med J"},{"key":"ref=690","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.urology.2007.01.038","volume":"69","author":"Shahani R.","year":"2007","unstructured":"Shahani R.; Streutker C.; Dickson B.; Stewart R.J.; Ketamine-associated ulcerative cystitis: A new clinical entity. Urology  2007,69(5),810-812","journal-title":"Urology"},{"key":"ref=691","first-page":"267","volume":"17","author":"Cheung RYK","year":"2011","unstructured":"Cheung RYK; Chan SSC; Lee JHS; Urinary symptoms and impaired quality of life in female ketamine users: Persistence after cessation of use. Hong Kong Med J  2011,17(4),267-273","journal-title":"Hong Kong Med J"},{"key":"ref=692","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1751-2980.2010.00424.x","volume":"11","author":"Poon T.L.","year":"2010","unstructured":"Poon T.L.; Wong K.F.; Chan M.Y.; Fung K.W.; Chu S.K.; Man C.W.; Yiu M.K.; Leung S.K.; Upper gastrointestinal problems in inhalational ketamine abusers. J Dig Dis  2010,11(2),106-110","journal-title":"J Dig Dis"},{"key":"ref=693","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00213-021-05767-1","volume":"238","author":"Ng J.","year":"2021","unstructured":"Ng J.; Lui L.M.W.; Rosenblat J.D.; Teopiz K.M.; Lipsitz O.; Cha D.S.; Xiong J.; Nasri F.; Lee Y.; Kratiuk K.; Rodrigues N.B.; Gill H.; Subramaniapillai M.; Mansur R.B.; Ho R.; Cao B.; McIntyre R.S.; Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment. Psychopharmacology  2021,238(4),917-926","journal-title":"Psychopharmacology"},{"key":"ref=694","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00213-020-05611-y","volume":"237","author":"Findeis H.","year":"2020","unstructured":"Findeis H.; Sauer C.; Cleare A.; Bauer M.; Ritter P.; Urothelial toxicity of esketamine in the treatment of depression. Psychopharmacology  2020,237(11),3295-3302","journal-title":"Psychopharmacology"},{"key":"ref=695","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40264-021-01120-9","volume":"44","author":"Cotter S.","year":"2021","unstructured":"Cotter S.; Wong J.; Gada N.; Gill R.; Jones S.C.; Chai G.; Foster D.; Avigan M.; Mundkur M.; Repeated or continuous medically supervised ketamine administration associated with hepatobiliary adverse events: A retrospective case series. Drug Saf  2021,44(12),1365-1374","journal-title":"Drug Saf"},{"key":"ref=696","doi-asserted-by":"publisher","first-page":"813103","DOI":"10.3389\/fpsyt.2022.813103","volume":"13","author":"Du R.","year":"2022","unstructured":"Du R.; Han R.; Niu K.; Xu J.; Zhao Z.; Lu G.; Shang Y.; The multivariate effect of ketamine on PTSD: Systematic review and meta-analysis. Front Psychiatry  2022,13,813103","journal-title":"Front Psychiatry"},{"key":"ref=697","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11920-017-0829-z","volume":"19","author":"Krystal J.H.","year":"2017","unstructured":"Krystal J.H.; Abdallah C.G.; Averill L.A.; Kelmendi B.; Harpaz-Rotem I.; Sanacora G.; Southwick S.M.; Duman R.S.; Synaptic loss and the pathophysiology of PTSD: Implications for ketamine as a prototype novel therapeutic. Curr Psychiatry Rep  2017,19(10),74","journal-title":"Curr Psychiatry Rep"},{"key":"ref=698","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41386-021-01104-4","volume":"46","author":"Norbury A.","year":"2021","unstructured":"Norbury A.; Rutter S.B.; Collins A.B.; Costi S.; Jha M.K.; Horn S.R.; Kautz M.; Corniquel M.; Collins K.A.; Glasgow A.M.; Brallier J.; Shin L.M.; Charney D.S.; Murrough J.W.; Feder A.; Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: Preliminary evidence. Neuropsychopharmacology  2021,46(13),2266-2277","journal-title":"Neuropsychopharmacology"},{"key":"ref=699","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.neubiorev.2012.06.003","volume":"36","author":"Patel R.","year":"2012","unstructured":"Patel R.; Spreng R.N.; Shin L.M.; Girard T.A.; Neurocircuitry models of posttraumatic stress disorder and beyond: A meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev  2012,36(9),2130-2142","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=700","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.biopsych.2021.03.014","volume":"89","author":"Wu H.","year":"2021","unstructured":"Wu H.; Savalia N.K.; Kwan A.C.; Ketamine for a boost of neural plasticity: How, but also when? Biol Psychiatry  2021,89(11),1030-1032","journal-title":"Biol Psychiatry"},{"key":"ref=701","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.coph.2014.11.005","volume":"20","author":"Kavalali E.T.","year":"2015","unstructured":"Kavalali E.T.; Monteggia L.M.; How does ketamine elicit a rapid antidepressant response? Curr Opin Pharmacol  2015,20,35-39","journal-title":"Curr Opin Pharmacol"},{"key":"ref=702","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212305","volume":"8","author":"Liriano F.","year":"2019","unstructured":"Liriano F.; Hatten C.; Schwartz T.L.; Ketamine as treatment for post-traumatic stress disorder: A review. Drugs Context  2019,8,1-7","journal-title":"Drugs Context"},{"key":"ref=703","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2016.12.026","volume":"100","author":"Girgenti M.J.","year":"2017","unstructured":"Girgenti M.J.; Ghosal S.; LoPresto D.; Taylor J.R.; Duman R.S.; Ketamine accelerates fear extinction via mTORC1 signaling. Neurobiol Dis  2017,100,1-8","journal-title":"Neurobiol Dis"},{"key":"ref=704","doi-asserted-by":"publisher","first-page":"833259","DOI":"10.3389\/fpsyt.2022.833259","volume":"13","author":"Evers A.G.","year":"2022","unstructured":"Evers A.G.; Murrough J.W.; Charney D.S.; Costi S.; Ketamine as a prophylactic resilience-enhancing agent. Front Psychiatry  2022,13,833259","journal-title":"Front Psychiatry"},{"key":"ref=705","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.biopsych.2015.04.022","volume":"79","author":"Brachman R.A.","year":"2016","unstructured":"Brachman R.A.; McGowan J.C.; Perusini J.N.; Lim S.C.; Pham T.H.; Faye C.; Gardier A.M.; Mendez-David I.; David D.J.; Hen R.; Denny C.A.; Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol Psychiatry  2016,79(9),776-786","journal-title":"Biol Psychiatry"},{"key":"ref=706","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.biopsych.2018.02.011","volume":"84","author":"Mastrodonato A.","year":"2018","unstructured":"Mastrodonato A.; Martinez R.; Pavlova I.P.; LaGamma C.T.; Brachman R.A.; Robison A.J.; Denny C.A.; Ventral CA3 activation mediates prophylactic ketamine efficacy against stress-induced depressive-like behavior. Biol Psychiatry  2018,84(11),846-856","journal-title":"Biol Psychiatry"},{"key":"ref=707","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/npp.2017.19","volume":"42","author":"McGowan J.C.","year":"2017","unstructured":"McGowan J.C.; LaGamma C.T.; Lim S.C.; Tsitsiklis M.; Neria Y.; Brachman R.A.; Denny C.A.; Prophylactic ketamine attenuates learned fear. Neuropsychopharmacology  2017,42(8),1577-1589","journal-title":"Neuropsychopharmacology"},{"key":"ref=708","doi-asserted-by":"publisher","first-page":"759626","DOI":"10.3389\/fphar.2022.759626","volume":"13","author":"Sala N.","year":"2022","unstructured":"Sala N.; Paoli C.; Bonifacino T.; Mingardi J.; Schiavon E.; La Via L.; Milanese M.; Tornese P.; Datusalia A.K.; Rosa J.; Facchinetti R.; Frumento G.; Carini G.; Salerno Scarzella F.; Scuderi C.; Forti L.; Barbon A.; Bonanno G.; Popoli M.; Musazzi L.; Acute ketamine facilitates fear memory extinction in a rat model of PTSD along with restoring glutamatergic alterations and dendritic atrophy in the pre-frontal cortex. Front Pharmacol  2022,13,759626","journal-title":"Front Pharmacol"},{"key":"ref=709","doi-asserted-by":"publisher","first-page":"7425","DOI":"10.1038\/s41380-021-01246-3","volume":"26","author":"Lazarevic V.","year":"2021","unstructured":"Lazarevic V.; Yang Y.; Flais I.; Svenningsson P.; Ketamine decreases neuronally released glutamate via retrograde stimulation of pre-synaptic adenosine A1 receptors. Mol Psychiatry  2021,26(12),7425-7435","journal-title":"Mol Psychiatry"},{"key":"ref=710","doi-asserted-by":"publisher","first-page":"103723","DOI":"10.1016\/j.mcn.2022.103723","volume":"120","author":"Asim M.","year":"2022","unstructured":"Asim M.; Hao B.; Waris A.; Liang Y.M.; Wang X.G.; Ketamine attenuates the PTSD-like effect via regulation of glutamatergic signaling in the nucleus accumbens of mice. Mol Cell Neurosci  2022,120,103723","journal-title":"Mol Cell Neurosci"},{"key":"ref=711","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/bs.apha.2020.05.004","volume":"89","author":"Feder A.","year":"2020","unstructured":"Feder A.; Rutter S.B.; Schiller D.; Charney D.S.; The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Adv Pharmacol  2020,89,261-286","journal-title":"Adv Pharmacol"},{"key":"ref=712","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1017\/S1092852919001007","volume":"25","author":"Hasler G.","year":"2020","unstructured":"Hasler G.; Toward specific ways to combine ketamine and psychotherapy in treating depression. CNS Spectr  2020,25(3),445-447","journal-title":"CNS Spectr"},{"key":"ref=713","year":"2021","unstructured":"NCT04889664 Clinical Trial Available from:  https:\/\/ClinicalTrials.gov\/show\/NCT04889664 2021","journal-title":"NCT04889664"},{"key":"ref=714","doi-asserted-by":"publisher","first-page":"695335","DOI":"10.3389\/fpsyt.2021.695335","volume":"12","author":"Mollaahmetoglu O.M.","year":"2021","unstructured":"Mollaahmetoglu O.M.; Keeler J.; Ashbullby K.J.; Ketzitzidou-Argyri E.; Grabski M.; Morgan C.J.A.; \u201cThis is something that changed my life\u201d: A qualitative study of patients\u2019 experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry  2021,12,695335","journal-title":"Front Psychiatry"},{"key":"ref=715","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","volume":"29","author":"Krupitsky E.M.","year":"1997","unstructured":"Krupitsky E.M.; Grinenko A.Y.; Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. J Psychoactive Drugs  1997,29(2),165-183","journal-title":"J Psychoactive Drugs"},{"key":"ref=716","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/0269881120970879","volume":"35","author":"Rothberg R.L.","year":"2021","unstructured":"Rothberg R.L.; Azhari N.; Haug N.A.; Dakwar E.; Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. J Psychopharmacol  2021,35(2),150-158","journal-title":"J Psychopharmacol"},{"key":"ref=717","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.drugalcdep.2013.12.019","volume":"136","author":"Dakwar E.","year":"2014","unstructured":"Dakwar E.; Anerella C.; Hart C.L.; Levin F.R.; Mathew S.J.; Nunes E.V.; Therapeutic infusions of ketamine: Do the psychoactive effects matter? Drug Alcohol Depend  2014,136,153-157","journal-title":"Drug Alcohol Depend"},{"key":"ref=718","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","volume":"142","author":"Dakwar E.","year":"2018","unstructured":"Dakwar E.; Nunes E.V.; Hart C.L.; Hu M.C.; Foltin R.W.; Levin F.R.; A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology  2018,142,270-276","journal-title":"Neuropharmacology"},{"key":"ref=719","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/7854_2017_34","author":"Veen C.","year":"2018","unstructured":"Veen C.; Jacobs G.; Philippens I.; Vermetten E.;  Subanesthetic dose ketamine in posttraumatic stress disorder: A role for reconsolidation during trauma-focused psychotherapy?Behavioral Neurobiology of PTSD Current Topics in Behavioral Neurosciences  2018,137-162","journal-title":"Subanesthetic dose ketamine in posttraumatic stress disorder: A role for reconsolidation during trauma-focused psychotherapy?Behavioral Neurobiology of PTSD Current Topics in Behavioral Neurosciences"},{"key":"ref=720","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0269881121998321","volume":"35","author":"Sumner R.L.","year":"2021","unstructured":"Sumner R.L.; Chacko E.; McMillan R.; Spriggs M.J.; Anderson C.; Chen J.; French A.; Jung S.H.; Rajan A.; Malpas G.; Hay J.; Ponton R.; Muthukumaraswamy S.D.; Sundram F.; A qualitative and quantitative account of patient\u2019s experiences of ketamine and its antidepressant properties. J Psychopharmacol  2021,35(8),946-961","journal-title":"J Psychopharmacol"},{"key":"ref=721","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2022.07.030","volume":"315","author":"Joneborg I.","year":"2022","unstructured":"Joneborg I.; Lee Y.; Di Vincenzo J.D.; Ceban F.; Meshkat S.; Lui L.M.W.; Fancy F.; Rosenblat J.D.; McIntyre R.S.; Active mechanisms of ketamine-assisted psychotherapy: A systematic review. J Affect Disord  2022,315,105-112","journal-title":"J Affect Disord"},{"key":"ref=722","first-page":"20220216","author":"Price RB","year":"2022","unstructured":"Price RB; Spotts C; Panny BA; Novel, Brief, Fully automated intervention to extend the antidepressant effect of a single ketamine infusion: A randomized clinical trial. Am J Psychiat  2022,20220216","journal-title":"Am J Psychiat"},{"key":"ref=723","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","volume":"178","author":"Feder A.","year":"2021","unstructured":"Feder A.; Costi S.; Rutter S.B.; Collins A.B.; Govindarajulu U.; Jha M.K.; Horn S.R.; Kautz M.; Corniquel M.; Collins K.A.; Bevilacqua L.; Glasgow A.M.; Brallier J.; Pietrzak R.H.; Murrough J.W.; Charney D.S.; A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry  2021,178(2),193-202","journal-title":"Am J Psychiatry"},{"key":"ref=724","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41386-022-01266-9","volume":"47","author":"Abdallah C.G.","year":"2022","unstructured":"Abdallah C.G.; Roache J.D.; Gueorguieva R.; Averill L.A.; Young-McCaughan S.; Shiroma P.R.; Purohit P.; Brundige A.; Murff W.; Ahn K-H.; Sherif M.A.; Baltutis E.J.; Ranganathan M.; D\u2019Souza D.; Martini B.; Southwick S.M.; Petrakis I.L.; Burson R.R.; Guthmiller K.B.; L\u00f3pez-Roca A.L.; Lautenschlager K.A.; McCallin J.P.; Hoch M.B.; Timchenko A.; Souza S.E.; Bryant C.E.; Mintz J.; Litz B.T.; Williamson D.E.; Keane T.M.; Peterson A.L.; Krystal J.H.; Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: A double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology  2022,47(8),1574-1581","journal-title":"Neuropsychopharmacology"},{"key":"ref=725","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/JCP.0000000000001395","volume":"41","author":"Mischel N.A.","year":"2021","unstructured":"Mischel N.A.; Balon R.; Esketamine. J Clin Psychopharmacol  2021,41(3),233-235","journal-title":"J Clin Psychopharmacol"},{"key":"ref=726","unstructured":"FDA approves new nasal spray medication for treatmentresistant depression: Available only at a certified doctor\u2019s office or clinic Commissioner Oot Available from:  https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medicationtreatment-resistant-depression-available-only-certified ([updated Tue, 03\/24\/2020 - 22:210"},{"key":"ref=727","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"Murrough J.W.","year":"2013","unstructured":"Murrough J.W.; Iosifescu D.V.; Chang L.C.; Al Jurdi R.K.; Green C.E.; Perez A.M.; Iqbal S.; Pillemer S.; Foulkes A.; Shah A.; Charney D.S.; Mathew S.J.; Antidepressant efficacy of ketamine in treatmentresistant major depression: A two-site randomized controlled trial. Am J Psychiatry  2013,170(10),1134-1142","journal-title":"Am J Psychiatry"},{"key":"ref=728","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","volume":"10","author":"Shiroma P.R.","year":"2020","unstructured":"Shiroma P.R.; Thuras P.; Wels J.; Albott C.S.; Erbes C.; Tye S.; Lim K.O.; A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry  2020,10(1),206","journal-title":"Transl Psychiatry"},{"key":"ref=729","first-page":"271","volume":"31","author":"Ross C.","year":"2019","unstructured":"Ross C.; Jain R.; Bonnett C.J.; Wolfson P.; High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Ann Clin Psychiatry  2019,31(4),271-279","journal-title":"Ann Clin Psychiatry"},{"key":"ref=730","first-page":"17m11634","volume":"79","author":"Albott C.S.","year":"2018","unstructured":"Albott C.S.; Lim K.O.; Forbes M.K.; Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatmentresistant depression. The J Clin Psych  2018,79(3),17m11634","journal-title":"The J Clin Psych"},{"key":"ref=731","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000507095","volume":"89","author":"Keizer B.M.","year":"2020","unstructured":"Keizer B.M.; Roache J.D.; Jones J.R.; Kalpinski R.J.; Porcerelli J.H.; Krystal J.H.; Continuous ketamine infusion for pain as an opportunity for psychotherapy for PTSD: A case series of ketamine-enhanced psychotherapy for PTSD and Pain (KEP-P2). Psychother Psychosom  2020,89(5),326-329","journal-title":"Psychother Psychosom"},{"key":"ref=732","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2013.10.036","volume":"155","author":"Shiroma P.R.","year":"2014","unstructured":"Shiroma P.R.; Johns B.; Kuskowski M.; Wels J.; Thuras P.; Albott C.S.; Lim K.O.; Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord  2014,155,123-129","journal-title":"J Affect Disord"},{"key":"ref=733","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4103\/2542-3932.211589","volume":"2","author":"Pradhan B.","year":"2017","unstructured":"Pradhan B.; Wainer I.; Moaddel R.; Torjman M.C.; Goldberg M.; Sabia M.; Parikh T.; Pumariega A.J.; Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy prolong the therapeutic effects of single ketamine infusion on post-traumatic stress disorder and comorbid depression: a pilot randomized, placebo-controlled, crossover clinical trial. Asia Pacif J Clin TrialNerv Sys Dis  2017,2(3),80","journal-title":"Asia Pacif J Clin TrialNerv Sys Dis"},{"key":"ref=734","year":"2021","unstructured":"ClinicalTrialsgov. NCT04560660, Research VOo Available from:  https:\/\/ClinicalTrials.gov\/show\/NCT045606602021"},{"key":"ref=735","year":"2021","unstructured":"Combined Ketamine and eCBT Intervention for PTSD. University Qs Available from:  https:\/\/ClinicalTrials.gov\/show\/NCT047717672021"},{"key":"ref=736","doi-asserted-by":"publisher","first-page":"800072","DOI":"10.3389\/fpsyt.2021.800072","volume":"12","author":"Kelly J.R.","year":"2021","unstructured":"Kelly J.R.; Gillan C.M.; Prenderville J.; Kelly C.; Harkin A.; Clarke G.; O\u2019Keane V.; Psychedelic therapy\u2019s transdiagnostic effects: A research domain criteria (RDoC) perspective. Front Psychiatry  2021,12,800072","journal-title":"Front Psychiatry"},{"key":"ref=737","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/jamapsychiatry.2019.0097","volume":"76","author":"Baldwin J.R.","year":"2019","unstructured":"Baldwin J.R.; Reuben A.; Newbury J.B.; Danese A.; Agreement between prospective and retrospective measures of childhood maltreatment. JAMA Psychiatry  2019,76(6),584-593","journal-title":"JAMA Psychiatry"},{"key":"ref=738","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.chiabu.2007.02.004","volume":"31","author":"Collishaw S.","year":"2007","unstructured":"Collishaw S.; Pickles A.; Messer J.; Rutter M.; Shearer C.; Maughan B.; Resilience to adult psychopathology following childhood maltreatment: Evidence from a community sample. Child Abuse Negl  2007,31(3),211-229","journal-title":"Child Abuse Negl"},{"key":"ref=739","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0749-3797(98)00017-8","volume":"14","author":"Felitti V.J.","year":"1998","unstructured":"Felitti V.J.; Anda R.F.; Nordenberg D.; Williamson D.F.; Spitz A.M.; Edwards V.; Koss M.P.; Marks J.S.; Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med  1998,14(4),245-258","journal-title":"Am J Prev Med"},{"key":"ref=740","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1017\/S0033291709992121","volume":"40","author":"McLaughlin K.A.","year":"2010","unstructured":"McLaughlin K.A.; Conron K.J.; Koenen K.C.; Gilman S.E.; Childhood adversity, adult stressful life events, and risk of past-year psychiatric disorder: A test of the stress sensitization hypothesis in a population-based sample of adults. Psychol Med  2010,40(10),1647-1658","journal-title":"Psychol Med"},{"key":"ref=741","year":"2014","unstructured":"Trauma-Informed Care in Behavioral Health Services Rockville (MD) (US) CfSAT 2014","journal-title":"Trauma-Informed Care in Behavioral Health Services Rockville (MD)"},{"key":"ref=742","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1176\/ajp.148.11.1548","volume":"148","author":"Carlson E.B.","year":"1991","unstructured":"Carlson E.B.; Rosser-Hogan R.; Trauma experiences, posttraumatic stress, dissociation, and depression in Cambodian refugees. Am J Psychiatry  1991,148(11),1548-1551","journal-title":"Am J Psychiatry"},{"key":"ref=743","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1037\/a0012591","volume":"117","author":"Grant D.M.","year":"2008","unstructured":"Grant D.M.; Beck J.G.; Marques L.; Palyo S.A.; Clapp J.D.; The structure of distress following trauma: Posttraumatic stress disorder, major depressive disorder, and generalized anxiety disorder. J Abnorm Psychol  2008,117(3),662-672","journal-title":"J Abnorm Psychol"},{"key":"ref=744","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.psychres.2011.10.022","volume":"196","author":"Gros D.F.","year":"2012","unstructured":"Gros D.F.; Price M.; Magruder K.M.; Frueh B.C.; Symptom overlap in posttraumatic stress disorder and major depression. Psychiatry Res  2012,196(2-3),267-270","journal-title":"Psychiatry Res"},{"key":"ref=745","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1176\/ajp.155.12.1746","volume":"155","author":"Levitan R.D.","year":"1998","unstructured":"Levitan R.D.; Parikh S.V.; Lesage A.D.; Hegadoren K.M.; Adams M.; Kennedy S.H.; Goering P.N.; Major depression in individuals with a history of childhood physical or sexual abuse: relationship to neurovegetative features, mania, and gender. Am J Psychiatry  1998,155(12),1746-1752","journal-title":"Am J Psychiatry"},{"key":"ref=746","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/jama.1995.03520300051036","volume":"273","author":"Singer M.I.","year":"1995","unstructured":"Singer M.I.; Anglin T.M.; Song L.Y.; Lunghofer L.; Adolescents\u2019 exposure to violence and associated symptoms of psychological trauma. JAMA  1995,273(6),477-482","journal-title":"JAMA"},{"key":"ref=747","doi-asserted-by":"publisher","first-page":"201","DOI":"10.5498\/wjp.v11.i6.201","volume":"11","author":"Artin H.","year":"2021","unstructured":"Artin H.; Zisook S.; Ramanathan D.; How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. World J Psychiatry  2021,11(6),201-214","journal-title":"World J Psychiatry"},{"key":"ref=748","doi-asserted-by":"publisher","DOI":"10.1177\/24705470221115342","volume":"6","author":"Kuburi S.","year":"2022","unstructured":"Kuburi S.; Di Passa A.M.; Tassone V.K.; Mahmood R.; Lalovic A.; Ladha K.S.; Dunlop K.; Rizvi S.; Demchenko I.; Bhat V.; Neuroimaging correlates of treatment response with psychedelics in major depressive disorder: A systematic review. Chronic Stress  2022,6","journal-title":"Chronic Stress"},{"key":"ref=749","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"Carhart-Harris R.L.","year":"2016","unstructured":"Carhart-Harris R.L.; Bolstridge M.; Rucker J.; Day C.M.J.; Erritzoe D.; Kaelen M.; Bloomfield M.; Rickard J.A.; Forbes B.; Feilding A.; Taylor D.; Pilling S.; Curran V.H.; Nutt D.J.; Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry  2016,3(7),619-627","journal-title":"Lancet Psychiatry"},{"key":"ref=750","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"Carhart-Harris R.L.","year":"2018","unstructured":"Carhart-Harris R.L.; Bolstridge M.; Day C.M.J.; Rucker J.; Watts R.; Erritzoe D.E.; Kaelen M.; Giribaldi B.; Bloomfield M.; Pilling S.; Rickard J.A.; Forbes B.; Feilding A.; Taylor D.; Curran H.V.; Nutt D.J.; Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology  2018,235(2),399-408","journal-title":"Psychopharmacology"},{"key":"ref=751","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5798285","volume":"2020","author":"Pribish A.","year":"2020","unstructured":"Pribish A.; Wood N.; Kalava A.; A review of nonanesthetic uses of ketamine. Anesthesiol Res Pract  2020,2020,1-15","journal-title":"Anesthesiol Res Pract"},{"key":"ref=752","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11599770-000000000-00000","volume":"26","author":"Mathew S.J.","year":"2012","unstructured":"Mathew S.J.; Shah A.; Lapidus K.; Clark C.; Jarun N.; Ostermeyer B.; Murrough J.W.; Ketamine for treatment-resistant unipolar depression: Current evidence. CNS Drugs  2012,26(3),189-204","journal-title":"CNS Drugs"},{"key":"ref=753","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/bcp.12845","volume":"82","author":"Ign\u00e1cio Z.M.","year":"2016","unstructured":"Ign\u00e1cio Z.M.; R\u00e9us G.Z.; Arent C.O.; Abelaira H.M.; Pitcher M.R.; Quevedo J.; New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs. Br J Clin Pharmacol  2016,82(5),1280-1290","journal-title":"Br J Clin Pharmacol"},{"key":"ref=754","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1503\/jpn.160175","volume":"42","author":"Aleksandrova L.R.","year":"2017","unstructured":"Aleksandrova L.R.; Phillips A.G.; Wang Y.T.; Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci  2017,42(4),222-229","journal-title":"J Psychiatry Neurosci"},{"key":"ref=755","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1017\/S1461145713000485","volume":"16","author":"Lara D.R.","year":"2013","unstructured":"Lara D.R.; Bisol L.W.; Munari L.R.; Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol  2013,16(9),2111-2117","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=756","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/0269881113478283","volume":"27","author":"Rasmussen K.G.","year":"2013","unstructured":"Rasmussen K.G.; Lineberry T.W.; Galardy C.W.; Kung S.; Lapid M.I.; Palmer B.A.; Ritter M.J.; Schak K.M.; Sola C.L.; Hanson A.J.; Frye M.A.; Serial infusions of low-dose ketamine for major depression. J Psychopharmacol  2013,27(5),444-450","journal-title":"J Psychopharmacol"},{"key":"ref=757","doi-asserted-by":"publisher","first-page":"pyv124","DOI":"10.1093\/ijnp\/pyv124","volume":"19","author":"Xu Y.","year":"2016","unstructured":"Xu Y.; Hackett M.; Carter G.; Loo C.; G\u00e1lvez V.; Glozier N.; Glue P.; Lapidus K.; McGirr A.; Somogyi A.A.; Mitchell P.B.; Rodgers A.; Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. Int J Neuropsychopharmacol  2016,19(4),pyv124","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=758","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/da.20751","volume":"27","author":"Khoury L.","year":"2010","unstructured":"Khoury L.; Tang Y.L.; Bradley B.; Cubells J.F.; Ressler K.J.; Substance use, childhood traumatic experience, and Posttraumatic Stress Disorder in an urban civilian population. Depress Anxiety  2010,27(12),1077-1086","journal-title":"Depress Anxiety"},{"key":"ref=759","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2007.01.010","volume":"34","author":"Sacks J.Y.","year":"2008","unstructured":"Sacks J.Y.; McKendrick K.; Banks S.; The impact of early trauma and abuse on residential substance abuse treatment outcomes for women. J Subst Abuse Treat  2008,34(1),90-100","journal-title":"J Subst Abuse Treat"},{"key":"ref=760","author":"Khantzian E.J.","year":"1987","unstructured":"Khantzian E.J.;  The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence  1987","journal-title":"The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence"},{"key":"ref=761","doi-asserted-by":"publisher","first-page":"9791","DOI":"10.1007\/s11033-020-06009-x","volume":"47","author":"DiVito A.J.","year":"2020","unstructured":"DiVito A.J.; Leger R.F.; Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review. Mol Biol Rep  2020,47(12),9791-9799","journal-title":"Mol Biol Rep"},{"key":"ref=762","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","volume":"64","author":"Bogenschutz M.P.","year":"2016","unstructured":"Bogenschutz M.P.; Johnson M.W.; Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry  2016,64,250-258","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=763","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"Bogenschutz M.P.","year":"2015","unstructured":"Bogenschutz M.P.; Forcehimes A.A.; Pommy J.A.; Wilcox C.E.; Barbosa P.C.R.; Strassman R.J.; Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol  2015,29(3),289-299","journal-title":"J Psychopharmacol"},{"key":"ref=764","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00406-021-01267-7","volume":"272","author":"Rodrigues L.S.","year":"2022","unstructured":"Rodrigues L.S.; Rossi G.N.; Rocha J.M.; L Os\u00f3rio F.; Bouso J.C.; Hallak J.E.C.; dos Santos R.G.; Effects of ayahuasca and its alkaloids on substance use disorders: An updated (2016-2020) systematic review of preclinical and human studies. Eur Arch Psychiatry Clin Neurosci  2022,272(4),541-556","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=765","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugalcdep.2010.03.024","volume":"111","author":"F\u00e1bregas J.M.","year":"2010","unstructured":"F\u00e1bregas J.M.; Gonz\u00e1lez D.; Fondevila S.; Cutchet M.; Fern\u00e1ndez X.; Barbosa P.C.R.; Alc\u00e1zar-C\u00f3rcoles M.\u00c1.; Barbanoj M.J.; Riba J.; Bouso J.C.; Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend  2010,111(3),257-261","journal-title":"Drug Alcohol Depend"},{"key":"ref=766","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/15733998113099990003","volume":"6","author":"Thomas G.","year":"2013","unstructured":"Thomas G.; Lucas P.; Capler N.; Tupper K.; Martin G.; Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Curr Drug Abuse Rev  2013,6(1),30-42","journal-title":"Curr Drug Abuse Rev"},{"key":"ref=767","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/02791072.2005.10399794","volume":"37","author":"Doering-Silveira E.","year":"2005","unstructured":"Doering-Silveira E.; Grob C.S.; de Rios M.D.; Lopez E.; Alonso L.K.; Tacla C.; Da Silveira D.X.; Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs  2005,37(2),141-144","journal-title":"J Psychoactive Drugs"},{"key":"ref=768","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-3-642-40426-9_6","author":"Bouso J.C.","year":"2014","unstructured":"Bouso J.C.; Riba J.; Ayahuasca and the treatment of drug addiction. The Therapeutic use of Ayahuasca  2014,95-104","journal-title":"The Therapeutic use of Ayahuasca"},{"key":"ref=769","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/02791072.2013.873157","volume":"46","author":"Loizaga-Velder A.","year":"2014","unstructured":"Loizaga-Velder A.; Verres R.; Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence\u2014qualitative results. J Psychoactive Drugs  2014,46(1),63-72","journal-title":"J Psychoactive Drugs"},{"key":"ref=770","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fpsyt.2019.00138","volume":"10","author":"Sessa B.","year":"2019","unstructured":"Sessa B.; Higbed L.; Nutt D.; A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Front Psychiatry  2019,10,138","journal-title":"Front Psychiatry"},{"key":"ref=771","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","volume":"179","author":"Grabski M.","year":"2022","unstructured":"Grabski M.; McAndrew A.; Lawn W.; Marsh B.; Raymen L.; Stevens T.; Hardy L.; Warren F.; Bloomfield M.; Borissova A.; Maschauer E.; Broomby R.; Price R.; Coathup R.; Gilhooly D.; Palmer E.; Gordon-Williams R.; Hill R.; Harris J.; Mollaahmetoglu O.M.; Curran H.V.; Brandner B.; Lingford-Hughes A.; Morgan C.J.A.; Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry  2022,179(2),152-162","journal-title":"Am J Psychiatry"},{"key":"ref=772","first-page":"625","volume":"42","author":"Jovai\u0161a T.","year":"2006","unstructured":"Jovai\u0161a T.; Laurin\u0117nas G.; Vosylius S.; Effects of ketamine on precipitated opiate withdrawal. Medicina  2006,42(8),625-634","journal-title":"Medicina"},{"key":"ref=773","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","volume":"176","author":"Dakwar E.","year":"2019","unstructured":"Dakwar E.; Nunes E.V.; Hart C.L.; Foltin R.W.; Mathew S.J.; Carpenter K.M.; Choi C.J.J.; Basaraba C.N.; Pavlicova M.; Levin F.R.; A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. Am J Psychiatry  2019,176(11),923-930","journal-title":"Am J Psychiatry"},{"key":"ref=774","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","volume":"23","author":"Krupitsky E.","year":"2002","unstructured":"Krupitsky E.; Burakov A.; Romanova T.; Dunaevsky I.; Strassman R.; Grinenko A.; Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. J Subst Abuse Treat  2002,23(4),273-283","journal-title":"J Subst Abuse Treat"},{"key":"ref=775","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/7854_2021_278","author":"Yaden D.B.","year":"2021","unstructured":"Yaden D.B.; Nayak S.M.; Gukasyan N.; Anderson B.T.; Griffiths R.R.;  The potential of psychedelics for end of life and palliative care  2021,169-184","journal-title":"The potential of psychedelics for end of life and palliative care"},{"key":"ref=776","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/rapm-2020-101273","volume":"45","author":"Castellanos J.P.","year":"2020","unstructured":"Castellanos J.P.; Woolley C.; Bruno K.A.; Zeidan F.; Halberstadt A.; Furnish T.; Chronic pain and psychedelics: A review and proposed mechanism of action. Reg Anesth Pain Med  2020,45(7),486-494","journal-title":"Reg Anesth Pain Med"},{"key":"ref=777","doi-asserted-by":"publisher","first-page":"958","DOI":"10.30773\/pi.2021.0209","volume":"18","author":"Yu C.L.","year":"2021","unstructured":"Yu C.L.; Yang F.C.; Yang S.N.; Tseng P.T.; Stubbs B.; Yeh T.C.; Hsu C.W.; Li D.J.; Liang C.S.; Psilocybin for end-of-life anxiety symptoms: A systematic review and meta-analysis. Psychiatry Investig  2021,18(10),958-967","journal-title":"Psychiatry Investig"},{"key":"ref=778","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"Gasser P.","year":"2015","unstructured":"Gasser P.; Kirchner K.; Passie T.; LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. J Psychopharmacol  2015,29(1),57-68","journal-title":"J Psychopharmacol"},{"key":"ref=779","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0272-7358(00)00071-4","volume":"21","author":"Sharp T.J.","year":"2001","unstructured":"Sharp T.J.; Harvey A.G.; Chronic pain and posttraumatic stress disorder: Mutual maintenance? Clin Psychol Rev  2001,21(6),857-877","journal-title":"Clin Psychol Rev"},{"key":"ref=780","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1037\/a0021263","volume":"3","author":"Beck J.G.","year":"2011","unstructured":"Beck J.G.; Clapp J.D.; A different kind of comorbidity: Understanding posttraumatic stress disorder and chronic pain. Psychol Trauma  2011,3(2),101-108","journal-title":"Psychol Trauma"},{"key":"ref=781","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/7854_2022_365","author":"Schindler E.A.D.","year":"2022","unstructured":"Schindler E.A.D.;  Psychedelics in the treatment of headache and chronic pain disorders Disruptive Psychopharmacology Current Topics in Behavioral Neurosciences  2022,261-285","journal-title":"Psychedelics in the treatment of headache and chronic pain disorders Disruptive Psychopharmacology Current Topics in Behavioral Neurosciences"},{"key":"ref=782","doi-asserted-by":"publisher","first-page":"939302","DOI":"10.3389\/fpsyt.2022.939302","volume":"13","author":"Christie D.","year":"2022","unstructured":"Christie D.; Yazar-Klosinski B.; Nosova E.; Kryskow P.; Siu W.; Lessor D.; Argento E.; MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder. Front Psychiatry  2022,13,939302","journal-title":"Front Psychiatry"},{"key":"ref=783","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3390\/neurolint14020035","volume":"14","author":"Edinoff A.N.","year":"2022","unstructured":"Edinoff A.N.; Fort J.M.; Singh C.; Wagner S.E.; Rodriguez J.R.; Johnson C.A.; Cornett E.M.; Murnane K.S.; Kaye A.M.; Kaye A.D.; Alternative options for complex, recurrent pain states using cannabinoids, psilocybin, and ketamine: A narrative review of clinical evidence. Neurol Int  2022,14(2),423-436","journal-title":"Neurol Int"},{"key":"ref=784","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/0269881120940937","volume":"35","author":"Ramaekers J.G.","year":"2021","unstructured":"Ramaekers J.G.; Hutten N.; Mason N.L.; Dolder P.; Theunissen E.L.; Holze F.; Liechti M.E.; Feilding A.; Kuypers K.P.C.; A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. J Psychopharmacol  2021,35(4),398-405","journal-title":"J Psychopharmacol"},{"key":"ref=785","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1177\/20494637221114962","volume":"16","author":"Bonnelle V.","year":"2022","unstructured":"Bonnelle V.; Smith W.J.; Mason N.L.; Cavarra M.; Kryskow P.; Kuypers K.P.C.; Ramaekers J.G.; Feilding A.; Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: A population survey. Br J Pain  2022,16(6),619-631","journal-title":"Br J Pain"},{"key":"ref=786","first-page":"CD008307","volume":"2013","author":"Chaparro L.E.","year":"2013","unstructured":"Chaparro L.E.; Smith S.A.; Moore R.A.; Wiffen P.J.; Gilron I.; Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst Rev  2013,2013(7),CD008307","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=787","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/AJP.0000000000000033","volume":"30","author":"Aveline C.","year":"2014","unstructured":"Aveline C.; Roux A.L.; Hetet H.L.; Gautier J.F.; Vautier P.; Cognet F.; Bonnet F.; Pain and recovery after total knee arthroplasty: a 12-month follow-up after a prospective randomized study evaluating Nefopam and Ketamine for early rehabilitation. Clin J Pain  2014,30(9),749-754","journal-title":"Clin J Pain"},{"key":"ref=788","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ejp.1153","volume":"22","author":"Michelet D.","year":"2018","unstructured":"Michelet D.; Brasher C.; Horlin A.L.; Bellon M.; Julien-Marsollier F.; Vacher T.; Pontone S.; Dahmani S.; Ketamine for chronic non-cancer pain: A meta-analysis and trial sequential analysis of randomized controlled trials. Eur J Pain  2018,22(4),632-646","journal-title":"Eur J Pain"},{"key":"ref=789","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1213\/ANE.0000000000004185","volume":"129","author":"Orhurhu V.","year":"2019","unstructured":"Orhurhu V.; Orhurhu M.S.; Bhatia A.; Cohen S.P.; Ketamine infusions for chronic pain: A systematic review and meta-analysis of randomized controlled trials. Anesth Analg  2019,129(1),241-254","journal-title":"Anesth Analg"},{"key":"ref=790","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.jpain.2016.01.394","volume":"17","author":"Grande L.","year":"2016","unstructured":"Grande L.; Delacruz H.; Thompson M.; Terman G.; Rosenblatt R.; (417) Oral ketamine for chronic pain: A 32-subject placebo-controlled trial in patients on chronic opioids. J Pain  2016,17(4),S78-S79","journal-title":"J Pain"},{"key":"ref=791","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ejp.624","volume":"19","author":"Marchetti F.","year":"2015","unstructured":"Marchetti F.; Coutaux A.; Bellanger A.; Magneux C.; Bourgeois P.; Mion G.; Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients. Eur J Pain  2015,19(7),984-993","journal-title":"Eur J Pain"},{"key":"ref=792","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bcp.12094","volume":"77","author":"Niesters M.","year":"2014","unstructured":"Niesters M.; Martini C.; Dahan A.; Ketamine for chronic pain: Risks and benefits. Br J Clin Pharmacol  2014,77(2),357-367","journal-title":"Br J Clin Pharmacol"},{"key":"ref=793","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40261-022-01122-0","volume":"42","author":"Avance\u00f1a A.L.V.","year":"2022","unstructured":"Avance\u00f1a A.L.V.; Kahn J.G.; Marseille E.; The costs and health benefits of expanded access to MDMA-assisted therapy for chronic and severe PTSD in the USA: A modeling study. Clin Drug Investig  2022,42(3),243-252","journal-title":"Clin Drug Investig"},{"key":"ref=794","doi-asserted-by":"publisher","first-page":"e0239997","DOI":"10.1371\/journal.pone.0239997","volume":"15","author":"Marseille E.","year":"2020","unstructured":"Marseille E.; Kahn J.G.; Yazar-Klosinski B.; Doblin R.; The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLoS One  2020,15(10),e0239997","journal-title":"PLoS One"},{"key":"ref=795","doi-asserted-by":"publisher","first-page":"e0263252","DOI":"10.1371\/journal.pone.0263252","volume":"17","author":"Marseille E.","year":"2022","unstructured":"Marseille E.; Mitchell J.M.; Kahn J.G.; Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. PLoS One  2022,17(2),e0263252","journal-title":"PLoS One"},{"key":"ref=796","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40501-020-00215-x","volume":"7","author":"Morland L.A.","year":"2020","unstructured":"Morland L.A.; Wells S.Y.; Glassman L.H.; Greene C.J.; Hoffman J.E.; Rosen C.S.; Advances in PTSD treatment delivery: Review of findings and clinical considerations for the use of telehealth interventions for PTSD. Curr Treat Options Psychiatry  2020,7(3),221-241","journal-title":"Curr Treat Options Psychiatry"},{"key":"ref=797","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/jts.22456","volume":"33","author":"Smith J.R.","year":"2020","unstructured":"Smith J.R.; Workneh A.; Yaya S.; Barriers and facilitators to help-seeking for individuals with posttraumatic stress disorder: A systematic review. J Trauma Stress  2020,33(2),137-150","journal-title":"J Trauma Stress"},{"key":"ref=798","doi-asserted-by":"publisher","first-page":"727117","DOI":"10.3389\/fpsyt.2021.727117","volume":"12","author":"Vargas M.V.","year":"2021","unstructured":"Vargas M.V.; Meyer R.; Avanes A.A.; Rus M.; Olson D.E.; Psychedelics and other psychoplastogens for treating mental illness. Front Psychiatry  2021,12,727117","journal-title":"Front Psychiatry"},{"key":"ref=799","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.biopsych.2018.09.004","volume":"85","author":"Wilkinson S.T.","year":"2019","unstructured":"Wilkinson S.T.; Holtzheimer P.E.; Gao S.; Kirwin D.S.; Price R.B.; Leveraging neuroplasticity to enhance adaptive learning: The potential for synergistic somatic-behavioral treatment combinations to improve clinical outcomes in depression. Biol Psychiatry  2019,85(6),454-465","journal-title":"Biol Psychiatry"},{"key":"ref=800","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1111\/bph.14683","volume":"176","author":"Zanos P.","year":"2019","unstructured":"Zanos P.; Highland J.N.; Liu X.; Troppoli T.A.; Georgiou P.; Lovett J.; Morris P.J.; Stewart B.W.; Thomas C.J.; Thompson S.M.; Moaddel R.; Gould T.D.; (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. Br J Pharmacol  2019,176(14),2573-2592","journal-title":"Br J Pharmacol"},{"key":"ref=801","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fnbeh.2018.00258","volume":"12","author":"Watkins L.E.","year":"2018","unstructured":"Watkins L.E.; Sprang K.R.; Rothbaum B.O.; Treating PTSD: A review of evidence-based psychotherapy interventions. Front Behav Neurosci  2018,12,258","journal-title":"Front Behav Neurosci"},{"key":"ref=802","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1037\/tra0000062","volume":"8","author":"Gutner C.A.","year":"2016","unstructured":"Gutner C.A.; Gallagher M.W.; Baker A.S.; Sloan D.M.; Resick P.A.; Time course of treatment dropout in cognitive-behavioral therapies for posttraumatic stress disorder. Psychol Trauma  2016,8(1),115-121","journal-title":"Psychol Trauma"},{"key":"ref=803","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1037\/ser0000212","volume":"15","author":"Hundt N.E.","year":"2018","unstructured":"Hundt N.E.; Helm A.; Smith T.L.; Lamkin J.; Cully J.A.; Stanley M.A.; Failure to engage: A qualitative study of veterans who decline evidence-based psychotherapies for PTSD. Psychol Serv  2018,15(4),536-542","journal-title":"Psychol Serv"},{"key":"ref=804","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1037\/ser0000714","volume":"20","author":"Wells S.Y.","year":"2022","unstructured":"Wells S.Y.; Morland L.A.; Hurst S.; Veterans\u2019 reasons for dropping out of prolonged exposure therapy across three delivery modalities: A qualitative examination. Psychol Serv  2022,20(3),483-495","journal-title":"Psychol Serv"},{"key":"ref=805","doi-asserted-by":"publisher","first-page":"843","DOI":"10.5664\/jcsm.6638","volume":"13","author":"Goldstein L.A.","year":"2017","unstructured":"Goldstein L.A.; Colvonen P.J.; Sarmiento K.F.; Advancing treatment of comorbid PTSD and OSA. J Clin Sleep Med  2017,13(6),843-844","journal-title":"J Clin Sleep Med"},{"key":"ref=806","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","volume":"18","author":"Michaels T.I.","year":"2018","unstructured":"Michaels T.I.; Purdon J.; Collins A.; Williams M.T.; Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry  2018,18(1),245","journal-title":"BMC Psychiatry"},{"key":"ref=807","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00127-016-1208-5","volume":"51","author":"Goldstein R.B.","year":"2016","unstructured":"Goldstein R.B.; Smith S.M.; Chou S.P.; Saha T.D.; Jung J.; Zhang H.; Pickering R.P.; Ruan W.J.; Huang B.; Grant B.F.; The epidemiology of DSM-5 posttraumatic stress disorder in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol  2016,51(8),1137-1148","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"ref=808","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/09687637.2021.1897331","volume":"28","author":"Thrul J.","year":"2021","unstructured":"Thrul J.; Garcia-Romeu A.; Whitewashing psychedelics: Racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs Educ Prev Policy  2021,28(3),211-214","journal-title":"Drugs Educ Prev Policy"},{"key":"ref=809","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-019-7969-5","volume":"20","author":"Eylem O.","year":"2020","unstructured":"Eylem O.; De Wit L.; Van Straten A.; Stigma for common mental disorders in racial minorities and majorities a systematic review and meta-analysis. BMC Public Health  2020,20(1),1-20","journal-title":"BMC Public Health"},{"key":"ref=810","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1037\/pri0000076","volume":"3","author":"Williams M.T.","year":"2018","unstructured":"Williams M.T.; Metzger I.W.; Leins C.; DeLapp C.; Assessing racial trauma within a DSM-5 framework: The UConn Racial\/] Ethnic Stress and Trauma Survey. Pract Innov  2018,3(4),242-260","journal-title":"Pract Innov"},{"key":"ref=811","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/jcop.21580","volume":"41","author":"Meyer O.L.","year":"2013","unstructured":"Meyer O.L.; Zane N.; The influence of race and ethnicity in clients\u2019 experiences of mental health treatment. J Community Psychol  2013,41(7),884-901","journal-title":"J Community Psychol"},{"key":"ref=812","author":"Leary T.","year":"1961","unstructured":"Leary T.; Drugs, set and suggestibility [Paper presentation]. Annual meeting of the American Psychological Association  1961","journal-title":"Annual meeting of the American Psychological Association"},{"key":"ref=813","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jenvp.2018.05.002","volume":"57","author":"Ulrich R.S.","year":"2018","unstructured":"Ulrich R.S.; Bogren L.; Gardiner S.K.; Lundin S.; Psychiatric ward design can reduce aggressive behavior. J Environ Psychol  2018,57,53-66","journal-title":"J Environ Psychol"},{"key":"ref=814","first-page":"97","volume":"3","author":"Ulrich R.S.","year":"1991","unstructured":"Ulrich R.S.; Effects of interior design on wellness: Theory and recent scientific research. J Health Care Interior Design  1991,3,97-109","journal-title":"J Health Care Interior Design"},{"key":"ref=815","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1192\/bjp.bp.114.144873","volume":"205","author":"Papoulias C.","year":"2014","unstructured":"Papoulias C.; Csipke E.; Rose D.; McKellar S.; Wykes T.; The psychiatric ward as a therapeutic space: Systematic review. Br J Psychiatry  2014,205(3),171-176","journal-title":"Br J Psychiatry"},{"key":"ref=816","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijnurstu.2016.08.008","volume":"63","author":"Iyendo T.O.","year":"2016","unstructured":"Iyendo T.O.; Exploring the effect of sound and music on health in hospital settings: A narrative review. Int J Nurs Stud  2016,63,82-100","journal-title":"Int J Nurs Stud"},{"key":"ref=817","first-page":"1","author":"McCartney A.","year":"2022","unstructured":"McCartney A.; McGovern H.; De Foe A.; Predictors of psychedelic experience: A thematic analysis. J Psychoactive Drugs  2022,1-9","journal-title":"J Psychoactive Drugs"},{"key":"ref=818","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","volume":"142","author":"Rucker J.J.H.","year":"2018","unstructured":"Rucker J.J.H.; Iliff J.; Nutt D.; J. Psychiatry and the psychedelic drugs. Past, present and future. Neuropharmacology  2018,142,200-218","journal-title":"Neuropharmacology"},{"key":"ref=819","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1056\/NEJMra1907805","volume":"382","author":"Colloca L.","year":"2020","unstructured":"Colloca L.; Barsky A.J.; Placebo and nocebo effects. N Engl J Med  2020,382(6),554-561","journal-title":"N Engl J Med"},{"key":"ref=820","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","volume":"2","author":"Ioannidis J.P.A.","year":"2005","unstructured":"Ioannidis J.P.A.; Why most published research findings are false. PLoS Med  2005,2(8),e124","journal-title":"PLoS Med"},{"key":"ref=821","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/ana.25387","volume":"85","author":"Burke M.J.","year":"2019","unstructured":"Burke M.J.; Kaptchuk T.J.; Pascual-Leone A.; Challenges of differential placebo effects in contemporary medicine: The example of brain stimulation. Ann Neurol  2019,85(1),12-20","journal-title":"Ann Neurol"},{"key":"ref=822","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41591-021-01524-1","volume":"27","author":"Burke M.J.","year":"2021","unstructured":"Burke M.J.; Blumberger D.M.; Caution at psychiatry\u2019s psychedelic frontier. Nat Med  2021,27(10),1687-1688","journal-title":"Nat Med"},{"key":"ref=823","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","volume":"48","author":"Goodwin G.M.","year":"2023","unstructured":"Goodwin G.M.; Croal M.; Feifel D.; Kelly J.R.; Marwood L.; Mistry S.; O'Keane V.; Peck S.K.; Simmons H.; Sisa C.; Stansfield S.C.; Tsai J.; Williams S.; Malievskaia E.; Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology  2023,48(10),1492-1499","journal-title":"Neuropsychopharmacology"},{"key":"ref=824","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/09540261.2018.1474088","volume":"30","author":"Walsh Z.","year":"2018","unstructured":"Walsh Z.; Thiessen M.S.; Psychedelics and the new behaviourism: Considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy. Int Rev Psychiatry  2018,30(4),343-349","journal-title":"Int Rev Psychiatry"},{"key":"ref=825","doi-asserted-by":"publisher","first-page":"104124","DOI":"10.1016\/j.brat.2022.104124","volume":"154","author":"Maples-Keller J.","year":"2022","unstructured":"Maples-Keller J.; Watkins L.E.; Nylocks K.M.; Yasinski C.; Coghlan C.; Black K.; Jovanovic T.; Rauch S.A.M.; Rothbaum B.O.; Norrholm S.D.; Acquisition, extinction, and return of fear in veterans in intensive outpatient prolonged exposure therapy: A fear-potentiated startle study. Behav Res Ther  2022,154,104124","journal-title":"Behav Res Ther"},{"key":"ref=826","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1503\/jpn.170021","volume":"43","author":"Boyd J.E.","year":"2018","unstructured":"Boyd J.E.; Lanius R.A.; McKinnon M.C.; Mindfulness-based treatments for posttraumatic stress disorder: A review of the treatment literature and neurobiological evidence. J Psychiatry Neurosci  2018,43(1),7-25","journal-title":"J Psychiatry Neurosci"},{"key":"ref=827","author":"Monson C.M.","year":"2012","unstructured":"Monson C.M.; Fredman S.J.;  Cognitive-behavioral conjoint therapy for PTSD: Harnessing the healing power of relationships  2012","journal-title":"Cognitive-behavioral conjoint therapy for PTSD: Harnessing the healing power of relationships"},{"key":"ref=828","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","volume":"14","author":"Johnson M.W.","year":"2017","unstructured":"Johnson M.W.; Griffiths R.R.; Potential therapeutic effects of psilocybin. Neurotherapeutics  2017,14(3),734-740","journal-title":"Neurotherapeutics"},{"key":"ref=829","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/02791072.2019.1593559","volume":"51","author":"Trope A.","year":"2019","unstructured":"Trope A.; Anderson B.T.; Hooker A.R.; Glick G.; Stauffer C.; Woolley J.D.; Psychedelic-assisted group therapy: A systematic review. J Psychoactive Drugs  2019,51(2),174-188","journal-title":"J Psychoactive Drugs"},{"key":"ref=830","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/jts.2490080106","volume":"8","author":"Blake D.D.","year":"1995","unstructured":"Blake D.D.; Weathers F.W.; Nagy L.M.; Kaloupek D.G.; Gusman F.D.; Charney D.S.; Keane T.M.; The development of a clinician-administered PTSD scale. J Trauma Stress  1995,8(1),75-90","journal-title":"J Trauma Stress"},{"key":"ref=831","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1037\/pas0000486","volume":"30","author":"Weathers F.W.","year":"2018","unstructured":"Weathers F.W.; Bovin M.J.; Lee D.J.; Sloan D.M.; Schnurr P.P.; Kaloupek D.G.; Keane T.M.; Marx B.P.; The clinician-administered PTSD scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess  2018,30(3),383-395","journal-title":"Psychol Assess"},{"key":"ref=832","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1177\/1745691613504115","volume":"8","author":"Galatzer-Levy I.R.","year":"2013","unstructured":"Galatzer-Levy I.R.; Bryant R.A.; 636,120 ways to have posttraumatic stress disorder. Perspect Psychol Sci  2013,8(6),651-662","journal-title":"Perspect Psychol Sci"},{"key":"ref=833","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1002\/mpr.211","volume":"16","author":"Kraemer H.C.","year":"2007","unstructured":"Kraemer H.C.; DSM categories and dimensions in clinical and research contexts. Int J Methods Psychiatr Res  2007,16(S1),S8-S15","journal-title":"Int J Methods Psychiatr Res"},{"key":"ref=834","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11920-017-0761-2","volume":"19","author":"McFarlane A.C.","year":"2017","unstructured":"McFarlane A.C.; Lawrence-Wood E.; Van Hooff M.; Malhi G.S.; Yehuda R.; The need to take a staging approach to the biological mechanisms of PTSD and its treatment. Curr Psychiatry Rep  2017,19(2),10","journal-title":"Curr Psychiatry Rep"},{"key":"ref=835","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11920-018-0908-9","volume":"20","author":"Rasmusson A.M.","year":"2018","unstructured":"Rasmusson A.M.; Pineles S.L.; Neurotransmitter, peptide, and steroid hormone abnormalities in PTSD: biological endophenotypes relevant to treatment. Curr Psychiatry Rep  2018,20(7),52","journal-title":"Curr Psychiatry Rep"},{"key":"ref=836","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jpsychires.2021.07.004","volume":"141","author":"Held P.","year":"2021","unstructured":"Held P.; Smith D.L.; Bagley J.M.; Kovacevic M.; Steigerwald V.L.; Van Horn R.; Karnik N.S.; Treatment response trajectories in a three-week CPT-Based intensive treatment for veterans with PTSD. J Psychiatr Res  2021,141,226-232","journal-title":"J Psychiatr Res"},{"key":"ref=837","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.janxdis.2016.01.006","volume":"38","author":"Korte K.J.","year":"2016","unstructured":"Korte K.J.; Allan N.P.; Gros D.F.; Acierno R.; Differential treatment response trajectories in individuals with subclinical and clinical PTSD. J Anxiety Disord  2016,38,95-101","journal-title":"J Anxiety Disord"},{"key":"ref=838","first-page":"748","author":"Insel T.","year":"2010","unstructured":"Insel T.; Cuthbert B.; Garvey M.; Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. In: Am Psychiatric Assoc  2010,748-751","journal-title":"In: Am Psychiatric Assoc"},{"key":"ref=839","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1037\/abn0000258","volume":"126","author":"Kotov R.","year":"2017","unstructured":"Kotov R.; Krueger R.F.; Watson D.; Achenbach T.M.; Althoff R.R.; Bagby R.M.; Brown T.A.; Carpenter W.T.; Caspi A.; Clark L.A.; Eaton N.R.; Forbes M.K.; Forbush K.T.; Goldberg D.; Hasin D.; Hyman S.E.; Ivanova M.Y.; Lynam D.R.; Markon K.; Miller J.D.; Moffitt T.E.; Morey L.C.; Mullins-Sweatt S.N.; Ormel J.; Patrick C.J.; Regier D.A.; Rescorla L.; Ruggero C.J.; Samuel D.B.; Sellbom M.; Simms L.J.; Skodol A.E.; Slade T.; South S.C.; Tackett J.L.; Waldman I.D.; Waszczuk M.A.; Widiger T.A.; Wright A.G.C.; Zimmerman M.; The hierarchical taxonomy of psychopathology (HiTOP): A dimensional alternative to traditional nosologies. J Abnorm Psychol  2017,126(4),454-477","journal-title":"J Abnorm Psychol"},{"key":"ref=840","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev-clinpsy-081219-093304","volume":"17","author":"Kotov R.","year":"2021","unstructured":"Kotov R.; Krueger R.F.; Watson D.; Cicero D.C.; Conway C.C.; DeYoung C.G.; Eaton N.R.; Forbes M.K.; Hallquist M.N.; Latzman R.D.; Mullins-Sweatt S.N.; Ruggero C.J.; Simms L.J.; Waldman I.D.; Waszczuk M.A.; Wright A.G.C.; The hierarchical taxonomy of psychopathology (HiTOP): A quantitative nosology based on consensus of evidence. Annu Rev Clin Psychol  2021,17(1),83-108","journal-title":"Annu Rev Clin Psychol"},{"key":"ref=841","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1037\/a0038546","volume":"32","author":"Lingiardi V.","year":"2015","unstructured":"Lingiardi V.; McWilliams N.; Bornstein R.F.; Gazzillo F.; Gordon R.M.; The psychodynamic diagnostic manual version 2 (PDM-2): Assessing patients for improved clinical practice and research. Psychoanal Psychol  2015,32(1),94-115","journal-title":"Psychoanal Psychol"},{"key":"ref=842","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/0706743721998044","volume":"67","author":"Passos I.C.","year":"2022","unstructured":"Passos I.C.; Ballester P.; Rabelo-da-Ponte F.D.; Kapczinski F.; Precision psychiatry: The future is now. Can J Psychiatry  2022,67(1),21-25","journal-title":"Can J Psychiatry"},{"key":"ref=843","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1192\/bjp.2021.188","volume":"220","author":"Rezaii N.","year":"2022","unstructured":"Rezaii N.; Wolff P.; Price B.H.; Natural language processing in psychiatry: The promises and perils of a transformative approach. Br J Psychiatry  2022,220(5),251-253","journal-title":"Br J Psychiatry"},{"key":"ref=844","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1017\/S0033291720002718","volume":"52","author":"Schultebraucks K.","year":"2022","unstructured":"Schultebraucks K.; Yadav V.; Shalev A.Y.; Bonanno G.A.; Galatzer-Levy I.R.; Deep learning-based classification of posttraumatic stress disorder and depression following trauma utilizing visual and auditory markers of arousal and mood. Psychol Med  2022,52(5),957-967","journal-title":"Psychol Med"},{"key":"ref=845","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41746-018-0046-0","volume":"1","author":"Hsin H.","year":"2018","unstructured":"Hsin H.; Fromer M.; Peterson B.; Walter C.; Fleck M.; Campbell A.; Varghese P.; Califf R.; Transforming psychiatry into data-driven medicine with digital measurement tools. NPJ Digit Med  2018,1(1),37","journal-title":"NPJ Digit Med"},{"key":"ref=846","doi-asserted-by":"publisher","first-page":"1706910","DOI":"10.1002\/adma.201706910","volume":"30","author":"Yetisen A.K.","year":"2018","unstructured":"Yetisen A.K.; Martinez-Hurtado J.L.; \u00dcnal B.; Khademhosseini A.; Butt H.; Wearables in medicine. Adv Mater  2018,30(33),1706910","journal-title":"Adv Mater"},{"key":"ref=847","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jama.2017.11295","volume":"318","author":"Insel T.R.","year":"2017","unstructured":"Insel T.R.; Digital phenotyping. JAMA  2017,318(13),1215-1216","journal-title":"JAMA"},{"key":"ref=848","first-page":"13","volume":"31","author":"Moskowitz D.S.","year":"2006","unstructured":"Moskowitz D.S.; Young S.N.; Ecological momentary assessment: What it is and why it is a method of the future in clinical psychopharmacology. J Psychiatry Neurosci  2006,31(1),13-20","journal-title":"J Psychiatry Neurosci"},{"key":"ref=849","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s11280-019-00764-z","volume":"23","author":"Yue L.","year":"2020","unstructured":"Yue L.; Tian D.; Chen W.; Han X.; Yin M.; Deep learning for heterogeneous medical data analysis. World Wide Web  2020,23(5),2715-2737","journal-title":"World Wide Web"},{"key":"ref=850","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.clon.2021.12.002","volume":"34","author":"Appelt A.L.","year":"2022","unstructured":"Appelt A.L.; Elhaminia B.; Gooya A.; Gilbert A.; Nix M.; Deep learning for radiotherapy outcome prediction using dose data: A review. Clin Oncol  2022,34(2),e87-e96","journal-title":"Clin Oncol"},{"key":"ref=851","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41571-021-00560-7","volume":"19","author":"Bera K.","year":"2022","unstructured":"Bera K.; Braman N.; Gupta A.; Velcheti V.; Madabhushi A.; Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol  2022,19(2),132-146","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=852","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41416-021-01689-z","volume":"126","author":"Capobianco E.","year":"2022","unstructured":"Capobianco E.; High-dimensional role of AI and machine learning in cancer research. Br J Cancer  2022,126(4),523-532","journal-title":"Br J Cancer"},{"key":"ref=853","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s43674-022-00034-y","volume":"2","author":"Tuppad A.","year":"2022","unstructured":"Tuppad A.; Patil S.D.; Machine learning for diabetes clinical decision support: A review. AdvComput Intell  2022,2(2),22","journal-title":"AdvComput Intell"},{"key":"ref=854","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/wps.20882","volume":"20","author":"Chekroud A.M.","year":"2021","unstructured":"Chekroud A.M.; Bondar J.; Delgadillo J.; Doherty G.; Wasil A.; Fokkema M.; Cohen Z.; Belgrave D.; DeRubeis R.; Iniesta R.; Dwyer D.; Choi K.; The promise of machine learning in predicting treatment outcomes in psychiatry. World Psychiatry  2021,20(2),154-170","journal-title":"World Psychiatry"},{"key":"ref=855","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/cns.13048","volume":"24","author":"Gao S.","year":"2018","unstructured":"Gao S.; Calhoun V.D.; Sui J.; Machine learning in major depression: From classification to treatment outcome prediction. CNS Neurosci Ther  2018,24(11),1037-1052","journal-title":"CNS Neurosci Ther"},{"key":"ref=856","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00406-022-01418-4","volume":"273","author":"Rost N.","year":"2023","unstructured":"Rost N.; Binder E.B.; Br\u00fcckl T.M.; Predicting treatment outcome in depression: An introduction into current concepts and challenges. Eur Arch Psychiatry Clin Neurosci  2023,273(1),113-127","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=857","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S2215-0366(15)00471-X","volume":"3","author":"Chekroud A.M.","year":"2016","unstructured":"Chekroud A.M.; Zotti R.J.; Shehzad Z.; Gueorguieva R.; Johnson M.K.; Trivedi M.H.; Cannon T.D.; Krystal J.H.; Corlett P.R.; Cross-trial prediction of treatment outcome in depression: A machine learning approach. Lancet Psychiatry  2016,3(3),243-250","journal-title":"Lancet Psychiatry"},{"key":"ref=858","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","volume":"4","author":"Aday J.S.","year":"2021","unstructured":"Aday J.S.; Davis A.K.; Mitzkovitz C.M.; Bloesch E.K.; Davoli C.C.; Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects. ACS Pharmacol Transl Sci  2021,4(2),424-435","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref=859","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bpsc.2021.11.002","volume":"7","author":"Neria Y.","year":"2022","unstructured":"Neria Y.; Lazarov A.; Zhu X.; Identifying neurobiological markers of posttraumatic stress disorder using resting-state functional magnetic resonance imaging data: The promise of data-driven computational approaches. Biol Psychiatry Cogn Neurosci Neuroimaging  2022,7(2),121-123","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"ref=860","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jpsychires.2021.03.002","volume":"137","author":"Romeo B.","year":"2021","unstructured":"Romeo B.; Hermand M.; P\u00e9tillion A.; Karila L.; Benyamina A.; Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. J Psychiatr Res  2021,137,273-282","journal-title":"J Psychiatr Res"},{"key":"ref=861","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1556\/2054.2021.00172","volume":"5","author":"Cavanna F.","year":"2021","unstructured":"Cavanna F.; Pallavicini C.; Milano V.; Cuiule J.; Di Tella R.; Gonz\u00e1lez P.; Tagliazucchi E.; Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic. J Psychedelic Stud  2021,5(2),83-93","journal-title":"J Psychedelic Stud"},{"key":"ref=862","doi-asserted-by":"publisher","first-page":"647909","DOI":"10.3389\/fpsyt.2021.647909","volume":"12","author":"Mans K.","year":"2021","unstructured":"Mans K.; Kettner H.; Erritzoe D.; Haijen E.C.H.M.; Kaelen M.; Carhart-Harris R.L.; Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample. Front Psychiatry  2021,12,647909","journal-title":"Front Psychiatry"},{"key":"ref=863","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/20503245221097649","author":"Gandy S.","year":"2022","unstructured":"Gandy S.; Bonnelle V.; Jacobs E.; Luke D.; Psychedelics as potential catalysts of scientific creativity and insight. Drug Sci Policy Law  2022,8","journal-title":"Drug Sci Policy Law"},{"key":"ref=864","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.expneurol.2016.07.002","volume":"284","author":"Horn S.R.","year":"2016","unstructured":"Horn S.R.; Charney D.S.; Feder A.; Understanding resilience: New approaches for preventing and treating PTSD. Exp Neurol  2016,284,119-132","journal-title":"Exp Neurol"},{"key":"ref=865","doi-asserted-by":"publisher","first-page":"841648","DOI":"10.3389\/fphar.2022.841648","volume":"13","author":"McCulloch D.E.W.","year":"2022","unstructured":"McCulloch D.E.W.; Grzywacz M.Z.; Madsen M.K.; Jensen P.S.; Ozenne B.; Armand S.; Knudsen G.M.; Fisher P.M.D.; Stenb\u00e6k D.S.; Psilocybin-induced mystical-type experiences are related to persisting positive effects: A quantitative and qualitative report. Front Pharmacol  2022,13,841648","journal-title":"Front Pharmacol"},{"key":"ref=866","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/psychoactives1010003","volume":"1","author":"Ona G.","year":"2022","unstructured":"Ona G.; R\u00e9v\u00e9sz D.; Kohek M.; Rossi G.N.; Rocha J.M.; dos Santos R.G.; Hallak J.E.C.; Alc\u00e1zar-C\u00f3rcoles M.\u00c1.; Bouso J.C.; Tripping to Cope: Coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts. Psychoactives  2022,1(1),16-30","journal-title":"Psychoactives"},{"key":"ref=867","doi-asserted-by":"publisher","first-page":"607529","DOI":"10.3389\/fphar.2021.607529","volume":"12","author":"Roseman L.","year":"2021","unstructured":"Roseman L.; Ron Y.; Saca A.; Ginsberg N.; Luan L.; Karkabi N.; Doblin R.; Carhart-Harris R.; Relational processes in ayahuasca groups of Palestinians and Israelis. Front Pharmacol  2021,12,607529","journal-title":"Front Pharmacol"},{"key":"ref=868","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1089\/jpm.2017.0684","volume":"21","author":"Byock I.","year":"2018","unstructured":"Byock I.; Taking psychedelics seriously. J Palliat Med  2018,21(4),417-421","journal-title":"J Palliat Med"},{"key":"ref=869","doi-asserted-by":"publisher","DOI":"10.1177\/24705470211035607","volume":"5","author":"Davis A.K.","year":"2021","unstructured":"Davis A.K.; Xin Y.; Sepeda N.D.; Garcia-Romeu A.; Williams M.T.; Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chronic Stress  ecollection 20212021,5","journal-title":"Chronic Stress"},{"key":"ref=870","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1177\/02698811221104052","volume":"36","author":"Ching T.H.W.","year":"2022","unstructured":"Ching T.H.W.; Williams M.T.; Wang J.B.; Jerome L.; Yazar-Klosinski B.; Emerson A.; Doblin R.; MDMA-assisted therapy for post-traumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial. J Psychopharmacol  2022,36(8),974-986","journal-title":"J Psychopharmacol"},{"key":"ref=871","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fpsyt.2019.00672","volume":"10","author":"Hutten N.R.P.W.","year":"2019","unstructured":"Hutten N.R.P.W.; Mason N.L.; Dolder P.C.; Kuypers K.P.C.; Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front Psychiatry  2019,10,672","journal-title":"Front Psychiatry"},{"key":"ref=872","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0269881114565653","volume":"29","author":"Hendricks P.S.","year":"2015","unstructured":"Hendricks P.S.; Thorne C.B.; Clark C.B.; Coombs D.W.; Johnson M.W.; Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol  2015,29(3),280-288","journal-title":"J Psychopharmacol"},{"key":"ref=873","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/0269881118806297","volume":"32","author":"Ot\u2019alora G.","year":"2018","unstructured":"Ot\u2019alora G.; M.; Grigsby, J.; Poulter, B.; Van Derveer, J.W., III; Giron, S.G.; Jerome, L.; Feduccia, A.A.; Hamilton, S.; Yazar-Klosinski, B.; Emerson, A.; Mithoefer, M.C.; Doblin, R. 3,4-methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic post-traumatic stress disorder: A randomized phase 2 controlled trial. J Psychopharmacol  2018,32(12),1295-1307","journal-title":"J Psychopharmacol"},{"key":"ref=874","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"Oehen P.","year":"2013","unstructured":"Oehen P.; Traber R.; Widmer V.; Schnyder U.; A randomized, controlled pilot study of MDMA (\u00b13,4-methylenedioxy-methamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol  2013,27(1),40-52","journal-title":"J Psychopharmacol"},{"key":"ref=875","doi-asserted-by":"publisher","DOI":"10.1177\/2470547020981670","volume":"4","author":"Dadabayev A.R.","year":"2020","unstructured":"Dadabayev A.R.; Joshi S.A.; Reda M.H.; Lake T.; Hausman M.S.; Domino E.; Liberzon I.; Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: A randomized double-blind clinical trial. Chronic Stress  ecollection 20202020,4","journal-title":"Chronic Stress"},{"key":"ref=876","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000467984","volume":"8","author":"Grof S.","year":"1973","unstructured":"Grof S.; Goodman L.E.; Richards W.A.; Kurland A.A.; LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry  1973,8(3),129-144","journal-title":"Int Pharmacopsychiatry"},{"key":"ref=877","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","volume":"174","author":"Wilkinson S.T.","year":"2017","unstructured":"Wilkinson S.T.; Toprak M.; Turner M.S.; Levine S.P.; Katz R.B.; Sanacora G.; A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry  2017,174(7),695-696","journal-title":"Am J Psychiatry"},{"key":"ref=878","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/02791072.2019.1607956","volume":"51","author":"Berlowitz I.","year":"2019","unstructured":"Berlowitz I.; Walt H.; Ghasarian C.; Mendive F.; Martin-Soelch C.; Short-term treatment effects of a substance use disorder therapy involving traditional Amazonian medicine. J Psychoactive Drugs  2019,51(4),323-334","journal-title":"J Psychoactive Drugs"},{"key":"ref=879","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fpsyt.2018.00136","volume":"9","author":"Barbosa P.C.R.","year":"2018","unstructured":"Barbosa P.C.R.; T\u00f3foli L.F.; Bogenschutz M.P.; Hoy R.; Berro L.F.; Marinho E.A.V.; Areco K.N.; Winkelman M.J.; Assessment of alcohol and tobacco use disorders among religious users of ayahuasca. Front Psychiatry  2018,9,136","journal-title":"Front Psychiatry"},{"key":"ref=880","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","volume":"177","author":"Dakwar E.","year":"2020","unstructured":"Dakwar E.; Levin F.; Hart C.L.; Basaraba C.; Choi J.; Pavlicova M.; Nunes E.V.; A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial. Am J Psychiatry  2020,177(2),125-133","journal-title":"Am J Psychiatry"},{"key":"ref=881","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","volume":"39","author":"Krupitsky E.M.","year":"2007","unstructured":"Krupitsky E.M.; Burakov A.M.; Dunaevsky I.V.; Romanova T.N.; Slavina T.Y.; Grinenko A.Y.; Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs  2007,39(1),13-19","journal-title":"J Psychoactive Drugs"},{"key":"ref=882","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","volume":"235","author":"Danforth A.L.","year":"2018","unstructured":"Danforth A.L.; Grob C.S.; Struble C.; Feduccia A.A.; Walker N.; Jerome L.; Yazar-Klosinski B.; Emerson A.; Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study. Psychopharmacology  2018,235(11),3137-3148","journal-title":"Psychopharmacology"},{"key":"ref=883","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","volume":"93","author":"Holze F.","year":"2023","unstructured":"Holze F.; Gasser P.; M\u00fcller F.; Dolder P.C.; Liechti M.E.; Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry  2023,93(3),215-223","journal-title":"Biol Psychiatry"},{"key":"ref=884","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000517074","volume":"90","author":"Wilkinson S.T.","year":"2021","unstructured":"Wilkinson S.T.; Rhee T.G.; Joormann J.; Webler R.; Ortiz Lopez M.; Kitay B.; Fasula M.; Elder C.; Fenton L.; Sanacora G.; Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: A randomized clinical trial. Psychother Psychosom  2021,90(5),318-327","journal-title":"Psychother Psychosom"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666231027111147","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/222817\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666231027111147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T08:37:25Z","timestamp":1707727045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/222817\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":884,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x22666231027111147","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}